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It is the possibility of  
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acteria are in and on all of us from the moment we are born. In fact, it is 
estimated that we host more bacterial cells than our own human cells (39:30 
trillion cells)1. These bacteria are limited to the areas of the body with contact to the 
outside world, to include the gastrointestinal tract, and exist in a commensalistic or 
mutualistic relationship. The closed cardiovascular system is a sterile environment, 
which is crucial to maintain since a pathogenic bacterium gaining access would be able 
to travel anywhere in the body. Most people, if not all, reading this thesis actually have 
had at least one point in their lives when bacteria entered their blood stream, such as 
from a scraped knee, paper cut, or vigorous tooth brushing. With a healthy immune 
system these bacteria are often easily cleared from the body. However, when the 
immunological triggered response is ineffective at neutralizing the invading bacteria, a 
life-threatening situation can quickly develop. Since the 1940s, there are prescribed 
medications, i.e. antibiotics, that can specifically kill these bacteria or slow the growth 
to give the body enough time to overcome the infection. The advent of antibiotics 
significantly changed the uncertain course of bacterial infections, where a simple cut or 
scrape becoming infected no longer meant life or death depending only on how the 
body could manage. Finally, after being plagued by bacteria since our existence, an 
effective new tool that dramatically reduced mortality was added to our arsenal. 
Unfortunately, this relief was to be short-lived.  
   
Although initially most people viewed antibiotics as a cure-all, and some may still do, 
it is not. Soon after Alexander Fleming discovered the fungus-produced antibacterial 
substance named penicillin, resistance was already identified before the first 
prescription3 and became a clinical problem by the 1950s4. Ever since then, 
scientists have been in a perpetual, quick-pace race against bacteria developing 
resistance to each new antibiotic (over 150). Resistance generally refers to when 
bacteria can render an antibiotic ineffective, such as by producing new degrading 
enzymes or altering the physical structure of the target binding site5. Despite general 
resistance development, with the continued antibiotic and vaccine development, 
dramatically less people died from acute infections caused by planktonic, i.e. free-
floating, bacteria. This is when chronic (persistent) infections took center-stage, 









Figure 1.1. Illustration depicting biofilm formation and maturation (not drawn to scale). 
 
Chronic bacterial infections occur when bacteria aggregate or (~80%)6 form a biofilm. 
Bacterial aggregates have similar characteristics to biofilms, albeit not surface- 
associated. Although the bacterial findings presented in this thesis could potentially be 
extrapolated to aggregates, the research focus is on biofilm. Biofilms begin with the 
successful attachment of at least one bacterium to a surface, which then 
proliferates into a dense, heterogenous community protected by a continually 
constructed extracellular polymeric matrix consisting of microbial and host 
components (Fig. 1.1)7. Bacteria residing in biofilms were first observed in dental 
plaque and described as “an innumerable quantity of Animals” by the Dutch 
microbiology and microscopy pioneer Antoni van Leeuwenhoek in 16838. However, 
biofilms were only formerly recognized as the source of chronic infections some 300 
years later and the name ‘biofilm’ introduced into medical microbiology in 19859. This 
time-lag was largely due initially to both van Leeuwenhoek’s secrecy over his 
intellectual property (i.e., the design and methods for his single-lens microscopes) and 
the ensuing skepticism which led many to believe these tiny animals were either 
imaginative or relatively unimportant10. Fast-forward to the first decades of the 
antibiotic era, and people were perplexed as to the cause of these infections because 
bacteria were often not detected using culture-based clinical sampling and antibiotic 






Today, we now understand that the characteristic nature of biofilms was responsible 
for the baffling results. Certain phenotypic trade-offs that bacteria make to thrive in 
biofilms, and thus the human body, can give rise to viable, yet planktonically growth-
impaired populations that are nonculturable and thus, escape laboratory detection11. 
Bacteria embedded within a biofilm matrix are extremely well-protected against 
the multitude of potential assaults aimed at their removal. In this setting, host 
defenses, such as phagocytosis and free radical production, are rendered 
inconsequential and the immune response itself can be skewed to one that does not 
favor clearance12. Biofilm formation additionally confers a decreased susceptibility to 
antimicrobials, which was also first observed by van Leeuwenhoek with the use of a 
strong wine-vinegar8. Antibiotics are found to be 10-1000x less effective against 
bacteria in biofilms versus in a planktonic state13,14. To clarify, this is also due to 
antimicrobial tolerance, meaning bacteria liberated from a biofilm will become 
susceptible again if not resistant to the compound15. Furthermore, resistance 
development is facilitated within the densely packed biofilms by enhancing the cell-to-
cell exchange of both plasmids carrying resistance genes and communication signals 
controlling gene expression (i.e., quorum sensing)16,17.  
 
Around 100 formerly known bacterial species have so far been identified as pathogenic 
to humans18. Many use the same bacterial protective mechanisms, however they can be 
used differently. For example, Pseudomonas aeruginosa skews the immune response 
towards anti-inflammatory, whereas Staphylococcus aureus (S. aureus) towards 
proinflammatory12. These can also be species-specific, including the secreted toxins 
and immune evasion factors. The microbial focus of this thesis is on S. aureus, a 
common commensal residing either permanently or transiently in ~50% of the 
population. The clinical impact of S. aureus biofilms is high, for it is implicated in 
and the predominate infecting agent of many chronic infections, associated with 
higher mortality rates and twice as long hospital stays, and the majority require 
surgical removal for infection resolution7,19.  
 
The biofilm matrix composition and micromilieu within can vary between species and 
strains, and also the environment surrounding the biofilm has a strong influential role. 
In the cardiovascular system, certain S. aureus strains releases coagulases that converts 





matrix to provide further cover and concealment from antimicrobials and the immune 
system20. Therefore, thesis chapters that focus on cardiovascular biofilms use strains 
isolated from patients with S. aureus infective endocarditis, a life-threatening (22-66% 
mortality19) biofilm infection of the heart valves, surrounding endocardial tissue, or 
indwelling cardiac device. The environment is also taken into consideration, such as by 
growing biofilms under turbulent conditions and using mammalian cell culture media 
or human plasma for fibrin strand development. Despite the rapid expansion of 
biofilm research and new technologies, these infections have increasing 
morbidity rates and mortality rates that have not improved over the last 
decades19,21,22. Now untreatable bacterial infections threaten us once again, driving the 
necessity to direct focus on the discovery of not only new “traditional” antibiotics, but 
also towards novel or repurposed diagnostic and therapeutic strategies.  
  
ound is amazingly influential. Both heard and unheard frequencies can induce 
a vast array of effects. If you can take a moment, close your eyes and open up to 
the sound around you. What do you hear? Perhaps it’s waves crashing against the 
shore line, possibly it’s rain hitting against the roof, or maybe it’s the sound of an 
engine humming on your way to a thesis defense. The sound you heard (20 - 20,000 
Hz) began as mechanical energy 
transmitted as a pressure wave in 
air that vibrated across the 
intricate auditory system within 
your ear, transforming it into an 
electrical nerve impulse resulting 
in a physiological and emotional 
response, such as a decreased 
heart rate and calmness. Using 
sound as a healing tool can be 
traced back to the Aboriginal 
Australians with the didgeridoo  
estimated at least 40,000 years 
ago23. Today, we use medical ultrasonography, which uses electrical energy converted 
into inaudible sound waves (> 20,000 Hz) for a variety of applications in diagnostics, 
procedural guidance, and therapeutics.  
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One of the best-known applications of ultrasound is in fetal monitoring (See Fig. 1.2). 
As a clinical diagnostic, this modality is portable, inexpensive, and harmless. When 
ultrasound comes into contact with echogenic tissue, it is reflected back, which can be 
processed into an electrical signal to allow for visualization inside the human body. 
The tissue type and the boundaries between tissues with different densities 
determines the amount of ultrasound reflected. The acoustical parameters can be 
tuned to the application, such as high-intensity (103-105 W/m2), focused ultrasound 
with short microsecond pulses to mechanically break-up tissue or long millisecond 
pulses for thermal ablation, or low-intensity (1-10 mW/cm2), unfocused ultrasound 
for diagnostic imaging24,25. Ultrasound is instrumental for the diagnosis and 
assessment of many diseases, including infective endocarditis. However, often the 
infection is missed in the early stages of disease, where the patient then presents 
weeks later with a dangerously large 
biofilm, as seen in Figure 1.3.  
 
Over the last decades, ultrasound has 
been investigated as a possible addition 
or alternative in the treatment of 
bacterial infectious diseases. The first 
experiments investigating ultrasound as a 
therapeutic tool were inspired by the 
observation of small fish killed when 
swimming into a high frequency, high 
intensity beam during the development 
of submarine SONAR in 191726. Bacteria 
were the only organisms, out of a variety 
tested ranging from frogs to unicellular 
eukaryotes, to survive all exposures27. 
Depending on the acoustical parameters, 
it can induce various bio-effects in 
mammalian cells, both thermal and non-thermal related, such as ultrastructural 
changes (e.g., plasma membrane disruption, lysosome damage, and cytoplasmic 
vacuolation), protein synthesis stimulation, and intracellular calcium ion 
elevation28. Ultrasound-induced bioeffects have also been observed in bacteria,  
Figure 1.3. Ultrasound image of an infective 
endocarditis vegetation, i.e. biofilm, attached 
to the mitral valve indicated by the white 
arrows. Image reprinted, with permission 





to include non-lethal enhanced membrane permeability, lethal physical 
destruction of both inner and outer cell structures, and biochemical triggered 
apoptosis29,30. For the last 26 years, research has been further directed towards 
combining ultrasound and antimicrobials31-33. The majority of these studies 
demonstrated a synergistic response against biofilms, thus advocating for the use of 
ultrasound as an adjunct to antibiotic therapy. However, it is yet to be seen in the 
clinical setting, and several ultrasound studies observed no change or enhancement in 
bacterial viability30,31. Increasing the footprint of ultrasound-induced bactericidal 
effects and antibiotic synergy could improve therapeutic efficacy for clinical 
consideration. 
 
ubbles are a natural enigma that exist in almost all facets of life, beguiling us 
and perplexing some of the greatest minds for thousands of years. This holds 
true for bubbles used in medical ultrasound contrast imagining, albeit for a shorter 
time frame (decades). These bubbles, called microbubbles, are smaller than 1/10th the 
thickness of this sheet of paper (<10 micrometers) and consist of a gas encapsulated 
by a shell commonly composed of phospholipids. This gas core responds to ultrasound 
waves by volumetrically expanding when the pressure is low and compressing when 
high. For cardiac diagnostic imaging, a frequency of 2 MHz is often used, which means 
microbubbles in this field expand and compress 2 million times a second. These 
oscillating microbubbles scatter the ultrasound allowing for visualization. The 
mechanical power of these oscillations is known to induce mammalian cellular 
responses that can be used for drug delivery enhancement beyond that of ultrasound 
alone34. The addition of biomarkers to the shells of microbubbles, known as targeted 
microbubbles, can allow for the molecular guidance of both disease diagnosis and 
therapy enhancement35. For the experiments investigating the ultrasound-induced 
effects of bacteria/biofilm, acoustic cavitation is often acknowledged as the main 
driver30. Therefore, the addition of exogenous cavitation nuclei to an acoustic field, 
specifically microbubbles for this thesis, could increase the therapeutic effect against 
bacteria beyond preexisting microscopic gas bubbles as seen with mammalian cells34. 
This thesis proposes sonobactericide, which is the use of ultrasound and exogenous 
cavitation nuclei, either alone or as a therapeutic complement, for biofilm eradication 
or as a theranostic for bacterial infections. The current research, concepts, and 






Aim and Thesis Outline 
his thesis is primarily focused on sonobactericide. The overarching aim is to 
investigate its potential as a therapeutic tool for combatting life-threatening 
chronic bacterial infections, with a particular focus on cardiovascular biofilms and 
infective endocarditis. In addition to the chapters directly addressing the aim, there are 
supportive chapters that provide insight separately into important aspects on biofilm 
and microbubbles that have potential to negatively or positively impact the 
effectiveness of sonobactericide.  
 
Sonobactericide is a multidisciplinary approach, and thus, not only an understanding 
of the inflicted organ system(s) is critical, but also that of the bacteria, ultrasonic 
waves, and microbubbles. In Chapter 2, a comprehensive overview of the relevant 
literature (up to August 2019) on sonobactericide is provided, with additional 
attention directed at how the various aspects of the different disciplines, such as 
bacterial structure, acoustic frequency, and microbubble composition, could impact 
therapeutic success.  
 
Intriguingly, the ‘Father’ of both microscopy and microbiology, van Leeuwenhoek, was 
a Dutchman from Delft (~17 km from Erasmus MC), and so it seems appropriate that 
this thesis also includes chapters specifically on these two areas, Chapter 3 and 4 
respectively. Chapter 3 describes in detail the state-of-the-art imaging system, a 
custom-built Nikon A1R+ confocal microscope (nanometer spatial resolution) 
coupled to the Brandaris-128 ultra-high-speed camera (nanosecond temporal 
resolution), that was used, either together or apart, in Chapters 4-6 and 8-11 for 
cellular and microbubble response visualization. Chapter 4 highlights the capability of 
drugs commonly taken during an infection, in this case paracetamol (acetaminophen), 
to possibly induce more resilient forms of biofilm, which may necessitate the tuning of 
Sonobactericide to these drug-induced changes to be most effective.  
 
In Chapters 5-7, non-targeted microbubbles are used to explore their potential to 
induce biofilm therapeutic effects. Each of these chapters builds towards a more in 
vivo-like cardiovascular S. aureus biofilm model. Chapter 5 investigates in real-time, 






(i.e., sonoporation) of bacteria within biofilms as a result of microbubble oscillation. 
Chapter 6 expands upon this with focus on the structural effects ultrasound-activated 
microbubbles have on both the bacteria and fibrin matrix of more cardiovascular-like 
biofilms. Chapter 7 uses infected human blood clots to emulate infective endocarditis 
pathophysiology and with flow, treats these using sonobactericide. 
 
Targeting microbubbles directly to biofilms could enhance sonobactericide’s 
theranostic potential. However, it is then crucial to understand how they differ from 
non-targeted microbubbles in both acoustic signal and induced cellular effects. In 
Chapter 8, various acoustical parameters are investigated to determine if key 
distinguishable differences exist between bound and unbound microbubbles alone. 
Chapter 9 then varies acoustic pressure and cycles to examine both the targeted and 
non-targeted microbubble response and the influence it has on endothelial cells.  
 
Chapters 10 and 11 are both targeted microbubble studies. Chapter 10 furthers 
mechanistic research on the cellular responses to insonified microbubbles using αVβ3 as 
the target to endothelial cells, and focusing on both the microbubble and the ensuing 
sonoporation and cell-cell contact opening. In Chapter 11, a new targeted MB is 
developed using the antibiotic vancomycin to target S. aureus biofilms and tested in 
vitro under flow, along with providing a therapeutic proof-of-concept. Lastly, all of the 
chapters are placed into a larger context in Chapter 12, which provides a discussion 
on several key topics central to Sonobactericide and an outlook into the future. 
 
Together, these chapters aim to provide more depth and breadth into the 
understanding of ultrasound-activated microbubble therapy, with a specific interest 
towards sonobactericide. Finally, I hope you, the reader of this thesis, never lose an 
insatiable curiosity in the midst of a society full of black and white boundaries; at least 





Not all those who wander     
are lost. 
“ 
- The Lord of the Rings,  
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Ultrasound has been developed as both a diagnostic tool and a potent promoter of 
beneficial bioeffects for the treatment of chronic bacterial infections. Bacterial 
infections, especially those involving biofilm on implants, indwelling catheters and heart 
valves, affect millions of people each year, and many deaths occur as a consequence. 
Exposure of microbubbles or droplets to ultrasound can directly affect bacteria and 
enhance the efficacy of antibiotics or other therapeutics, which we have termed 
sonobactericide. This review summarizes investigations that have provided evidence for 
ultrasound-activated microbubble or droplet treatment of bacteria and biofilm. In 
particular, we review the types of bacteria and therapeutics used for treatment and the 
in vitro and pre-clinical experimental setups employed in sonobactericide research. 
Mechanisms for ultrasound enhancement of sonobactericide, with a special emphasis 
on acoustic cavitation and radiation force, are reviewed, and the potential for clinical 






















n recent decades, the combination of ultrasound and cavitation nuclei has been 
investigated as an alternative approach to treatment of several life-threatening 
diseases. Ultrasound is a common diagnostic tool and offers several advantages: it is 
non-invasive and inexpensive, available at the point-of-care, and is a safe medical 
application. Many different types of cavitation nuclei exist, including gas or liquid filled 
and coated or non-coated. These include micro- and nanobubbles, nanocups, droplets 
and echogenic liposomes. When exposed to ultrasound pressure waves, gas-filled nuclei 
respond by expanding and contracting volumetrically, and droplets vaporize into 
microbubbles. Microbubble oscillations and acoustic droplet vaporization impart 
theragnostic potential because this characteristic response can both be detected by 
clinical diagnostic ultrasound scanners and locally enhance treatment by inducing 
cellular responses36-38. “Sonobactericide” describes the enhancement of bactericidal 
action aided by ultrasound and the presence of cavitation nuclei, both endogenous and 
exogenous. This terminology is consistent with the nomenclature of other therapeutic 
applications of ultrasound-activated cavitation nuclei such as sonoporation—the 
formation of micropores within cell membranes36, sonothrombolysis—the lysis of 
thrombi37, sonoreperfusion—the restoration of perfusion after microvascular 
obstruction39 and sonodynamic therapy—the treatment of neoplastic cells using a 
sonosensitizer40. Sonobactericide, like the other approaches, can be used either alone or 
in combination with other drugs, such as antimicrobials. 
 
Sonobactericide arrives at a time when traditional microbial therapy is limited by the 
increasing prevalence of multidrug-resistant bacteria. There are several resistance 
mechanisms and a large contributing factor is the development of biofilms, bacterial 
communities encased in a complex extracellular polymeric matrix consisting of variable 
amounts of numerous constituents, such as polysaccharides and proteins. This matrix 
provides both a scaffold for antibiotic binding and an anoxic and acidic environment that 
can deactivate antibiotics and decrease bacterial susceptibility via a reduced 
metabolism41. In addition to the presence of a protective extracellular matrix, the large 
heterogeneity and general 3-D structure of a biofilm hinder antibiotic delivery, 
penetration and effectiveness. Additionally, it is difficult to diagnose bacterial 
infections before they become extensively established42,43. Sonobactericide, as illustrated in  
I 
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Figure 2.1, may increase the “footprint” of antibiotic bactericidal action, directly kill 







Figure 2.1. Concept of sonobactericide (not drawn to scale). (a) Potential infection environments 
before ultrasound. Sizing of bacteria and cavitation nuclei is denoted with a double-headed arrow. (b) 
Ultrasound application in which cavitating microbubbles and activated nanodroplets disrupt 
bacteria and biofilm composition. Bacteria that have become red in (b) are considered dead or to 











This review focuses specifically on the principles of sonobactericide using exogenous 
cavitation nuclei for potential clinical translation. As this new line of research gains 
ground, it is pertinent to establish important considerations for future work. Main 
concepts of the variability of bacteria, microbubble composition and acoustic behavior 
and ultrasound parameters are addressed, and the experimental setups and measured 
outcomes are evaluated. Articles on sonobactericide published before August 2019 were 
identified using PubMed, Web of Science and Google Scholar search engines with the 
keywords “ultrasound,” “microbubble” (or “bubble” or “contrast”) and “bacteria” or 
“biofilm.” Sonobactericide articles referenced by those found in our search were also 
included. Articles were excluded if they were not written in English or if ultrasound 
alone, that is, without added cavitation nuclei (i.e., microbubbles or droplets), was 
investigated as a potential application for treatment. For treatment with ultrasound 
alone, the reader is referred to other excellent reviews30,31,44. Twenty-seven 
sonobactericide articles were selected for this review (Table 2.1). One article that 
investigated microbubbles targeted to biofilm for diagnostic application45 and six articles 
that studied the effect of cavitation nuclei on bacteria without ultrasound46-51 were 













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































here exists a vast diversity among bacteria; even closely related bacteria can have 
different morphologies, metabolisms and defenses. Considering shape 
morphology, besides the familiar rod (bacillus), spherical (coccus) and spiral (twisted) 
types, at least six other general shapes exist52. Though current sonobactericide research 
into pathogenic bacteria is dominated by bacillus- and coccus-shaped bacteria, infectious 
diseases are also caused by bacteria with other morphologies. Microbubbles may 
oscillate differently when paired with similarly spherical-shaped Staphylococcus aureus, 
versus rod-shaped Escherichia coli or the junction of the kidney-shaped diplococcus 
Neisseria meningitidis because of total surface area contact, tension and rigidity. These 
shape differences along with variation in cell surface could influence treatment success. 
For example, fimbriae are bristle-like external filamentous structures protruding from 
some bacterial cell surfaces which may create a stand-off distance between the cavitation 
nuclei and cell wall. It has been observed that as the initial stand-off distance increases, 
biofilm disruption, sonoporation and cytoskeleton disassembly decrease53,54. Moreover, 
microbubble dynamics also depend on the distance from and material properties of a 
surface55,56. 
 
Based on the cell envelope (a multilayered structure on the outside of the cell), almost 
all bacteria can be subdivided into two main groups: Gram+ or Gram–. The cell envelope 
of Gram+ bacteria consists of a thick (20–80 nm) peptidoglycan layer, which is threaded 
with teichoic acid, but lacks an outer membrane, as illustrated in Figure 2.2a. 
Peptidoglycan is made up of repeating units of muramic acid, which are cross-linked by 
peptide side chains. Gram– bacteria are covered by a thin peptidoglycan cell wall (<10 
nm), surrounded by an outer lipid bilayer membrane containing pores, lipoproteins and 
lipopolysaccharide57, as illustrated in Figure 2.2b. It is possible that these structural 
differences between Gram+ and Gram– bacteria will also result in dissimilar responses 
to sonobactericide. Several studies have compared treatment efficacy on both bacteria 
types58, including ultrasound (67 and 20 kHz) paired with antibiotics without exogenous 
cavitation nuclei59,60, and observed a markedly different response. Furthermore, the size 
of the bacteria (∼0.5–5 µm), whether a single bacterium, dividing bacterium or 
aggregates of several bacteria, and its location (in a suspension, on a surface, or 
intracellular) could have an impact on the therapeutic effectiveness of sonobactericide. 
T 
29




Seemingly subtle differences within a group of eukaryote cells can affect the differential 
reaction to oscillating microbubbles. This variable cell response to microbubbles is 
supported by sonoporation studies that have reported differences in drug delivery 
efficiency in two different cancer cell lines61. The top three types of bacteria on which 
sonobactericide has been evaluated are (i) Staphylococcus epidermidis (Gram+, 7 studies, 
26%); (ii) S. aureus (Gram+, 6 studies, 22%); and (iii) E. coli (Gram–, 4 studies, 15%) 
(Table 2.1). Methicillin-resistant S. epidermidis was employed in the majority of the 
studies (6 out of 7), whereas methicillin-resistant S. aureus (MRSA) was used in 4 of the 
6 studies. Two research teams used a green fluorescent protein containing Gram– strain 
(E. coli, Pseudomonas aeruginosa)62,63. The majority of the studies used only one type of 
bacteria. Only one study used mixed types of bacteria64. Two articles compared two 
different types of bacteria65,66, and another compared a bacterium and a fungus63. Only 
four studies used patient-derived clinical isolates originating from a central venous 
catheter67, infective endocarditis blood culture68, pneumonia-induced sputum69, and 
urine from a patient with lower urinary tract symptoms70. With the exception of Agarwal 
et al.64, who used bacteria from a wastewater reclamation plant to investigate membrane 
biofouling removal, the other groups used lab-derived strains, which may limit clinical 
applicability. Though a laboratory strain may be deemed wild type, the preparation and 
(worldwide) dissemination can lead to genetic changes that cause both disruption of 
virulence regulatory pathways, which often imparts loss of typical in vivo virulence 
potential, and phenotypic variation among an entire strain pedigree71. Also, typing 
clinical isolates, such as staphylococcal protein A (spa) typing performed by Lattwein et 
al.68 or core-genome multi-locus sequence typing, would aid in the verification of disease 
association. 
 
Three modes of growth exist for bacteria: planktonic, associated with a surface and 
intracellular. Bacteria in different growth modes have distinctly different characteristics. 
Planktonic refers to free living bacterial cells, which can occur in two forms: as single 
bacterial cells or in clusters known as planktonic aggregates72. Clinically, this planktonic 
mode generally refers to bacteria that gain entrance to the human body in the 
bloodstream and cause bacteremia, which results in acute infections often effectively 
treated by the host immune system and antibiotics73,74. Seven sonobactericide studies 










Figure 2.2. Interaction of cavitation nuclei with bacteria: (a) interaction between phospholipid-
coated microbubbles and Gram+ bacteria, (b) interaction between phospholipid-coated 
nanodroplets and Gram– bacteria. PEG = polyethylene glycol. 
 
 
In contrast, bacteria adhering to living (biotic) and non-living (abiotic) surfaces cover 
themselves with a protective matrix, classically known as a biofilm. Bacteria in a biofilm 











resistant to antimicrobial therapy than planktonic bacteria75. Biofilm formation is 
abundant, and an estimated 60% of human bacterial infections are biofilm related76,77. 
Correspondingly, 63% (17/27) of the sonobactericide studies focused on treatments for 
biofilm infections. Biofilm can occur on teeth; native and prosthetic heart valves; medical 
implants, such as prosthetic joints, surgical mesh and screws; pacemakers; and 
indwelling catheters78. These biofilms consist of surface aggregates of bacteria imbedded 
in an extracellular matrix of sugars of bacterial origin, extracellular DNA and proteins, 
both originating from either the host or the bacteria. For instance, when S. aureus is 
exposed to blood, the coagulation cascade is activated by coagulase produced by the 
bacterium. The fibrin forms a scaffold to which the bacteria bind, facilitating the 
formation of a biofilm79. Other biofilm composition examples include Pseudomonas 
aeruginosa forming sputum-encased biofilms surrounded by immune cells in lungs 
affected by cystic fibrosis80, and Proteus mirabilis forming crystalline biofilms by inducing 
urinary salt precipitation in the catharized urinary tract81. Biofilm extracellular matrix 
composition and architecture are complex and highly influenced by 
species/strain/lineage, developmental conditions, nutrient availability, cell–cell 
signaling and interactions with the (host) environment82. Moreover, most biofilm 
infections are polymicrobial83, which adds to the microenvironment complexity. The 
various processes driving bacterial responses are not completely understood. Thus 
simulating human in vivo biofilms remains highly challenging84,85. 
 
There are indications that bacteria in a single biofilm do not behave en groupe. Archer et 
al.7 found that S. aureus biofilms contain cells in at least four distinct metabolic states: 
aerobic, fermentative, dormant (including very slow growing cells and persisters) or 
dead. It is likely that bacterial cells in different metabolic states, stages of cell division 
or growth phases will respond differently to sonobactericide. This hypothesis is 
supported by the observation that planktonic bacteria in stationary growth phase are 
more resistant to ultrasound alone or combined with cavitation nuclei86. 
 
Bacteria can be dispersed from mature biofilms and become planktonic again87. 
Dispersal agents, including chemical, enzymatic and mechanical methods, can also be 
used to make biofilm bacteria more susceptible to therapeutics. Recent literature on P. 







from those of both planktonic and biofilm growth modes88. This difference suggests a 
possible transitional growth mode for bacteria acclimating to the planktonic state. These 
researchers found that the dispersed cell phenotype was highly virulent and remained 
for at least 2 h. This finding is supported further by studies that manipulated biofilm 
dispersal, which led to increased disease severity and progression in mice and a 
transition from asymptomatic colonization to active infection, respectively89,90. Chua et 
al.88 discovered that dispersed cells exhibited lower iron uptake gene expression and 
paired the dispersal agent with an iron chelator, which led to significant reduced 
viability. Other work revealed that dispersed bacteria exhibited increased antibiotic 
susceptibility and, only after lag phase (≥3 h), were more active91. Thus, biofilm 
dispersal should be considered and investigated for sonobactericide development. 
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he first to report sonobactericide in combination with an antimicrobial was Ikeda-
Dantsuji et al. in 2011. Since then, 18 articles on sonobactericide using 
antimicrobials have been published (Table 2.1). The most studied clinical antibiotic was 
vancomycin (7 studies, 26%). Six other antibiotics were investigated, with different ones 
for Gram+ and Gram– bacteria except gentamicin. Two groups investigated two 
antibiotics separately on the same bacterial strain. Ikeda-Dantsuji et al.92 investigated 
one antibiotic to which the Chlamydia trachomatis strain was susceptible (doxycycline) 
and one to which this bacterial strain was resistant (ceftizoxime). Ronan et al.62 used 
two aminoglycosides (gentamicin and streptomycin) to which the P. aeruginosa PAO1 
strain was susceptible as determined by CO2 metabolic production. 
 
In addition to the antibiotics, three other antimicrobials were investigated: sodium 
hypochlorite (NaOCl), lysozyme and human β-defensin 3 (Table 2.1). The studies 
included either clinically appropriate antimicrobials (dental, NaOCl93) or antimicrobials 
testing a new approach (lysozyme94; human β-defensin 365,66,95). Sodium hypochlorite is 
a disinfectant used widely in endodontic irrigation and health care facilities96. Human β-
defensin 3, an endogenous broad-spectrum antimicrobial peptide produced by various 
cells in the human body97, was administered in free form or encapsulated in liposomes95. 
The aim was to load the liposomes onto SonoVue microbubbles, but proof thereof was 
not provided. Lysozyme is a naturally occurring antimicrobial protein and was used in 
five (non-sonobactericide) papers as the microbubble coating material46-49,51. 
 
All sonobactericide studies used an appropriate antibiotic targeting a specific microbe, 
according to therapeutic guidelines98-103, excluding 2 studies that could not be linked to 
guidelines because of nondisclosure of microbe information beyond species104 and no 
disease aim65. Two examples of correct antibiotic and microbe pairings are found 
in Sugiyama et al.105, who aimed to treat severe Gram– bacterial pneumonia and used an 
E. coli strain for which the Canadian guideline recommends gentamicin99, and Lattwein 
et al.68, who aimed to treat infective endocarditis and used a methicillin-susceptible S. 
aureus isolate for which both the European102 and American101 guidelines recommend 








bacteria used strains already resistant to first-line antibiotics. Many infections are not 
dominated by resistant microbes, and Gram– bacteria can have higher resistance profiles 
than Gram+ bacteria106. This choice could be influenced by media coverage, strain 
access or geographic location. All articles using vancomycin and methicillin-resistant 
microbes originated from China, which has high levels of reported antimicrobial 
resistance106. 
 
A few groups performed sonobactericide using non-antimicrobial therapeutics. One 
paper used recombinant tissue plasminogen activator (rt-PA), a clinically approved 
fibrinolytic agent, in combination with the antibiotic oxacillin68. Two articles 
investigated gene transfection of plasmid DNA into planktonic bacteria107,108. The 
microbubble-mediated accumulation of bone marrow mesenchymal stem cells, which 
can suppress inflammation, was investigated as a treatment for chronic bacterial 
prostatitis109. Although the majority of sonobactericide studies paired their treatments 
with therapeutics, 5 (19%) focused directly on the mechanical and biological effects 
resulting from ultrasound and microbubbles alone53,63,64,86,110. 
 
Many of the in vitro studies were performed in polystyrene tissue culture well-plates, 
ranging from 96- to 6-well plates, for both planktonic and biofilm studies (10 studies, 
37%; Table 2.1). To the well-plates, Zhu et al.65 added a 10-mm diameter titanium plate 
(1 mm thick); Guo et al.111 a 13-mm glass coverslip; Fu et al.69 a 12-mm glass coverslip; 
and Nishikawa et al.110 a polystyrene disk (dimensions not provided). Two studies also 
cultured biofilm in a FluoroDish, a 35-mm dish containing a 23.5-mm glass window67,112. 
The geometry of both these containers could result in the reflection of ultrasound at the 
bottom of the well and at the medium–air interface. As a result, constructive and 
deconstructive interference leading to standing waves could have occurred113. Standing 
waves may also form within the body, especially in the presence of bone114. Microbubbles 
may aggregate at the nodes of a standing wave115. Increases in in situ acoustic pressure 
caused by constructive interference can cause unwanted bio-effects mediated by 
inertial cavitation116,117. The presence of standing waves produces acoustic field 
variations that are sensitive to changes in transducer position, excitation frequency or 
temperature118. The acoustic intensity of the ultrasound field is proportional to the 
square of the pressure amplitude when the ultrasound wavelength is much smaller than the 
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transducer aperture119. Under the plane wave approximation, the acoustic pressure is 
related to the intensity as follows: I = P2/2pc, where P is the peak acoustic pressure, p is 
the density and c is the speed of sound120. For traveling waves, the intensity is a function 
of time; that is, once the wave has passed a given spatial location, the intensity drops to 
zero. However, for standing waves, the peak intensity at a spatial location remains 
constant over time. Effects of standing wave formation during insonation of cells in 
different holders have previously been investigated in detail121. 
 
Measurement of in situ acoustic parameters is critical to understanding treatment effects, 
correlating the treatment effects to specific outcomes and translating these to an in vivo 
setting122. Only 5 sonobactericide studies reported calibrating the output in situ53,62,63,68,70. 
The lack of standardization of exposure setups makes it difficult to compare the results 
in the literature. Reporting spatial maps of the acoustic field in situ could help improve 
the reproducibility and interpretation of in vitro studies between groups122. 
 
In the well-plates and FluorDishes, cavitation nuclei were administered once for 
treatment times varying from 20 s to 10 min (see Table 2.1), with the exception of one 
study in which fresh microbubbles were administered every 4 h for 24 h104. It is unclear 
whether microbubbles were still present beyond a few minutes during insonification 
because of destruction or dissolution. For example, Mannaris and Averkiou123 reported 
that SonoVue microbubbles, insonified in vitro for 20 ms at 1 MHz using 10 cycle pulses 
at a pulse repetition frequency (PRF) of 100 Hz, were destroyed and/or dissolved after 
only a few pulses at 400 kPa acoustic pressure, whereas microbubbles were still present 
after all pulses at an acoustic pressure of 100 kPa. In addition, pulses longer than 100 
cycles at acoustic pressures >0.4 did not give any added benefit in terms of microbubble 
oscillation. One group used the OptiCell cell culture system for their biofilm 
experiments124,125, which consists of two gas-permeable, thin (75 µm) polystyrene 
membranes, spaced parallel and 2 mm apart, providing 50 cm2 area of cell culture. 
Microbubbles were administered once for a 5 min treatment (0.3 or 1 MHz, 0.12 MPa, 
50% duty cycle) period. 
 
Several groups used a less commercial in vitro setup. Goh et al.53 used an acetate film 







ultrasound (250 kHz or 1 MHz, 0.1–1 MPa, 50-µs pulse) transducer positioned below. 
One coverslip had a biofilm, such that the microbubbles were either floating beneath 
the biofilm or optically trapped at varying distances from the side. Lattwein et al.68 
performed sonobactericide under plasma flow (0.65 mL/min) on biofilms grown 
statically on human whole blood clots placed in glass capillaries (2.15-mm inner 
diameter). Microbubbles were continuously infused, and ultrasound (120 kHz, 0.44 
MPa, continuous wave, 50 s on 30 s off) was applied intermittently for 30 min. Ronan 
et al.62 grew biofilms in a cylindrical flow cell (17 mL/h) with an acoustically transparent 
membrane on one side and a glass coverslip on the other, and flow was halted to perform 
sonobactericide (0.5 MHz, 1.1 MPa, 16-cycle tone burst, PRF = 1 kHz) for 5 min, with 
microbubbles administered once. Flow was also used by Tandiono et al.63 to treat 
planktonic bacteria in a microfluidic system composed of polydimethylsiloxane-made 
channels. In humans, biofilms can develop in variable fluid flow environments 
depending on the location or under static conditions. Biofilms are highly sensitive to 
these different conditions126. Thus, selection of the appropriate static or flow condition 
setting should be tailored to the specific aimed application, such as superficial skin 
wound or intravascular device infections. 
 
For dental application, Halford et al.93 grew biofilms in the root canal (12 mm length) 
of single-rooted extracted human teeth under constant agitation (120 rpm). 
Microbubbles were delivered into canals and insonified with a P5 Newtron dental 
ultrasonic hand piece (28 to 36 kHz ultrasound) for 1 min. Horsley et al.70 employed a 
bladder organoid model using a modified acoustically compatible chamber127. Briefly, a 
polycarbonate filter insert (12 mm diameter) cultured with infected human bladder cells 
was fixed between an Ibidi culture dish (35 mm) and a polydimethylsiloxane lid. 
Cavitation nuclei were added, and the dish and lid were coupled and then insonified (1.1 
MHz, 2.5 MPa, 5500 cycles, 20 ms pulse duration) for 20 s. Other in vitro experimental 
setups were on nylon membranes (47 mm diameter, pore size = 0.2 µm) and in 
centrifuge tubes (2 and 5 mL) (Table 2.1). Nylon membrane biofilms were treated in a 
beaker placed in a sonicator (0.042 MHz, on for 2 s every 2 min) while microbubbles 
were continuously introduced for 15 min64. The planktonic bacteria in tubes were treated 
(1 MHz, 500 W/cm2, 2% duty cycle) for 5 min86 or 12 h (0.0465 MHz, 0.01 W/cm2, 33% 
duty cycle)128 and in Eppendorf tubes (1 MHz, 1–3 W/cm2, 50% duty cycle) for 1 min94, 
all with a one-time administration of microbubbles. 
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Three in vitro studies were followed up with a corresponding in vivo study in the same 
article94,104,112. Thirty percent of the articles on sonobactericide (8/27) have investigated 
therapeutic efficacy in pre-clinical animal models (Table 2.1). Four groups chose to 
emulate implanted medical device infections using subcutaneous implants, near the 
spine, with biofilm grown on catheter pieces or polyethylene disks in rabbits112,129 and 
titanium plates in mice66,95. Microbubbles were injected subcutaneously into the implant 
area before ultrasound. For each of the three ultrasound exposures (20 min) per day, He 
et al.112 injected 200 µL of microbubbles (2 × 108 to 5 × 108/mL) every 5 min, and 
both Li et al.66 and Zhou et al.95 injected 30 µL once, 2 × 108 to 5 × 108/mL and 
concentration not disclosed, respectively. Dong et al.129 applied ultrasound twice a day 
for 5 min, and injected 500 µl (1.2 × 109/mL diluted to 1% v/v) each time. All studies 
used a 50% duty cycle. However, acoustic parameters, treatment intervals and duration 
times varied (Table 2.1). 
 
Lin et al.104 investigated the ability of sonobactericide to increase the elution rate of 
antibiotics from vancomycin-loaded bone cement in a periprosthetic infection rabbit 
tibia model. Ultrasound (1 MHz, 0.3 W/cm2, 30% duty cycle) was applied 
transcutaneously for 24 h, and microbubbles (2 × 108 to 5 × 108/mL) were injected into 
the same space as the S. aureus bacteria at four time points. Surrounding tissues were 
evaluated directly after treatment. For chronic bacterial prostatitis modeled in rats, Yi 
et al.109 used sonobactericide to induce accumulation of bone marrow mesenchymal stem 
cells to reduce inflammatory reactions and resolve infection. After 4 wk of infection 
induction with E. coli, microbubbles (0.1 mL/kg) were directly injected into prostates 
and insonified (1 MHz, 0.5 MPa, 1% duty cycle) for 5 min. Afterward, stems cells 
(1 × 107) were administered intravenously, and therapeutic effectiveness was evaluated 
after 24 h and 2 wk. 
 
Another study focused on harnessing sonobactericide in a model of severe bacterial 
pneumonia with the goal of enhancing antibiotic delivery to infected lung tissue in 
mice105. E. coli were administered intratracheally, and 6 h later gentamicin was injected 
intraperitoneally. After 30 min, microbubbles (1 × 109) were intravenously 
administered and ultrasound (1.3 MHz, 0.9–1.2 MPa, pulse every 5 s; pulse duration 








evaluated at 30 min and 2 h, respectively, after ultrasound application. Liao et al.94 also 
used mice and aimed to improve acne vulgaris treatment using transdermal 
sonobactericide with lysozyme-shelled microbubbles. Ears were infected intradermally 
with Propionibacterium acnes. Gel loaded with lysozyme microbubbles was placed on top 
of the infected area and insonified (1 MHz, 3 W/cm2, 50% duty cycle) daily for 1 min. 
Effectiveness was assessed at several time points during the 13 d of treatment. 
 
 
Figure 2.3. Bright-field micrographs of in vitro-produced Staphylococcus aureus-infected clots after 
30-min treatment with (a) plasma alone; (b) plasma, recombinant tissue plasminogen activator 
(rt-PA, thrombolytic) and oxacillin (antibiotic); and (c) plasma, rt-PA, oxacillin, ultrasound and 
Definity (microbubble). The black arrow in image (a) indicates the biofilm (beige). The thick black 
line, seen in all images and denoted by a white arrow in image (a), is the suture to which the 
respective infected clots were adhered. Ultrasound parameters were 0.12 MHz and 0.44 MPa peak-
to-peak pressure, intermittent (50 s on, 30 s off) continuous waves for 30 minutes. Adapted, with 






Various techniques were used for assessing sonobactericide efficacy. The colony-
forming unit plate-counting method was utilized to determine antimicrobial efficacy 
(14/27, 52%), for some in vitro and all except one in vivo study109. Bacterial plating is 
relatively easy to perform and considered the “gold standard” for determining viable 
bacteria counts. This technique, however, is widely known to underestimate the 
absolute number of bacteria. Another potential limitation is that often to obtain post-
treatment samples, biofilms have been mechanically disrupted, scraped, centrifuged, 
digested, vortexed or sonicated, which might have induced microbial alterations. Several 
articles employed histopathologic staining, either crystal violet or hematoxylin and xeosin, 
to observe bacterial morphology (macroscopy and light microscopy), quantify biofilm 
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Figure 4. Bright-field light microscopy imaging of infected clots acquired directly following treatment. Infected 
clot treated only with plasma at 4x (a) and at 10x magnification (b). The black arrow in image b points out the 
biofilm (beige). (c) A plasma, rt-PA, and oxacillin treated infected clot at 4x magnification. (d) A plasma, rt-PA, 
oxacillin, ultrasound, and Definity treated infected clot at 4x magnification. The sutures (black line) are situated 
at the bottom of the clots, which can be observed to the right of the clot in images a–c.
Figure 5. The ultraharmonic (a) and broadband (b) cavitation energy detected by the passive cavitation 
detector in response to 120-kHz ultrasound insonification. Boxes represent the interquartile range. The lines 
within the boxes represent the median and the whiskers indicate 1.5 times the interquartile range. Black 
circles depict outliers as determined using the Tukey method. A single asterisk (p < 0.05) above a dashed line 
represents a statistically significant difference between the ultraharmonic and broadband energies of the same 
treatment group. Two asterisks (p < 0.01) represent a statistically significant difference of ultraharmonic energy 
between the group and the ultrasound without Definity groups. The different treatment conditions are given in 
the table below the graph.
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density by absorbance levels in a microplate reader or compare inflammatory effects over 
time. This method can be used for high-throughput screening, but it does not 
discriminate between live and dead cells. Immunohistochemistry was used by Yi et al.109 
to quantify inflammatory cytokine expression and distribution. Agarwal et al.64 
desiccated their mixed species biofilms to determine fixed biomass for overall density 
quantification and also, albeit with additional steps, for extracellular protein and 
polysaccharide content. 
 
Several microscopic techniques were utilized for visualization of treatment, including 
light, epifluorescence, confocal laser scanning and transmission and scanning electron 
microscopy. Light microscopy was combined with or without time-lapse and high-speed 
camera observations53,63,68,93; see Figure 2.3 for a light microscopy example. Fluorescence 
detection, with either a widefield or a confocal microscope, was the most frequently 
utilized optical imaging modality for qualitative and quantitative visualization of live 
and fixed cell populations (16/27, 59%). These images can provide information not only 
on viability, but also biomass, average biofilm thickness and structural heterogeneity. 
Live/dead nucleic acid staining with Syto 9 (viable cells) and propidium iodide (dead or 
membrane-disrupted cells) were often used and the cells were observed with confocal 
microscopy (Fig. 2.4) to assess biofilm populations. Note that biofilm nucleic acid 
fluorescence signals might not only indicate a single bacterium, but also extracellular 
DNA found throughout many biofilms130. To investigate biofilm compositional changes, 
extracellular proteins were stained with fluorescein isothiocyanate (FITC), lipids with 
Nile red and α- and β-polysaccharides with lectin concanavalin A conjugated with 
tetramethyl rhodamine and fluorescence brightener, respectively64. These 
polysaccharides (α, β) can also be visualized with FITC-conjugated lectin concanavalin 
A and wheat germ agglutinin45. Scanning and transmission electron microscopy was 
used for post-treatment ultrastructural observations of planktonic bacteria and biofilm 
morphology (10/27; 37%). Scanning electron microscopy (Fig. 2.5) was also used to 
complement confocal findings65,66,95,111,124,129. For transmission microscopy, sample 
preparation of biofilms required removal from culture plate; thus, the biofilms were 













Figure 2.4. Confocal laser scanning micrographs of in vitro, propidium iodide (red)-stained, 
Pseudomonas aeruginosa PAO1:gfp-2 biofilms after treatment with (a) nothing (control); (b) 
ultrasound and Definity (microbubbles); (c) gentamicin (antibiotic) alone; and (d) gentamicin, 
ultrasound and Definity. Top: Top-down maximum intensity projection. Bottom: Corresponding 
3-SD volume rendering. Ultrasound parameters were 0.5 MHz at 1.1 MPa peak negative pressure 
with a 16-cycle tone burst and pulse repetition frequency of 1 kHz for 5 min. Reprinted, with 
permission, from Ronan et al.62. 
 
 
Genetic testing was performed in 7 studies, using the polymerase chain reaction (PCR) 
method63,65,66,95,96,107-109,125. PCR was used to investigate the impact of sonobactericide on 
(i) the expression of genes65,66,95,125 and mRNA109; (ii) the successful incorporation of a 
gene107,108; and (iii) the status of genes up- and downstream after incorporation108. PCR 
was also used to quantify intracellular DNA released into the supernatant after 
treatment, which provided an indication of disrupted (lysed) cells63. With respect to its 
advantages, PCR is not technically demanding and is fast and highly sensitive. High 
sensitivity is also a disadvantage concerning contamination; in addition, the specific 
target of interest must already be known, and caution should be taken in interpreting 
the results because of the potential for extracellular DNA released from bacteria not 
triggered by lysis. Two studies investigating intracellularly infected mammalian cells 
evaluated cytotoxicity in response to therapy using a trypan blue exclusion test92 and a 






The most profound changes in biofilm structure and morphol-
ogy occurred as a result of the combined gentamicin and USMB
exposures. When USMB was initiated concurrently during a
gentamicin challenge, large portions of the biofilm were removed
and the underlying attachment substratum became visible
(Fig. 4D). A statistically significant reduction occurred in overall
Fig. 4. Confocal laser scanning micrographs of PI-stained Pseudomonas aeruginosa PAO1:gfp-2 biofilms. Biofilms were subjected to either no treatment (A), USMB alone (B),
gentamicin alone (C), or concurrent treatments of gentamicin and USMB (D). For each type of treatment, a top-down maximum intensity projection as well as a three-
dimensional volume rendering is shown.
Fig. 5. Measurements of structural biofilm parameters was carried out on P. aeruginosa PAO1:gfp-2 biofilms prior to and immediately following exposure to individual or
combined USMB and gentamicin treatments. Each parameter was calculated as the average of ten replicate microscope fields per biofilm, and post-exposure measurements
were normalized to the pre-treatment averages. Error bars represent the normalized standard deviations among the replicate measurements. A single asterisk represents a
significant difference between pre-and post-exposure measurements within one treatment (p < 0.05), while a double asterisk represents a significant difference between
post-exposure measurements from different treatments (p < 0.05).










Changes in biofilm metabolism, in response to different treatments, were measured by 
confocal imaging with 5-cyano-2,3-ditolyltetrazolium chloride dye67, a CO2-evolution 
monitoring system62 or an absorbance-based resazurin assay69,111. Although investigation 
of cellular metabolism provides an indication of the overall bio-effect, the growth rate, 
biomass, cell viability and persister development could not be specified. Vollmer et al.86 
and Yi et al.109 used bioluminescence as an indicator of bacterial cell stress responses 
and the distribution of stem cells in rats, respectively. Besides using fluorophore 
internalization, one group used a fluorescence polarization immunoassay to determine 
the amount of vancomycin eluted from bone cement after in vitro treatments104. An 
enzyme-linked immunosorbent assay was also used after treatments to determine levels 
of gentamicin105 and inflammatory cytokines109 in tissue. Both immunoassays are highly 
specific, even in samples with protein content such as serum131,132, and are commercially 







Figure 2.5. Scanning electron micrographs of Staphylococcus epidermidis biofilms from catheters 
subcutaneously implanted in rabbits following treatment with (a) nothing (control); (b) 
ultrasound and custom-made microbubbles; (c) vancomycin (antibiotic) alone; and (d) 
vancomycin, ultrasound and custom-made microbubbles. Original magnification: × 2000. 
Ultrasound parameters were 0.3 MHz and 0.5 W/cm2 (or 0.12 MPa) with a 50% duty cycle for a 

















Cavitation Nuclei for Sonobactericide 
avitation nuclei are a key part of sonobactericide because their volumetric 
changes in response to an ultrasound field induce bio-effects. From the 
commercially available cavitation nuclei, SonoVue was used most often (8 studies, 
30%). SonoVue (available as Lumason in the United States, approved by the U.S. Food 
and Drug Administration [FDA] in 2016) consists of SF6 gas microbubbles (mean 
diameter: 1.5–2.5 µm, ≥99% of microbubbles ≤10 µm) stabilized by a lipid coating133. 
SonoVue/Lumason is approved for clinical diagnostic use in several countries 
worldwide134. Other commercially available lipid-coated microbubbles have also been 
used for sonobactericide studies, namely, Definity (4 studies, 15%, (octafluoropropane 
(C3F8) gas core; mean diameter 1.1–3.3 µm; 98% of microbubbles <10 µm) (Definity 
2011) and Sonazoid (1 study, 4%, C4F10 gas core; mean diameter 2.1 µm± 0.1; <0.1% 
of microbubbles larger than 7 µm)135. Definity and Sonazoid are approved for clinical 
diagnostic use in several countries worldwide134. Note that Albunex, used by Vollmer et 
al.86, was the first commercially available ultrasound contrast agent (in 1992), with a 
mean microbubble diameter of 3.8 µm (98.8% of microbubbles <10 µm), an air core 
and a human albumin coating136. However, Albunex is no longer available137. Optison is 
another human albumin-coated microbubble (C3F8 gas core, mean diameter: 3.0–4.5 µm; 
95% of microbubbles <10 µm; FDA approved in 2012) and approved for clinical use in 
the United States and Europe. Vollmer et al.86 also used custom-made microbubbles 
(ST68, mean diameter: 3.8 µm, air core, coating mixture of surfactants Span 60 and 
Tween 80138) in their study.  
 
The advantage of using commercially available cavitation nuclei is that their response to 
ultrasound has been thoroughly characterized139-145. In addition, these cavitation nuclei 
are sterile with minimal batch-to-batch variability. On the other hand, custom-made 
cavitation nuclei as used in 11 of the sonobactericide studies can offer advantages, such 
as targeting by incorporating a ligand in the coating and drug loading. 
 
Although there are several types of targeted microbubbles for ultrasound molecular 
imaging and drug-loaded microbubbles for ultrasound-mediated drug delivery, or a 
combination thereof35-37, so far only one study has employed microbubbles targeted to 








a lectin from P. aeruginosa for ultrasound molecular imaging45. These targeted 
microbubbles were found to bind to the biofilm matrix in proportion to the surface area. 
 
A few studies have reported on drug-loaded microbubbles or droplets for treatment of 
bacterial biofilms. Horsley et al.70 conjugated custom-made gentamicin-loaded liposomes 
onto microbubbles (ratio 1:5) using biotin–avidin bridging (mean diameter: 5.79 ± 1.53 
µm). The microbubbles had a gas core of SF6 and the lipid coating consisted of 1,2-
distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-carboxy(poly-ethylene glycol) (DSPE-PEG(2000)), DSPE-PEG-
biotin and 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B 
sulfonyl) (ammonium salt) (Rod-PE) in a molar ratio of 79.5:10:10:0.5. The protein 
lysozyme was used as the drug and also formed the coating of microbubbles. One study 
custom-made these microbubbles with an air gas core (mean diameter of 4 ± 1 or 6 ± 2 
µm, depending on the duration of protein denaturation: 15 and 2 min, respectively)46,48, 
and another used C3F8 (mean diameter: 2.5–2.9 µm, depending on the sonication power)94. 
Lysozyme-coated microbubbles loaded with either spherical bovine serum albumin-coated 
gold nanoparticles (4.5 nm in diameter) or polyvinylpyrrolidone-coated gold nanoparticles 
(15 nm in diameter) were also produced by Cavalieri et al.47. Both types of gold 
nanoparticles had no effect on microbubble size distribution or stability. Mahalingam et 
al.49 produced poly(vinyl alcohol)-lysozyme-coated microbubbles (10–250 µm, nitrogen 
gas core) loaded with gold nanoparticles (average diameter: ∼10 nm). These microbubbles 
were more stable when they contained gold nanoparticles than without them, which is in 
contrast to what Cavalieri et al.47 found. The difference in the type of coating or 
microbubble size could be the reason for the difference in stability. 
 
Nanodroplets that can be phase-transitioned into microbubbles using ultrasound, a 
phenomenon known as acoustic droplet vaporization146,147, have been loaded with the 
antibiotic vancomycin by Argenziano et al.50. The nanodroplets (average diameter ∼300 
nm) had a core of perfluoropentane and shell of lipid and dextran sulfate to which the 
vancomycin was coupled by electrostatic interaction. The authors sterilized their 
formulation using ultraviolet light. The nanodroplets (mean diameter: 309 nm) made 
by Guo et al.111 consisted of a core of perfluoropentane and a coating of lipids. 
Microbubbles (mean diameter: 1.5 µm) containing a C3F8 gas core and coating of the same 






Four groups produced custom microbubbles for co-administration with an 
antibiotic92,124,125,129, an antibiotic encapsulated in a liposome69 or stem cells109,124,125,129 
produced lipid-coated microbubbles with a gas core of C3F8 and diameter of 4–6 µm. The 
coating consisted of the lipids DSPC and 1,2-dipalmitoyl-sn-glycerol-3-phosphate-
ethanolamine at a molar ratio of 66:34. The microbubbles were sterilized by 60Co 
irradiation. Ikeda-Dantsuji et al.92 produced microbubbles (∼1 µm) encapsulating C3F8 
gas and coated with DSPC and DSPE-PEG(2000), at a molar ratio of 94:6. Microbubbles 
(mean diameter: 2.39 ± 0.05 µm) with a coating of 1,2-dipalmitoyl-sn-glycero-3-
phosphocholine, DSPE and cholesterol, mass ratio of 10:4:1 and a C3F8 gas core were 
produced by Fu et al.69. A thorough characterization of the response of these 
microbubbles to ultrasound was not reported in these publications. The lipid-coated 
microbubbles (1,2-dipalmitoyl-sn-glycero-3-phosphoglycerol, DSPC and PEG4000 at a 
mass ratio of 30:30:3000 w/w) with a C3F8 gas core (mean: 2 µm) made by Yi et al.109 
were compared with SonoVue for liver imaging148. Enhancement was similar but 
persisted longer (still present 6 min 30 s after injection) for these custom-made 
microbubbles. 
 
In the study by Halford et al.93, microbubbles were produced during ultrasound 
treatment (28–36 kHz) from a solution containing perfluorodecahydronaphthalene as 
oxygen carrier; 30% hydrogen peroxide, or H2O2, as oxidizer; and the non-ionic 
detergent surfactant Triton X-100 as shell stabilizer. The figure of the formed 
microbubbles indicates microbubble diameters on the order of 200 µm. Non-coated 
microbubbles were also produced during ultrasound treatment (130 kHz) in the study 
by Tandiono et al.63. In another study, non-coated microbubbles with a mean size of 5–
10 µm were produced with a microbubble generator64. No specifics on the gas core and 
microbubble coating were provided. 
 
The synergy between microbubbles and ultrasound exposure parameters is important 
for sonobactericide because the radial pulsation of microbubbles may increase the 
“footprint” of bactericidal action and reduce treatment times. The oscillation of each 
microbubble depends highly on its resonance behavior, that is, the ultrasound frequency  
at which the amplitude of oscillation is largest. In general, the resonance frequency is 
inversely related to the microbubble diameter, but the properties of the microbubble 
coating also play a role as rigid microbubble coatings increase the resonance frequency36,149.  
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Interestingly, 78% (21/27) of sonobactericide studies used lipid-coated microbubbles 
(see Table 2.1). A small fraction of the commercially available microbubbles are resonant 
for a particular insonification scheme because of the polydisperse population150. 
Different ultrasound center frequencies were used for sonobactericide, including 
frequencies used in clinical diagnostic imaging (1 MHz, 13 studies, and 1.3 MHz, 1 
study; see Table 2.1). At these frequencies, only a subpopulation of the microbubbles 
are expected to oscillate in resonant modes. The ultrasound frequency employed in the 
other studies was lower, namely, 500 kHz (1 study), on the order of 300 kHz (4 studies), 
120–130 kHz (2 studies) or between 28 and 80 kHz (7 studies). For these very low 
ultrasound frequencies, only microbubbles substantially larger than 10 µm in diameter 
would have been at resonance. Gas from the microbubbles was likely liberated and 
coalesced and grew by rectified diffusion in the acoustic field until the microbubbles 
reached resonant size151,152. Another important consideration for microbubble oscillation 
is the viscosity of the surrounding medium and confinement because oscillations are 
damped when the viscosity increases or when microbubbles are confined36. For the in 
vivo studies, the microbubbles were confined in tissue as a result of injection into the 
area of the implanted catheter129, dish112, titanium plate66 or tibial canal104. It appears 










ll sonobactericide studies have reported an enhanced effect beyond that of 
antibiotics alone. The goal of all of these studies was proof-of-principle and the 
approaches used generally differed. Directly comparing these 27 articles is difficult 
because of the large variability between them. Differences between the groups include 
the bacteria used and the different growth conditions, ultrasound parameters, cavitation 
nuclei and experimental setups. Nevertheless, this section aims to provide a discussion 
and make general comparisons between the experimental outcomes. 
 
Ultrasound interacts with tissue by heating153, radiation force154 and cavitation-based 
mechanism155,156. Heating and radiation force could enhance the effect of antibiotics157, 
increasing membrane permeability158 and cell detachment, respectively. Cavitation is an 
important mechanism for sonobactericide. Stable cavitation involves gentle oscillations 
of microbubbles159, and inertial cavitation denotes the rapid growth and rapid collapse 
of microbubbles160. The acoustic pressure required to initiate inertial cavitation can be 
higher than the pressure required for stable cavitation159 and also depends on fluid 
properties and the cavitation nuclei161. Inertial cavitation forms microjets that can 
damage or deform the biofilms53. Administration of cavitation nuclei can reduce the 
cavitation threshold159. 
 
When microbubbles oscillate in an ultrasound field, fluid flow is generated around the 
microbubbles149,162. This phenomenon is known as microstreaming. The effects of 
microstreaming are prominent when the oscillating bubble is located near a boundary 
and when it is excited at resonance149. Microstreaming can cause bio-effects by 
promoting fluid transport and producing shear stresses on cells163. Microbubble 
destruction in response to ultrasound can occur through either acoustically driven 
diffusion or microbubble fragmentation164. Fragmentation in response to ultrasound 
exposure is typically associated with inertial cavitation165 and can produce mechanical 
bio-effects. 
 
Table 2.1 indicates that the majority of sonobactericide studies used one pressure 
amplitude, or acoustic intensity, and one center ultrasound frequency. Four studies 
tested multiple pressures/intensities53,92,94,107, and one employed two frequencies53. 
A 
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Ikeda-Dantsuji et al.92 reported that a higher ultrasound intensity (0.44 W/cm2) further 
increased sonobactericide efficacy above that of doxycycline alone by approximately 
three times that of the lower intensity setting (0.15 W/cm2). However, when another 
antibiotic (ceftizoxime), to which C. trachomatis is resistant, was employed, they found 
that the higher ultrasound intensity only slightly improved the therapeutic efficacy 
further. Liao et al.94 found that higher-intensity insonification (2 and 3 W/cm2) beyond 
1 W/cm2 did not further enhance sonobactericide. Han et al.107 also found that as the 
acoustic pressure increased (0.25, 0.5, >0.9 MPa), delivery of their model drug into 
bacteria correspondingly increased. 
 
Other ultrasound parameters were explored, such as PRF (0–100 Hz), duty cycle (5 and 
50%), concentration of cavitation nuclei (0, 3.3, 10, 33% v/v) and exposure duration (0, 
10, 90, 450 s)107. An increase in efficacy was seen with corresponding increased 
parameters, except PRF, which had no increased effect. As desired, bacterial viability 
was not affected among the parameters tested by Han et al.107 for the creation of an recA-
positive strain of Fusobacterium nucleatum. recA renders bacteria more sensitive to 
ultraviolet light and reportedly repairable sonoporation107. By using similar 
sonobactericide conditions also on planktonic, exponential growth phase, Gram– 
bacteria, albeit with E. coli, Vollmer et al.86 observed bacterial death (up to 49.7 ± 6.2%) 
and activation of stress-response genes. 
 
Goh et al.53 used high-speed optical imaging to investigate the impact of cavitating 
microbubbles on biofilm surfaces. At 0.1 MPa (1 MHz, 50-µs pulse), microbubble 
oscillation was reported to be small, and caused minimal biofilm disruption. At a higher 
pressure (0.7 MPa, 1 MHz, 50-µs pulse), a 7.4-µm SonoVue microbubble had an 
extremely large radial excursion (Rmax = 27.3 µm) with a liquid jet within that led to 
mechanical dislodgement of the bacteria from the biofilm. The direction of a jet with 
respect to the surface of the biofilm depends on the elasticity of the surface166. 
Accordingly, jet formation can create substantial shear force leading to either an 
indentation or an invagination of the surface167,168. Although Goh et al.53 used two 
ultrasound frequencies (0.25 and 1 MHz), they applied each frequency in a different 
setup (biofilm horizontally or vertically positioned). Therefore, the effects of the 







and the distance between the biofilm surface and the cavitating microbubbles affected 
the efficacy of biofilm disruption. Ultrasound alone did not disrupt the biofilm structure. 
As the initial distance between the microbubble and the biofilm increased, the 
disruption efficacy decreased. This observation provides support for the use of biofilm-
targeted microbubbles to increase the efficacy of sonobactericide. 
 
Ronan et al.62 also described biofilm disruption, in the form of craters, after ultrasound 
and microbubble exposure without antibiotics (Fig. 2.4). If bacteria are forcibly released 
from biofilms by microbubble oscillations, as suggested by several studies including 
Ronan et al.62 and Goh et al.53, then the viability and status of these dispersed cells after 
treatment need to be assessed. Sonobactericide could be combined with current 
“traditional” or other new antimicrobials to reduce the spread of or eliminate altogether 
transitional dispersed cells that may be more virulent. Planktonic bacteria are often 
sensitive to antibiotics at much lower concentrations than are the same bacteria in 
biofilms169. Thus, liberation of bacteria into the bloodstream after sonobactericide is not 
necessarily anticipated to pose additional risks. 
 
Inertial cavitation caused by ultrasound-mediated microbubble destruction can produce 
defects in the biofilm matrix, aiding the penetration of antibiotics112. Microbubbles and 
ultrasound exposure have been reported to increase the elution of an antibiotic from 
polymethylmethacrylate cement and increase the efficacy of bactericidal treatment in 
vitro and in vivo104. Ultrasound-mediated microbubble destruction can also increase the 
metabolic activity of the bacteria in the biofilm, making it responsive to treatment with 
antibiotics67. However, Ronan et al.62 reported a decrease in biofilm metabolism, by 
analyzing carbon dioxide production, after either antibiotic alone or antibiotic combined 
with ultrasound and microbubbles. Because of the experimental setup, it could not be 
definitively determined if the decrease was from growth rate or biofilm mass reduction, 
and is speculated to be both. Although bacteria can develop resistance to antimicrobials 
over time through genetic alterations, ultrasound acts without allowing these organisms 
to adapt to the physical stresses86. Additionally, Zhou et al.95 found in vivo that 
expression of the MecA gene responsible for encoding resistance to β-lactam antibiotics 
in MRSA was significantly reduced in the sonobactericide group with human β-defensin 
3, more than twice that of the antimicrobial alone. 
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It has been postulated that bacterial cells could be more susceptible to sonobactericide 
because of their rigid cell membranes, which contrasts with the compliant phospholipid 
bilayers of mammalian cells that may resist rupture owing to ultrasound exposure170. 
When ultrasound is combined with cavitation nuclei and an antibiotic, sonobactericide 
efficacy can be enhanced, as illustrated by the in vitro and in vivo studies in this review. 
For example, in vitro studies reported by Dong et al.124 utilized Sonovue and reduced 
colony-forming units of S. epidermidis eightfold relative to treatment with vancomycin 
and ultrasound (1-MHz frequency, 0.5-W/cm2 intensity, 50% duty cycle, 5 min). In in 
vivo studies, findings of enhanced bacterial killing when sonobactericide included an 
antimicrobial were also reported; for example, Sugiyama et al.105 observed an almost 1-
log reduction in colony-forming units compared with all controls. Sonobactericide could 
produce equivalent therapeutic effects at a lower antibiotic dose, which may reduce 
complications associated with systemic toxicity, especially renal and liver complications. 
Sonobactericide may increase antibiotic (and other therapeutics) cytotoxicity; Horsley 
et al.70 reported higher toxicity in human urothelial cells with ultrasound-exposed 
solutions of microbubbles coated with liposomes containing gentamicin at 2.64 and 5.28 
µg/mL than free gentamicin at the much higher clinically approved dosage (200 µg/mL). 
This finding highlights that cytotoxicity should be more widely considered as a 
sonobactericide test parameter in future studies. 
 
In addition to Han et al.107, the microbubble dose dependence of sonobactericide has 
been investigated by three other groups that found an increase in the efficacy of 
sonobactericide with increasing concentration of microbubbles 92,124,125, indicating dose-
dependent synergy. Only Han et al.107 used more than two concentrations, with which a 
near-linear trend between microbubble concentration and treatment efficacy could be 
observed. A similar increase in bio-effects with increasing microbubble concentration 
has been reported for sonoporation of eukaryotic cells171 and blood–brain barrier 
disruption172. Increasing the antibiotic concentration also resulted in an increasing dose–
effect relationship for all treatments of Acinetobacter baumannii, including microbubbles 
combined with free polymyxin B and microbubbles combined with free chitosan-
modified polymyxin B-loaded liposomes69. Horsley et al.70 increased both antibiotic and 
microbubble concentrations, because gentamicin was encapsulated on liposomes bound 







The “in vial” concentration of Definity is 4.2 × 109 microbubbles/mL, that of Albunex 
7 × 108 microbubbles/mL173 and that of SonoVue/Lumason 3.0 × 108 to 1.1 × 109 
microbubbles/mL. Assuming a blood volume of 5 L in an average human, the in vivo 
concentrations for Definity, Albunex and Lumason correspond to 8.4 × 105/mL, 
1.4 × 105/mL and 6 × 104 to 2.2 × 105/mL, respectively. Several sonobactericide studies 
reported thus far have used high concentrations of microbubbles (107 to 108/mL) both 
in vitro67,86,124,125 and in vivo66,112,129, relative to the concentrations currently used in clinical 
diagnostic imaging. This approach could potentially be employed in non-vascular 
applications such as dental, skin wound and implant biofilms66,112,129. Furthermore, pre-
clinical studies in both small animal and rodent models suggest that high concentrations 
of microbubbles administered intravenously, up to 250 times higher than the clinical 
dose, may be well tolerated133. Although in vitro studies have indicated that large 
microbubbles (∼0.3 mm) can destroy biofilms under flow by microbubble collision174,175, 
this mechanism is unlikely to occur for microbubbles of clinically relevant sizes for 
vascular applications (i.e., 1–10 µm). 
 
Five studies used custom-made lysozyme-coated microbubbles in the absence of 
ultrasound46-49,51. These exhibited antimicrobial properties on Micrococcus lysodeikticus, S. 
aureus and E. coli. Lysozyme-coated microbubbles, or poly(vinyl alcohol)-lysozyme-
coated microbubbles, loaded with gold nanoparticles were found to have a stronger 
antimicrobial effect than non-loaded microbubbles on planktonic Micrococcus 
lysodeikticus47 and E. coli49. The coated gold nanoparticles alone lacked lytic activity in the 
Cavalieri study, and thus the authors attributed the enhanced antimicrobial effect of the 
gold nanoparticles loaded on the lysozyme microbubbles to improved binding and, 
consequently, increased interaction of the bacteria with the surface of the lysozyme-
microbubbles. Contrarily, gold nanoparticles alone had an antibacterial rate of ∼50% at 
3 h in the Mahalingam et al.49 study. The difference in antibacterial activity of gold 
nanoparticles could be explained by the different bacteria employed. Combining these 
lysozyme-coated microbubbles with ultrasound could have further enhanced the 
antimicrobial properties as Liao et al.94 observed when using them in their in vitro and in 
vivo study. Sonobactericide used against P. acnes had an enhanced antibacterial effect and 
resulted in a 1.45-fold reduction in inflammatory reactions relative to lysozyme-coated 
microbubbles alone. Furthermore, after 13 d of treatment, inflammation was no longer 
observed. 
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Vancomycin-loaded nanodroplets50, in the absence of ultrasound, were significantly 
more effective at an earlier time point than vancomycin alone or non-loaded 
nanodroplets alone in killing planktonic MRSA (isolated from human ulcerated 
wounds). The authors attributed their findings to the time-sustained release of 
vancomycin from the loaded nanodroplets. However, the altered charge could also have 
played a role as vancomycin is positively charged and the vancomycin-loaded 
nanodroplets are negatively charged. Ultrasound exposure significantly enhanced 
vancomycin delivery from the loaded nanodroplets ex vivo through non-infected porcine 

































Clinical Translation of Sonobactericide 
iagnostic ultrasound contrast examinations are performed worldwide134, 176-178, 
including for the detection of the metastatic spread of bacterial infective 
endocarditis179,180. Fifteen of the 27 sonobactericide studies (56%) used microbubbles 
that are clinically approved, by the FDA and European Medicines Agency, which could 
help with the translation of sonobactericide into the clinic. Contrarily, sonobactericide 
with custom-made microbubbles containing Triton93 is not translatable because this 
surfactant is toxic to cells181,182. The ideal characteristics of a clinically relevant treatment 
can be broadly described as improved patient outcomes, reduction in treatment times 
and practical implementation in the clinic. More specifically, broad-spectrum 
bactericidal activity, low risk for inducing resistance and minimal mammalian cell 
cytotoxicity could be considered. The reader is referred to two review articles that 
provide conceptional discussions on the ideal antibiotic that could aid sonobactericide 
strategies183,184. The use of clinically relevant animal models of biofilm would help 
translate the development of sonobactericide. For example, Lin et al.104 used a 
periprosthetic infection rabbit tibia model. However, periprosthetic joint infection 
models have limited translational value as described in the review by Carli et al.185. While 
proposing criteria for an optimal animal model, this review stresses the critical 
importance of animal, pathogen, implant and outcome measurement selection and a 
method that replicates the “human” periprosthetic environment, wherein at least one 
of these areas current models fall short. 
 
The choice of ultrasound insonification parameters is important for the clinical 
translation of sonobactericide. A wide frequency range (tens of kilohertz to 1.3 MHz) 
has been reported for sonobactericide (see Table 2.1), along with pulsed70,86,104, 
continuous wave65,69 or intermittent64,68 ultrasound in sonification. More studies directly 
investigating different ultrasound parameters should be performed to better understand 
the effect they have on sonobactericide. The choice of frequency and exposure 
parameters needs to focus on safety, efficacy and compatibility with existing clinical 
workflows for rapid clinical translation. Several in vitro studies have been conducted in 
sonication baths at frequencies ranging from 20–80 kHz65,128, which are likely not 
directly suitable for in vivo applications. Physiotherapy probes66,67,112 and gene transfer 
equipment69,124,125 have also been adapted for sonobactericide studies. Development of 
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of specialized probes may be necessary for treating biofilms that are not easily accessible 
or where a small geometric footprint may be needed. Ultrasonic energy may be delivered 
to infected areas either extracorporeally or using catheter-based ultrasound probes. 
Catheters have been reported previously for sonothrombolysis186,187, and could be 
investigated for sonobactericide in vascular organs. 
 
Microbubble concentration, type and route depend on the location of the biofilm being 
treated. Microbubbles can be delivered intravenously, intra-arterially or by direct 
injection into the site of interest188. When necessary, high concentrations can be 
achieved site-specifically by local infusion of microbubbles. On the other hand, 
delivering microbubbles to biofilm infections associated with prosthetic joints may be 
challenging because the biofilm is typically located within the joint space189. In the case 
of bacterial infective endocarditis, contact between the microbubbles and the biofilm 
may be hampered by rapid pulsatile blood flow. Targeting the microbubbles to the 
biofilm could further aid in therapeutic efficacy. Clinical phase 0 trials have successfully 
been completed for ultrasound molecular imaging of prostate, ovarian and breast cancer 
using targeted microbubbles190,191, thereby paving the way for clinical use of targeted 
microbubbles. The S. aureus biofilm-targeted microbubbles developed by Anastasiadis et 
al.45 lack clinical translation because the P. aeruginosa lectin used as ligand causes red 
blood cell agglutination192, and the protein A antibody used as ligand must compete with 
host antibodies that cover protein A193. For other potential targeting possibilities, the 









Conclusions and Future Perspectives 
herapeutic effects of sonobactericide can include direct bacterial killing, biofilm 
degradation and dispersal and increased or synergistic therapeutic effectiveness 
of antimicrobials or other drugs, all resulting from the physical phenomena of 
ultrasound combined with cavitation nuclei aided by the addition of an antimicrobial 
agent. It is the different time scales at which these actions occur that makes 
sonobactericide challenging, as illustrated in Figure 2.6. The time scale of the 
microbubble vibration is on the order of microseconds in a megahertz ultrasound field, 
which is many orders of magnitude smaller than the time scale of physiologic effects 
(milliseconds), let alone that of biological effects (seconds to minutes) and clinical 
relevance (days to months). The link between, and the mechanistic aspects of, cavitation 
nucleation, the effect on (intracellular) bacteria/biofilms and antimicrobial drug release 
and uptake need to be elucidated in future studies to efficiently treat bacterial infections. 
 
The effect of the biofilm type on sonobactericide efficacy has received limited attention. 
For example, the age and composition of the biofilm196 may contribute to its resilience 
to sonobactericide. The antibiotic penetration through biofilm decreases appreciably 
with the age of the biofilm197. Additionally, biofilms formed in vivo may differ in 
composition and morphology from in vitro biofilm models84. For example, recent 
research has indicated that infective endocarditis can be a polymicrobial infection198. 
These effects should be elucidated in future pre-clinical and clinical studies, as also 
addressed in other reviews199,200. 
 
Nanoscale cavitation nucleating agents such as nanodroplets and polymeric nanocups201 
could be interesting for sonobactericide as they could penetrate the biofilm and help 
nucleate cavitation throughout the biofilm. In particular, the process of droplet 
vaporization may exert mechanical forces on the biofilm in addition to antibiotic activity 
111. Nanodroplets can nucleate sustained cavitation in closed fluid spaces202. Polymeric 
nanocups nucleate inertial cavitation activity with thresholds inversely proportional to 
size. For example, nanocups with mean sizes of 180 and 600 nm have been reported to 
nucleate inertial cavitation at peak rarefactional pressures of 3 and 0.5 MPa, 
respectively201. These agents have not yet been investigated for treating biofilms. Despite 
the potential advantages offered by nanodroplets and nanocups, these agents are not  
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yet clinically approved or readily available. Therefore, sonobactericide using these agents 
may not be clinically feasible in the near future. 
 
Recalcitrant biofilms may be treated with shock waves203,204 or histotripsy205,206. Jetting 
from shock waves has been used in the clinic to destroy kidney stones and gallstones 
with lithotripsy207. Highly focused image-guided ultrasound beams can help concentrate 
acoustic energy at the biofilm site, while avoiding collateral damage. Histotripsy can be 
combined with a cavitation nucleation agent, such as phase-shift nanodroplets208 and 
echogenic liposomes209, to lower the acoustic pressure thresholds for ablation, which 
could potentially improve the safety profile of treatment. Another potential application 
to treat biofilm infections harnessing sound is an ultrasonically activated stream. Birkin 
et al.210 reported that by applying low-amplitude ultrasound (135 kHz, 120–250 kPa) 
through a liquid stream directed at a surface, endogenous cavitation nuclei can be 
sufficiently activated at the solid/liquid interface to disrupt biofilm. 
 
Combining ultrasound, cavitation nuclei and antibiotic therapy with matrix-degrading 
enzymes implicated in biofilm dispersal, such as glycosidases, proteases and 
deoxyribonucleases65,66211, is a promising strategy for treating biofilms. Our group has 
recently reported the use of rtPA, a clinically approved fibrinolytic agent, along with 
Definity microbubbles, an antibiotic and 120-kHz intermittent ultrasound for 
sonobactericide in an in vitro flow model68. This strategy could be promising for treating 
biofilms that have fibrin as a primary structural component. The microstreaming 
produced by cavitation nuclei36 can help remove biofilm degradation products and 
enhance the delivery of drugs, similar to sonothrombolysis studies212. Although the 
feasibility of biofilm dispersal has been reported in previous studies211, more work needs 
to be done to elucidate the efficacy of combination therapy with matrix-degrading 
enzymes, ultrasound and microbubbles. Future research could also include the 
interference of quorum sensing, which is bacterial communication that regulates several 
virulence pathways through signaling molecules and increases with cell density213. 
Because of the high potential of this approach, many compounds are under development 
that could be combined with sonobactericide to enhance efficacy214. In addition, it is 








The safety and efficacy of sonobactericide are paramount. Accurate characterization of 
the acoustic fields122 and parameters used, standardization of protocols for the 
assessment of treatment efficacy and development of in vitro and pre-clinical models that 
mimic the in vivo milieu will help accelerate the transition of sonobactericide to the 
clinic. In addition, enabling image guidance methods, such as active215 or passive 
cavitation imaging216 and real-time feedback217, may help monitor treatment progress, 
standardize the acoustic dose and aid in improving the safety and efficacy of in situ 
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 It’s not what you  
look at that matters,  
it’s what you see. 
- Walden (Life in the Woods),  
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Controlling microbubble-mediated drug delivery requires the underlying biological and 
physical mechanisms to be unraveled. To image both microbubble oscillation upon 
ultrasound insonification and the resulting cellular response, we developed an optical 
imaging system that can achieve the necessary nanosecond temporal and nanometer 
spatial resolutions. We coupled the Brandaris 128 ultra-high-speed camera (up to 25 
million frames per second) to a custom-built Nikon A1R+ confocal microscope. The 
unique capabilities of this combined system are demonstrated with three experiments 
showing microbubble oscillation leading to either endothelial drug delivery, bacterial 
biofilm disruption, or structural changes in the microbubble coating. In conclusion, 
using this state-of-the-art optical imaging system, microbubble-mediated drug delivery 
can be studied with high temporal resolution to resolve microbubble oscillation and 
high spatial resolution and detector sensitivity to discern cellular response. Combining 
these two imaging technologies will substantially advance our knowledge on 
















o successfully treat diseases, administered drugs need to overcome barriers in 
the human body that hinder efficient delivery. Currently, high dosages are 
required because only a fraction of the therapeutic actually reaches the target site. This 
leads to high toxicity levels in healthy tissue, causing undesirable side effects218,219. 
However, lipid-coated gas microbubbles (1–10 µm) in combination with ultrasound can 
locally enhance drug delivery, allowing for therapeutics to be delivered efficiently and 
only to the intended target site. When ultrasound is applied, microbubbles oscillate and 
thereby permeabilize cell membranes (sonoporation), open intercellular junctions, and 
stimulate endocytosis36,220,221. The underlying physical and biological mechanisms 
enhancing these different pathways are poorly understood. Elucidating the 
microbubble–cell interaction is fundamentally important for controlling and optimizing 
drug delivery, and therefore, microbubble oscillation behavior and the cellular response 
should be studied simultaneously. 
 
To resolve the microbubble oscillation in an ultrasound field of clinically relevant 
frequencies (MHz), a system with nanosecond temporal resolution is required. 
Currently, there are two ultra-high-speed cameras that can achieve such high frame 
rates, up to 25 million frames per second (Mfps) with sufficient consecutive frames: the 
Brandaris 128222 and the UPMC Cam223. Both cameras have been coupled to an upright 
microscope (BXFM, Olympus, Tokyo, Japan) for brightfield and widefield fluorescence 
microscopy. This enables the concurrent visualization of microbubble oscillation and 
cellular response. Although these systems have been used to study vascular drug 
delivery224-227, imaging resolution showing the cellular response was very poor. 
Microbubble oscillation leading to bacterial biofilm disruption has been observed at a 
lower temporal resolution using a 3 Mfps camera53. With the use of high-speed cameras, 
it has been possible to study the microbubble–cell interaction; however, the cellular 
response was still imaged with poor sensitivity and at a low optical and temporal 
resolution. 
 
Confocal microscopy allows us to better unravel cellular response, as it provides 
nanometer spatial resolution, 3-D imaging with high axial resolution, and good detector 







microbubble-mediated drug delivery has revealed a wide-range of cellular effects: pore 
formation228 and recovery229, opening of intercellular junctions224, endocytosis230, 
lipoplex231 and doxorubicin232 delivery, changes in reactive oxygen species levels233, 
increased bacterial metabolism67, sonoprinting234, cytoskeleton disruption235, and 
intercalation of model drugs236. However, all these studies lack information on the 
specific microbubble behavior that was responsible for the observed cellular effect, 
because of the relatively low frame rates of confocal microscopy imaging (<500 fps). 
 
Microbubble response to ultrasound varies a lot, and even equal-sized microbubbles in 
the same ultrasound field do not respond identically237-239. We need to gain more insight 
into microbubble behavior to achieve a more predicable response to ultrasound. To 
understand how the response is affected by microbubble composition, we want to image 
both the microbubble oscillation behavior and the coating microstructure240. In the past, 
it has only been possible to image coating microstructure in a static setup, without 
ultrasound, using, for example, 4Pi high-resolution confocal microscopy241. 
 
To date, the technological gap has made it impossible to image microbubble oscillation 
(high temporal resolution) and detailed cellular response (high spatial resolution) in the 
same field of view of a single sample. To overcome this challenge, we developed a novel 
optical imaging system by coupling an upright custom-built Nikon confocal microscope 

























Figure 3.1. Combined confocal microscope and Brandaris 128 ultra-high-speed camera. (a) From 
the back of the system, the inside of the Brandaris 128 casing with the rotating mirror and 128 
charge-coupled devices (CCDs) is seen. (b) At the front of the system are the confocal microscope 
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Materials and Methods 
he Brandaris 128 ultra-high-speed camera is a programmable camera with 128 
sensitive charge-coupled devices (CCDs) and a fast rotating mirror that sweeps 
the image over the CCDs, resulting in a minimum interframe time of 40 ns (25 Mfps)222. 
Consecutive 128-frame recordings can be done at an 80 ms interval, with a maximum 
of 50 consecutive recordings242. The brightfield image is 500 × 292 pixels with 8-bit 
gray-scale values and a typical resolution of 400 nm222. 
 
The main body of the confocal microscope is a custom-built upright Eclipse Ni-E 
microscope (Nikon Instruments, Amsterdam, The Netherlands). By physically removing 
the conventional base of the main body, the microscope was customized to 
accommodate the water bath for ultrasound insonification. Microscope modules were 
chosen to meet our requirements such that the light path (Fig. 3.2) could be directed 
toward the four different output ports: (i) a binocular (NI-TT-E Motorized Quadrocular 
Tilting Tube, Nikon Instruments), (ii) a color camera (DS-Fi3, Nikon Instruments) for 
digital acquisition of brightfield and widefield fluorescence images, (iii) the A1R+ 
confocal scan head, and (iv) the Brandaris 128 ultra-high-speed camera. 
 
Two motorized turret modules (NI-FLT6-E Mot Epi-fluorescent turret, Nikon 
Instruments) were incorporated to rotate the desired filters or mirrors into the light 
path. One turret holds a full mirror to direct the light path toward the Brandaris 128 
camera (Fig. 3.2, turret A). The other turret is used for switching between filter cubes 
for widefield fluorescence imaging (Fig. 3.2, turret B). The four installed filter cubes have 
the following excitation (Ex), dichroic mirror (DM), and emission (Em) filters: BFP-A 
with Ex390/18, DM416, and Em460/60; GFP-A with Ex469/35, DM497, and 
Em525/39; TRITC-A with Ex542/20, DM570, and Em620/52; and Cy5-4040 C with 
Ex628/40, DM660, and Em692/40 (center wavelength/bandwidth in nanometers; 
Semrock Inc., Rochester, NY, USA). Widefield fluorescence is performed with a metal 
halide light source with motorized shutters and neutral density filters (C-HGFIE, Fiber 
Illuminator Intensilight, Nikon Instruments). During confocal imaging, excitation is 
achieved with a laser unit (LU-N4, Nikon Instruments) equipped with four lasers (405, 
488, 561, and 640 nm; all 15 mW at the output of the fiber tip). The system has a hybrid 
detector unit (A1-DUG, GaAsP Multi Detector Unit, Nikon Instruments) that includes 
T 
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Figure 3.2. Schematic of the light paths to the different imaging output ports (not to scale). The 
light path goes through the sample, the objective, and the main body of the microscope toward 
either the color camera (green), the confocal scan head (yellow) or the Brandaris 128 ultra-high-
speed camera (red). The light source is used for brightfield and Brandaris 128 imaging. The 
motorized turret A can place the full mirror in the light path for Brandaris 128 imaging, while 
turret B can insert the desired filter cubes for widefield fluorescence imaging. The sample can be 




two gallium arsenide phosphide (GaAsP) photomultiplier tubes (PMTs) and two 
standard multi-alkali PMTs. The GaAsP PMTs are highly efficient in detecting the 
525/50 and 595/50 nm ranges in comparison to the standard multi-alkali PMTs. To 
create four detection channels, the emitted light is split using three filter cubes. The first 
filter cube (DM FF495-Di03, Semrock Inc.; Em filter ET450/50 m, Chroma, Bellows 
Falls, VT, USA) delimits the 450/50 nm channel which is detected by a standard multi-





































Chroma) delimits the 525/50 nm channel, which is detected by a GaAsP PMT. The third 
filter cube (DM T640 LPXR, Chroma; Em filter ET595/50 m, Chroma; Em ET700/75 
m, Chroma) delimits the 595/50 and 700/75 nm channels, which are detected with a 
GaAsP PMT and a standard multi-alkali PMT, respectively. 
 
For high-precision focusing and 3-D z-stack imaging, the microscope's main body 
combines two z-scanning devices. First, long ranges (12 mm) can be scanned with the 
main body's motorized z functionality, which was retained despite the customization. 
Next, with a piezo element (MCL NANO-F200 N, Mad City Labs Inc., Madison, WI, 
USA), faster and more precise z-focusing can be performed in a 200 µm range, resulting 
in improved z-stack imaging. To isolate vibration, the confocal microscope was installed 
on an active anti-vibration optical table (74-9090 M Cleanbench top and 12M-424-88 
micro-g modular post mount support, Physik Instrumente, Karlsruhe, Germany). 
 
The field of view of the Brandaris 128 camera had to overlap with that of the microscope. 
Therefore, the Brandaris 128 camera's casing had to be aligned and coupled to the output 
port of the microscope's main body. This was achieved by fixing a laser pointer on the 
casing of the Brandaris 128 to project onto a target on the microscope body. Further, to 
reproduce alignment, the position of both systems with respect to the room was 
documented using a laser distance measuring tool (GLM 40, Bosch, Stuttgart, 
Germany). A second requirement was parfocality; that is, the Brandaris 128 and the 
confocal need to have the same focal plane. To that end, a range extender (XT2 
Collimating Emission-Port Adaptor, Photometrics, Tucson, AZ, USA) was inserted in 
the light path between the output port of the microscope and the Brandaris 128 input 
port. 
 
When fast switching between confocal imaging and Brandaris 128 acquisition is desired, 
a Multifunction I/O Device (USB-6000, National Instruments, Austin, TX, USA) can 
trigger the motorized turret to rotate the full mirror into the light path, temporarily 
intercepting time-lapse confocal imaging to acquire with the Brandaris 128 camera 
instead. The trigger is given when the rotating mirror in the Brandaris 128 reaches a 
desired rotation speed. Once the Brandaris 128 acquisition is complete, another trigger 
is given to remove the mirror from the light path, such that confocal imaging is restored. 
The confocal recording is intercepted at least for the duration of consecutive Brandaris  
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128 recordings and the mechanical turret rotation time of 300 ms. The trigger events 
and turbine speeds are registered in the confocal recording for correct data registration. 
 
The capabilities of the combined Brandaris 128 and confocal microscopy imaging system 
are demonstrated with three in vitro experiments: endothelial drug delivery, bacterial 
biofilm disruption, and microbubble coating microstructure alterations. The 
microbubbles used in the experiments were all in-house produced by probe sonication 
as previously described241. Briefly, the main lipid of the coating was 1,2-distearoyl-sn-
glycero-3-phosphocholine and the microbubbles had a C4F10 gas core. All images were 
acquired with a 100 × objective (CFI Plan 100XC W, Nikon Instruments) that is 
chromatic aberration-free infinity (CFI), corrected for field curvature (Plan) and water 
dipping (W). This objective has a numerical aperture of 1.10; therefore, the resolution 
achieved with confocal microscopy is 250 nm. The confocal scan speed varies from 0.03–
1 fps per acquisition channel, depending on the chosen pixel dwell time. By decreasing 
the field of view, we can image up to 5 fps. From the Brandaris 128 ultra-high-speed 
recordings, the microbubble radius as function of time was determined using custom-
designed image analysis software243. During the endothelial drug delivery and biofilm 
disruption experiments, the sample was inserted in the water tank at 37°C (Fig. 3.2) 
and insonified with a single-element focused transducer (2.25 MHz center frequency, 
76.2 mm focal length, –6 dB beam width at 2 MHz of 3 mm; V305, Panametrics-NDT, 
Olympus, Waltham, MA, USA). When the microbubble coating was studied, the sample 
was inserted in the water tank at room temperature and insonified with a single-element 
broadband transducer (1 to 9 MHz bandwidth, 25 mm focal distance, –6 dB beam width 









n the first experiment, the response of human umbilical vein endothelial cells to 
αvβ3-targeted microbubbles upon ultrasound insonification was imaged. 
Acquisition started with confocal microscopy time-lapse imaging (0.65 fps, CFI Plan 
100 × W objective), revealing the initial state of the cells and the location of the 
microbubble (Fig. 3.3a). Next, the light path was automatically switched toward the 
Brandaris 128 to record microbubble oscillation during ultrasound insonification (2 
MHz, 250 kPa peak-negative-pressure [PNP], single 10-cycle burst) (Fig. 3.3b). This 
temporarily intercepted confocal microscopy imaging until the Brandaris 128 recording 
finished and the light path was switched back. Confocal microscopy imaging proceeded 
for 3.5 min after ultrasound, monitoring the cellular response (Fig. 3.3c). Uptake of 
propidium iodide was observed locally around the microbubble (Fig. 3.3c, 00:30–00:44), 
followed by diffusion throughout the cytoplasm and into the nucleus (Fig. 3.3c, 02:25). 
Moreover, confocal microscopy imaging revealed opening of the intercellular junctions 
(Fig. 3.3c, 02:25–03:50, arrows). 
 
The second experiment started with confocal microscopy time-lapse imaging (0.32 fps, 
CFI Plan 100 × W objective) of a Staphylococcus aureus biofilm. This revealed vancomycin-
targeted microbubbles adhered to bacteria (Fig. 3.4a). Confocal time-lapse imaging was 
temporarily intercepted to record microbubble oscillation with the Brandaris 128 upon 
ultrasound insonification (2 MHz, 250 kPa PNP, single 10,000-cycle burst). After the 
Brandaris 128 recording, the light path was switched back and confocal imaging 
continued for 40 s. Confocal microscopy imaging after insonification revealed 
microbubbles had clustered (Fig. 3.4c). Moreover, bacteria detached in the area where 
microbubbles were originally located, revealing microbubble-mediated disruption of the 
biofilm (Fig. 3.4c, 0:22, arrows). Toward the end of the confocal recording, partial 
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Figure 3.4. Selected frames from time-lapse imaging 
of microbubble-mediated biofilm disruption. A clinical 
isolate of Staphylococcus aureus (SA25268) was grown in 
IMDM medium (Thermo Fisher Scientific) for 24 h in 
an ibiTreat µ-slide (0.8 mm channel height; I Luer; 
Ibidi GmbH, Martinsried, Germany). The live bacteria 
were stained with Syto9 (4 μg/ml; Thermo Fisher 
Scientific), the dead bacteria with propidium iodide 
(25 μg/ml; Sigma-Aldrich), and the microbubble shell 
with DiD (Thermo Fisher Scientific). (a) Confocal 
microscopy before ultrasound (US) to image the initial 
biofilm and microbubbles (arrowheads). (b) The 
oscillation of the microbubble located in the center of 
(a) was recorded with the Brandaris 128 ultra-high-
speed camera (bar=3 µm). The microbubble radius as 
a function of time was extracted from this recording. 




Sigma-Aldrich, St. Louis, MO, USA). The dashed line delineates the microbubble. (a) Confocal microscopy before 
ultrasound (US) to image initial cell state. (b) Microbubble oscillation recorded with the Brandaris 128 ultra-high-
speed camera (bar=3 µm) and the microbubble radius as a function of time determined from this recording. (c) 
Confocal microscopy after US to image cellular response. The arrows indicate opening of intercellular junctions. 
  
 
Figure 3.3. Selected frames from time-lapse imaging 
of microbubble-mediated endothelial drug delivery. 
Human umbilical vein endothelial cells (Lonza, 
Verviers, Belgium) were grown in MV2 medium 
(PromoCell GmbH, Heidelberg, Germany) to 
confluency for 2 d in a CLINIcell (50 µm membrane; 
Mabio, Turcoing, France). The cell nuclei were stained 
with Hoechst (5 μg/mL; Thermo Fisher Scientific, 
Waltham, MA, USA), cell membranes with CellMask 
Green (4 µg/ml; Thermo Fisher Scientific), and 
























(a) Confocal microscopy imaging before US
(b) Brandaris 128 imaging during US
(c) Confocal microscopy imaging after US
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Figure 3.5. Imaging of structural changes in 
microbubble coating. The lipid-expanded 
phase was stained with rhodamine-DHPE 
(0.01 mol%; Thermo Fisher Scientific). 
Microbubbles were studied in a CLINIcell 
(50 µm membrane; Mabio). (a) Selected z-
slices from 3-D confocal microscopy (i-iv) 
and the maximum intensity projection 
before ultrasound (US). (b) Selected frames 
of the Brandaris 128 ultra-high-speed 
recording revealing microbubble oscillation 
(bar=3 µm) and the resulting microbubble 
radius as a function of time. (c) Selected z-
slices (i-iv) and maximum intensity 
projection after US. The arrows indicate a 
focal area of increased fluorescence intensity 
(i.e., hot spot) suggestive of local 




The third experiment aimed to image the microbubble coating microstructures before 
and after ultrasound insonification. Before ultrasound, a z-stack was acquired (0.4 µm 
step size, 31 slices, CFI Plan 100 × W objective) of a microbubble that also contained 
rhodamine-B-1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine, triethylammonium 
salt (rhodamine-DHPE). The 3-D image (Fig. 3.5a) revealed that the lipid expanded 
phase, as stained by the rhodamine-DHPE244, was distributed in a characteristic 
honeycomb pattern. Next, Brandaris 128 ultra-high-speed imaging revealed 
microbubble oscillation (Fig. 3.5b) upon ultrasound insonification (1.4 MHz, 50 kPa 
PNP, single 8-cycle burst). After ultrasound, another z-stack was acquired revealing 







(b) Brandaris 128 imaging during US
(c) Confocal microscopy z-stack after US
(a) Confocal microscopy z-stack before US
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he novel combined confocal microscope and Brandaris 128 ultra-high-speed 
camera make it possible to study both the cell and microbubble structures with 
nanometer spatial resolution and the microbubble oscillation with nanosecond temporal 
resolution, as demonstrated with the three experiments. With this unique device we 
were able for the first time to relate microbubble oscillation behavior to alterations in 
cell integrity and microbubble coating microstructures. 
 
Microbubble-mediated endothelial drug delivery (Fig. 3.3) monitored with confocal 
microscopy provides better detector sensitivity and higher frame rates than the widefield 
microscope originally coupled to the Brandaris 128. As a result, low and fast changes of 
local propidium iodide uptake caused by sonoporation can now be detected. This is 
essential when studying safe drug delivery because low uptakes have been associated 
with reversible sonoporation and cell viability245. Moreover, specific fluorescent cell dyes 
can now be imaged with high resolution, revealing previously concealed cellular 
responses. For example, we were able to observe the opening of intercellular junctions 
using a cell membrane dye (Fig. 3.3c). 
 
The advantage of high-resolution confocal microscopy is also demonstrated when 
imaging biofilm disruption by oscillating microbubbles (Fig. 3.4). Because of the small 
size of bacteria (∼1 µm in diameter), they cannot be well resolved with widefield 
microscopy. The added value of this new optical system is that we can now distinguish 
individual bacteria and observe effects on biofilms caused by oscillating microbubbles, 
while also gaining insight into how microbubbles vibrate nearby a biofilm. Furthermore, 
the light path switching is quick enough to observe the disruption of the biofilm before 
redisposition of bacteria occurs (Fig. 3.4c). However, this data set also reveals a 
drawback of the Brandaris 128 ultra-high-speed camera recordings. Because a maximum 
of 128 frames can be acquired, it is only possible to partially image the 10,000-cycle 
microbubble oscillation. Therefore, in this Brandaris 128 acquisition, the microbubble 
clustering was not observed (Fig. 3.4b) and could only be inferred from the confocal 









The developed optical imaging system will be essential not only in understanding 
ultrasound-mediated drug delivery, but also in designing ultrasound contrast agents. 
We can finally image how microbubble oscillation behavior affects the structural 
organization of the coating and vice versa. Although 4Pi microscopy has higher axial 
resolution and overcomes the signal loss toward the part of the microbubble furthest 
away from the objective (Fig. 3.5, iv), because of the laser diffraction by the 
microbubble's gas core, we were able to discern the coating microstructures with the 
confocal microscope (Fig. 3.5). To date, lipid shedding and buckling of the phospholipid 
shell caused by microbubble oscillation has been observed only using widefield 
fluorescence microscopy, at 150,000 fps246 or 5 Mfps247. However, because of the poor 
axial resolution of widefield microscopy, structural details of the phospholipid shell 
could not be resolved. 
 
Simultaneous Brandaris 128 and confocal microscopy imaging is not possible with the 
combined system. This technical limitation remains as the Brandaris 128 requires 100% 
of the light path to overcome the CCD detection limits. Automatic switching between 
confocal and Brandaris 128 imaging minimizes the time during which confocal 
microscopy imaging is interrupted. It is difficult to precisely predict the start of a 
Brandaris 128 acquisition, as the acceleration of the turbine is variable. Therefore, 
confocal microscopy is often interrupted about 2 s before the Brandaris 128 recording 
starts. During this time no change is expected in the confocal image, because 
insonification has not taken place yet. As soon as the Brandaris 128 acquisition has 
completed, during which ultrasound was applied, the full mirror is rotated out of the 
light path. As a result, the confocal microscope can restore imaging to detect rapid 
cellular effects with a maximum delay of 300 ms plus the time to scan a confocal frame 
(which depends on the confocal scan speed chosen). For the endothelial drug delivery 
example, this corresponded to <1.8 s, and for the biofilm disruption example, this was 
<3.4 s. 
 
The confocal microscope can image a larger field of view than the Brandaris 128 ultra-
high-speed camera. For instance, with the CFI Plan 100 × W objective, the field of view 
of the confocal microscope is 128 × 128 µm and that of the Brandaris 128 is 45 × 32 µm. 
Hence, as seen in Figure 3.4, sometimes microbubbles are observed in the field of view  
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of the confocal microscope, but their oscillation cannot be recorded with the Brandaris  
128. Finally, adapting the microscope's main body by removing the conventional base 
disabled the automatic refocusing capability. Regardless, a desired focus depth can be 





state-of-the-art optical imaging system was developed by coupling a custom-built 
confocal microscope to the Brandaris 128 ultra-high-speed camera. Microbubble-
mediated drug delivery can now be studied at both high spatial and temporal resolution 
to evaluate cellular response upon microbubble oscillation. Additionally, changes in 
microbubble coating structure caused by oscillation behavior can be discerned. With this 
novel optical imaging system we expect to further elucidate microbubble-mediated drug 
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- Star Wars Episode V, 
Yoda (George Lucas) 
Try not. 
Do. Or do not. 
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Staphylococcus aureus biofilms are a major problem in modern healthcare due to their 
resistance to immune system defenses and antibiotic treatments. Certain analgesic 
agents are able to modulate S. aureus biofilm formation, but currently no evidence exists 
if paracetamol, often combined with antibiotic treatment, also has this effect. Therefore, 
we aimed to investigate if paracetamol can modulate S. aureus biofilm formation. 
Considering that certain regulatory pathways for biofilm formation and virulence factor 
production by S. aureus are linked, we further investigated the effect of paracetamol on 
immune modulator production. The in vitro biofilm mass of 21 S. aureus strains from 9 
genetic backgrounds was measured in the presence of paracetamol. Based on biofilm 
mass quantity, we further investigated paracetamol-induced biofilm alterations using a 
bacterial viability assay combined with N-Acetylglucosamine staining. Isothermal 
microcalorimetry was used to monitor the effect of paracetamol on bacterial metabolism 
within biofilms and green fluorescent protein (GFP) promoter fusion technology for 
transcription of staphylococcal complement inhibitor (SCIN). Clinically relevant 
concentrations of paracetamol enhanced biofilm formation particularly among strains 
belonging to clonal complex 8 (CC8), but had minimal effect on S. aureus planktonic 
growth. The increase of biofilm mass can be attributed to the marked increase of N-
Acetylglucosamine containing components of the extracellular matrix, presumably 
polysaccharide intercellular adhesion. Biofilms of RN6390A (CC8) showed a significant 
increase in the immune modulator SCIN transcription during co-incubation with low 
concentrations of paracetamol. Our data indicate that paracetamol can enhance biofilm 













ealthcare-related infections caused by biofilms formed by Staphylococcus aureus 
have a high mortality (up to 66%) and includes severe chronic infections, such 
as osteomyelitis and infective endocarditis, and those related to in-dwelling medical 
devices7,248-251. The unfavorable outcome of biofilm-associated infections has been 
attributed to the decreased susceptibility of S. aureus to antibiotics and host defenses7,252-
256. Furthermore, it is known that mature S. aureus biofilms produce numerous virulence 
factors that enhance pathogenicity7,248, such as staphylococcal complement inhibitor 
(SCIN), Protein A, and thermonuclease, already during the early stages of biofilm 
formation257,258. Biofilm development of S. aureus depends on its genetic background259 
and is highly affected by environmental conditions, including the substrate to which the 
biofilm is attached to7,248,259-261 and growth media composition257,261,262.  
 
It has been shown that some compounds and drugs that are often paired with antibiotics 
can modulate S. aureus responses that further reduces antibiotic susceptibility263,264. 
Nonsteroidal anti-inflammatory drugs, like acetylsalicylic acid (aspirin) and ibuprofen, 
can increase the inhibitory concentration of fusidic acid, an anti-staphylococcal drug263. 
Many other antibiotics used to treat S. aureus infections, such as beta-lactams and 
vancomycin, may actually promote biofilm formation252-255. Furthermore, non-antibiotic 
drugs like acetylsalicylic acid can even modulate biofilm generation264-265. Paracetamol, 
another antipyretic drug, is frequently used before and during early infection symptoms 
and is often given concomitantly with antibiotic treatment once infection has been 
confirmed. The mechanism of paracetamol remains uncertain on the molecular level and 
is different from acetylsalicylic acid in that it does not induce anti-inflammatory effects. 
Until now, it has not been investigated if paracetamol has an influence on biofilm 
formation and development.  
 
Clinical isolates of S. aureus consist of various genetic backgrounds with an unequal 
worldwide distribution266. One of the prominent clonal clusters, clonal complex 8 (CC8), 
causes a significant proportion of S. aureus infections in certain regions266. For example, 
methicillin-resistant USA300 is the most prevalent strain in the United states, while ST-
239 is mainly found in Asia, Australia, Eastern Europe, and South America266. 






factor production are correlated267,268, we also studied the impact of paracetamol on the 
transcription of staphylococcal complement inhibitor (SCIN) protein. SCIN is a 
potent immune modulator which is able to inhibit host complement activation 
pathways during the early stages of biofilm formation257. Since paracetamol is frequently 
being used in the early stages of infection when biofilms are formed257, we studied the 
effect of paracetamol exposure on S. aureus biofilm formation using 21 strains from 9 
genetic backgrounds, which includes the clinically relevant CC8 strains ST239 and 
USA300. In addition, the impact of paracetamol on the transcription of SCIN protein 
was determined.  
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Materials and Methods 
Bacterial strains and growth conditions 
 
The S. aureus strains used in this study are listed in Table 4.1. Strains were plated on 
blood agar (5% sheep blood; BD, TrypticaseTM, Thermo Fisher Scientific, Bleiswijk, the 
Netherlands) and incubated overnight at 37 oC. The green fluorescent protein (GFP) 
construct containing strains were plated on tryptic soy agar (TSA) supplemented with 
10 µg/mL chloramphenicol (Oxoid Limited, Basingstoke, UK). 
 
The effect of paracetamol on planktonic bacteria 
 
To determine the effect of paracetamol (Sigma Aldrich, Zwijndrecht, the Netherlands)  
on bacterial growth, a broth microdilution method was performed for all strains269,270. 
One hundred microliter of a 1:100 dilution (optical density (OD) of 0.50 (±0.05) at 600 
nm in NaCl 0.9%) of each strain in Iscove’s Modified Dulbecco’s Medium (IMDM) 
(Gibco®, Thermo Fisher Scientific) was added to 100 µL of culture media containing 
paracetamol for final concentrations of  0.5, 1, 2, 4, 8, 16,  and 32 µg/mL. After 24 h 
incubation at 37 oC in sterile round-bottom 96-well polystyrene tissue culture plates 
(Costar no. 3799; Corning Inc., Corning, NY), the optical densities (OD600nm) were read 
in a microplate reader (Epoch 2 Microplate reader, BioTek Instruments, Inc., Winooski, 
VT, USA). 
 
Biofilm formation mass assessment 
 
In vitro biofilms were generated from both wild type and GFP-containing strains (Table 
4.1) by the method described previously257. Biofilm formation was assessed using a 
dynamic, microtiter plate biofilm formation assay as previously described by 
Christensen et al.248,257,271,272, with slight modifications. Briefly, for each strain or isolate, 
5 mL of NaCl 0.9% was inoculated with overnight grown S. aureus (at 37 oC on blood 
agar) until an OD600nm of 0.50 (±0.05) was reached. Thereafter, 10 µL was dispensed 
into a sterile flat-bottom 96-well polystyrene tissue culture plates (Costar no. 3596; 
Corning Inc., Corning, NY) containing a serial dilution (0.5, 1, 2, 4, 8, 16, and 32 μg/mL) 
of paracetamol in 190 µL of IMDM. The plates were incubated at 37°C for 24 h with 
continuous shaking at 150 rpm. Bacterial growth was then measured using a microplate 





Table 4.1. S. aureus strains used in this study 
Strain Genetic background 
 
d 
    Description    Source / Ref 
    Mup903 CC1 Commensal strain [291] 
Mup3648 CC1 Commensal strain [291] 
Mup2778 CC5 Clinical strain [291] 
Mup3904 CC5 Clinical strain       [291] 
Mup568 CC15 Clinical strain [291] 
Mup1675 CC15 Clinical strain [291] 
M82 CC20 Clinical strain [257] 
Mup2091 CC30 Clinical strain         [291] 
Mup3534 CC30 Clinical strain [291] 
Mup1173 CC45 Clinical strain [291] 
Mup2396 CC45 Clinical strain [291] 
B-DYK 25337 CC223 Clinical strain Erasmus MC  
Mup2704 CC8, ST72  Clinical strain  [291] 
Mup4423 CC8, ST72  Commensal strain  [291] 
M116 CC8, ST239 Clinical strain [257] 
RWW337 CC8, ST239 Clinical strain        [292] 
RWW338 CC8, ST239 Clinical strain [292] 
SAC042W CC8, USA300 SAC042W, Clinical strain [293] 
8325-4 CC8 Laboratory strain [294] 
RN6390 CC8 Laboratory strain [295] 
Newman CC8 Laboratory strain [296] 
scn-GFP (+) CC8 scn promoter (pSK236GFP in RN6390)       [297] 
PrP-GFP (+) CC8 Page repressor promoter (pACL1484 in RN6390)    [274] 
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biofilms which had formed in the wells were washed once with 200 µL of sterile 
phosphate-buffered saline (PBS) containing 1% BSA and 0.05% azide. Biofilms were 
then air dried and stained with 50 µL of 1% crystal violet in distilled water for 2 min. 
Excess crystal violet was removed by washing the plates with distilled water for five 
times. The stained biofilm was then dissolved in 200 µL of extraction solution (50% 
dH2O, 40% EtOH, 10% acetyl acid) and the absorbance of crystal violet measured at 
OD490nm in the Epoch 2 microplate reader. 
 
Fluorescence staining of biofilm 
 
For visualization of the cellular and extracellular matrix components, biofilms were 
stained using a LIVE/DEAD® BacLight Bacterial Viability Kit (Thermo Fisher Scientific) 
and Wheat Germ Agglutinin (WGA) - Alexa Fluor® 350 conjugate (Invitrogen BV, 
Breda, the Netherlands), according to the manufacturer’s protocol with slight 
modification. Biofilms grown for 4 h were washed once with 200 µL of IMDM. Then 50 
µL  of IMDM, 50 µL  of 15 μM propidium iodide (PI), 50 µL  of 2.5 μM SYTO9, and 0.5 
µL  of 1 mg/mL WGA-Alexa fluor® 350 conjugate was added to each well and the plate 
incubated at 22 °C on an orbital shaker (300 rpm) in the dark for 35 min. The biofilms 
were then imaged using an Olympus IX51 fluorescence microscope (Olympus 
Nederland B.V., Zoeterwoude, the Netherlands) with 20- and 40-times magnification. 
For confocal microscopy, a custom-built Nikon A1R + confocal microscope273 (Nikon 
Instruments Europe, Amsterdam, the Netherlands) was used with a 60-times water 
immersion lens (CFI NIR Apo 60X W, Nikon Instruments). For imaging, WGA-Alexa 
fluor® 350 conjugate was excited at 405 nm, detected at 450/50 nm (center 
wavelength/bandwidth), SYTO 9 was excited at 488 nm, detected at 525/50 nm, and PI 
was excited at 561 nm, detected at 595/50 nm. Biofilms imaged with the confocal 
microscope were grown in CLINIcell culture chambers (CLINIcell25–50-T, REF 00106, 
MABIO, Tourcoing, France) in 12 mL using the same biofilm formation and fluorescence 
staining methods with volumes proportionally adjusted according to manufacturer 
protocol. 
 
Bacterial metabolism rate  measurement 
 
The effect of paracetamol on bacterial metabolism was monitored with a 





cultures of S. aureus on blood agar at 37 oC were suspended in 5 mL NaCl 0.9% until 
OD600nm of 0.50 (±0.5) was reached. Then 10 µL of this suspension was mixed with 9990 
µL IMDM to create a 1:1000 dilution. Ten µL of the diluted suspension was added into 
sterile plastic “insert” tubes (designed for the microcalorimeter) containing 190 µL of 
different concentrations (0.5 – 32 mg/mL) of paracetamol in IMDM. These tubes were 
then placed into sealed platinum tubes and placed inside a multi-channel 
microcalorimeter (calScreenerTMSymCel, Sverige AB, Sweden) for 24 h at 37 oC to 
determine real-time bacterial metabolic activity.  
 
Measurement of immune modulator SCIN transcription 
 
To study the effect of paracetamol on the transcription of the immune modulator SCIN 
during biofilm formation, RN6390 carrying a scn (SCIN) promotor GFP construct and 
RN6390 carrying a plasmid that constitutively produces GFP as a positive control (phage 
repressor promoter-GFP fusion construct) were used as previously described by 
Rooijakkers et al.274 (Table 4.1). In vitro biofilms were generated from both GFP-
containing strains (Table 4.1) by the method described previously257. After an hour of 
incubation at 37 oC, the growth medium was replaced with 200 µL of fresh IMDM 
medium containing paracetamol (serial dilution 0.5 – 32 μg/µL). The biofilms were then 
incubated in a FLUOstar Optima microplate fluorescence reader (BMG Lab 
Technologies, Chicago, IL, USA) at 37 oC  with 150 rpm periodic rotational shaking. The 
accumulation of fluorescence, used as a measure for gene transcription, was determined 
(excitation at 485nm, emission at 520nm, and gain setting 1738) automatically every 
five min during the 4th and 5th hours of biofilm formation. Median fluorescence 
intensities (MFI) of the scn promoter-GFP strain co-incubated with paracetamol were 




Statistical analysis was performed with GraphPad Prism (GraphPad Software Inc., 
Version 5.01, San Diego, CA, USA) and Microsoft Excel 2010. Data were analyzed with 
an unpaired t-test or one-way ANOVA; a P-value ≤ 0.05 was considered as statistically 
significant. All experiments were independently repeated at least three times and data 
are presented as mean (SEM) or as median with range.   
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Clinically relevant doses of paracetamol have limited effect on S. aureus planktonic 
growth  
 
Since the concentration of paracetamol in human serum is normally below 30 
µg/mL275,276, we overnight co-incubated S. aureus with  0.5, 1, 2, 4, 8, 16, and 32 µg/mL 
of paracetamol. We found that these clinically relevant concentrations of paracetamol 
had no significant effect on planktonic growth of S. aureus strains, except for some of the 
strains having a CC8 genetic background (Fig. 4.1). Results in these CC8 strains were 
variable: the growth rate of strain 8325-4 was higher in the presence of higher doses of 
paracetamol, while RN6390 and Newman had lower growth rates at higher 
concentrations.  
 
Low doses of paracetamol increase biofilm formation of CC8 genetic cluster strains 
 
To study the effect of paracetamol on biofilm formation, a biofilm quantification assay 
was performed on all strains following overnight incubation with paracetamol using the 
same concentrations as used in the planktonic growth experiments. In 15 of the 21 
strains, an increase in biofilm mass could be demonstrated (Fig. 4.2). Of particular note, 
this phenomenon was primarily observed in S. aureus strains belonging to CC8 (2774 
(ST72), M116 (ST239), RWW337 (ST239), RWW338 (ST239), SAC042W (USA300), 
8325-4, RN6390, and Newman), and less visible in non-CC8 strains (CC1 (903), CC5 
(2778, 3904), CC15 (1675), CC30 (2091, 3534), and CC223) when exposed to doses of 
paracetamol less than 32 µg/mL. Not every paracetamol concentration below 32 µg/mL 
always led to a clear increase in biofilm mass. For example, the mean value of strain 
M116 (ST239) indicates biofilm mass increased at 0.5 – 4 μg/mL and 16 μg/mL, whereas 
at 8 μg/mL biofilm mass was unaffected.Conversely at these doses, other strains of 
various backgrounds were observed with mainly reductions in biofilm and as low as 
obtaining only 63% (mean) of the control biofilm mass for 8 µg/mL paracetamol (strain 











Figure 4.1. Broth microdilution susceptibility tests were performed on all study strains. (A) Strains with 
genetic backgrounds of CC1, CC5, CC15, CC20, CC30 and CC45. (B) Strains with genetic backgrounds 
of CC45, CC72, CC223 and CC8. The results are depicted as the percentage of paracetamol treated S. 
aureus MICs relative to its control (untreated). The red horizontal line represents the control. The black 
box outlines CC8 strains. Each black circle represents one experiment. Data points are presented with 









Figure 4.2. Staphylococcus aureus biofilm mass changes in response to various concentrations of 
paracetamol. Paracetamol stimulates and reduces biofilm formation at clinical doses in strains with 
different genetic backgrounds, most notably those belonging to CC8 including ST239. Biofilms were 
grown and co-incubated with 0.5 (A), 1 (B), 2 (C), 4 (D), 8 (E), 16 (F), and 32 (G) μg/mL of paracetamol. 
Red boxes outline the biofilm mass increase of CC8 strains above control mass. Data from at least three 
separate experiments are presented as aligned dot plots with a blue line indicating the mean value. 
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Paracetamol did not significantly alter the metabolism rate of biofilm-associated S. 
aureus  
 
To determine if the paracetamol-associated increase in biofilm formation was only due 
to an increase in the number of bacterial cells, we studied the metabolic rate of S. aureus 
biofilms (CC20 strain M82 and CC8 strains: M116, RN6390, and Newman) when 
exposed to different concentrations of paracetamol. The addition of paracetamol did not 
change the heat flow by S. aureus during 24 h biofilm formation for all strains tested (Fig. 
4.3). Some minor, non-significant deviations included a delayed heat curve at 4 µg/mL 
in strain M82 (CC20) (Fig. 4.3a) and reduced heat flow at the highest therapeutic 
concentration (32 µg/mL) in strain RN6390 (CC8) (Fig. 4.3c). These data indicate that 
although the biomass of biofilms of CC8 strains generally increased when exposed to 
paracetamol, an increase of bacterial cells is unlikely to be the cause. 
 
 
Figure 4.3. The metabolic rate of biofilms in the presence of different dosages of paracetamol. Metabolic 
heat flow generated during overnight biofilm formation at 37°C and co-incubation without (red line) or 
with 0.5-32 µg/mL paracetamol of S. aureus CC20 strain M82 (A) and CC8 strains; M116 (B), RN6390 
(C), and Newman (D) were monitored with isothermal microcalorimetry in real-time. Data from three 
separate experiments are presented as mean value and SEM.  
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Figure 4.4. The effect of paracetamol on staphylococcal biofilm matrix composition. Biofilms of S. aureus 
strain M116 (CC8, ST239) were grown 37°C without (A, C, E) and with (B, D, F) paracetamol (2 μg/ml). 
Fluorescent images of stained biofilms were captured using inverted light fluorescence microscopy (A, 
B) and confocal laser scanning microscopy (C-F) with corresponding three-dimensional volume 
rendering (E,F). For all images, green fluorescence (SYTO 9 stained) are live bacteria, red fluorescence 
(PI stained) are dead bacteria and/or eDNA, and blue fluorescence (WGA stained) are N-
Acetylglucosamine. All images are representative of three separate experiments. 
 







Paracetamol modulates polysaccharide expression during biofilm formation 
 
An explanation for the increase of biofilm mass could be an increase in non-cellular 
components, such as extracellular DNA (eDNA), proteins and/or polysaccharides7,277-
281. To investigate this hypothesis, we co-incubated S. aureus strain M116 (CC8) 
biofilms with 2 μg/mL of paracetamol overnight and studied the biofilms using light 
fluorescence and confocal microscopy (Fig. 4.4). Paracetamol-exposed biofilms had an 





Figure 4.5. Transcription of the SCIN promoter following paracetamol incubation. Transcription of the 
SCIN gene promoter – GFP (scn-GFP+) in strain RN6390 (CC8) was monitored during overnight 
incubation at 37°C without and with 0.5 (A), 1 (B), 2 (C) or 4 (D) μg/mL of paracetamol. A single 
asterisk (p < 0.05) and two asterisks (p < 0.01) represent a statistically significant difference between 
without and with paracetamol treatment. Data from three separate experiments are presented as mean 
value and SEM. 
 
 






























































































Paracetamol modulates biofilm formation 
 
 
Small doses of paracetamol increase immune-modulator transcription 
 
RN6390 (CC8) containing a SCIN promoter-green fluorescence protein fusion was used 
to study the effect of paracetamol exposure on the transcription of the immune 
modulator SCIN protein.  During overnight co-incubation with paracetamol, the 
biofilms had a significant upregulation of scn promoter transcription (p = 0.009) when 
lower doses (< 4 µg/mL) of paracetamol were added during biofilm formation (Fig. 




n this study, we show that paracetamol exposure can lead to an increase in biofilm 
mass of S. aureus strains, particularly from the CC8 genetic background which 
includes the highly prevalent ST239 and USA300 strains. Bacterial metabolism during 
biofilm formation did not significantly increase as a consequence of adding paracetamol. 
It could be that the total number of biofilm-associated bacteria exposed to paracetamol 
is less than the untreated bacteria, but those fewer exposed cells are producing more 
heat due to the increased production of polysaccharides and secreted proteins. However, 
the heat production due to polysaccharide and secreted protein generation might be 
negligible in comparison to the heat produced due to cellular growth. Regardless, in 
both cases there is no increase in the number of biofilm-associated bacteria due to 
paracetamol treatment and thus, the observed increases of biofilm mass due to 
paracetamol exposure seems to be best explained by an increase of non-cellular 
components.  
 
Furthermore, the increase in biofilm mass was associated with an increase in the part of 
the biofilm rich in N-Acetyl glucosamine, presumably polysaccharide intercellular 
adhesin (PIA). PIA is a positively charged poly-β(1-6)-N-acetylglucosamine (PNAG) and 
the predominant exopolysaccharide component of the extracellular polymeric matrix of 
staphylococcal biofilms encapsulating bacteria281,282. Additionally, PIA mechanically and 
chemically prevents the killing of S. aureus by phagocytizing leukocytes, antimicrobial 
peptides, and antibiotics281-283. No previous data regarding PIA modulation by 
paracetamol exists to our knowledge. However, a study by Dotto, et al.264 showed that  
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acetylsalicylic acid promotes biofilm formation of S. aureus in a PIA-dependent manner. 
These data suggest that use of both paracetamol and acetylsalicylic acid during S. aureus 
infections may be potentially harmful due to increasing biofilm formation. 
 
Bacterial secreted proteins were another consideration in our study. Since the regulator 
pathway for biofilm formation and toxin production, including immune modulators, are 
correlated267,268, we expected to find that immune modulator production by S. aureus 
could be affected by paracetamol as well. Our data indeed showed that SCIN production 
can be stimulated significantly by low doses of paracetamol. This finding mimics the  
 
 
data from Price et al.284, which demonstrated that acetylsalicylic acid could modulate S. 
aureus virulence factor production. SCIN is a potent immune modulator, which is able 
to inhibit the release of chemoattractant C5a and therefore blocking the host 
complement activation pathways285,286. Previously, we showed that S. aureus produced 
SCIN already during the early stages of biofilm formation257. The observed increase in 
SCIN production, along with PIA and potentially other virulence factors yet to be 
investigated, in response to paracetamol would aid invading staphylococci to evade the 
innate immune system and potentiate infection. 
 
Currently, the mechanism of biofilm modulation by paracetamol has not been 
elucidated, but there are indications that an impaired iron regulation within cells may 
influence this phenomenon287,288, probably via iron chelation by paracetamol289. In an 
iron-restricted condition, biofilm and virulence factor production is increased264,290. 
Paracetamol has been demonstrated in vivo to reduce excess hepatic iron after 
administration289.  In addition, a previous study on acetylsalicylic acid and biofilm 
showed that free Fe2+ reduction in culture media by acetylsalicylic acid, via iron 
chelation, could promote biofilm formation of S. aureus CC5 and CC8 strains, including 
Newman and USA300264. This observation suggests that iron-modulation by 








n summary, this study indicates that current clinical concentrations of an analgesic-
antipyretic like paracetamol may have a role in the development and persistence of 
S. aureus biofilm-related infections, especially, but not limited to, strains belonging to 
CC8. For clinical practice our data suggest that in patients with a suspected S. aureus 
infection, the indication for paracetamol administration should be carefully weighed 
against the risk of increased biofilm formation. The mechanism of action and the effect 
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Infective endocarditis (IE) is associated with high morbidity and mortality rates. The 
predominant bacteria causing IE is Staphylococcus aureus (S. aureus), which can bind to 
existing thrombi on heart valves and generate vegetations (biofilms). In this in vitro 
flow study, we evaluated sonobactericide as a novel strategy to treat IE, using ultrasound 
and an ultrasound contrast agent with or without other therapeutics. We developed a 
model of IE biofilm using human whole-blood clots infected with patient-derived S. 
aureus (infected clots). Histology and live-cell imaging revealed a biofilm layer of fibrin-
embedded living Staphylococci around a dense erythrocyte core. Infected clots were 
treated under flow for 30 minutes and degradation was assessed by time-lapse 
microscopy imaging. Treatments consisted of either continuous plasma flow alone or 
with different combinations of therapeutics: oxacillin (antibiotic), recombinant tissue 
plasminogen activator (rt-PA; thrombolytic), intermittent continuous-wave low-
frequency ultrasound (120-kHz, 0.44 MPa peak-to-peak pressure), and an ultrasound 
contrast agent (Definity). Infected clots exposed to the combination of oxacillin, rt-PA, 
ultrasound, and Definity achieved 99.3 ± 1.7% loss, which was greater than the other 
treatment arms. Effluent size measurements suggested low likelihood of emboli 
formation. These results support the continued investigation of sonobactericide as a 
















nfective endocarditis (IE) is a life-threatening microbial infection of the heart valves 
and surrounding tissue, including endocardial prosthetic material. IE is associated 
with high morbidity and mortality (15-40% in-hospital and 40-69% 5-year 
mortality)21,43,341,342. Current standard treatment for IE consists of prolonged, intensive 
intravenous antibiotic therapy21.  
 
IE is characterized by valvular vegetations (biofilms) composed primarily of a thrombus-
like mesh consisting of platelets, fibrin, extracellular polymeric substance, and bacteria 
at different stages of replication334,7. Staphylococcal, streptococcal, and enterococcal 
species of bacteria have been implicated as the primary cause of IE21,43. Staphylococcus 
aureus has been reported to have the single highest prevalence (30-31%) in IE43 and is 
associated with the highest mortality and worst prognosis. These bacteria initiate 
colonization by adhering to microthrombi present on valves, caused either by 
endothelial inflammation, mechanical damage, or spontaneous formation on intact 
valvular surfaces43,334,352. 
 
High-risk surgical procedures may be required to treat IE, but this treatment is 
contraindicated in a large population of patients341. The presence of bacterial biofilm 
makes treatment challenging due to increased resistance to antibiotic action and the 
presence of bacteria in a dormant metabolic state. Bacteria situated within biofilms can 
be 100 - 1,000-fold less susceptible to antibiotics than the planktonic bacteria released 
from biofilms75,353. Furthermore, prolonged, high-dose antibiotic therapy paradoxically 
preserves persister cells within a biofilm that are tolerant to antibiotics75. When 
antibiotic therapy has concluded, persisters can switch phenotype and produce new 
biofilm, thereby reinitiating infection75. Adjuvant therapies for IE are desperately 
needed. 
 
To treat various bacteria, both planktonic and residing in biofilms, other groups have 
successfully used low-frequency ultrasound (US) [≤1 MHz] combined with 
antibiotics32,354-357. Acoustic cavitation and streaming have been identified as the dominant 
mechanisms for what appears as an increase in antibiotic efficacy and penetration into 







cavitation, which could induce undesirable bioeffects358. Using ultrasound contrast 
agents (UCAs) as cavitation nuclei reduces the acoustic pressure threshold for 
producing cavitation359, which could help translate this therapy to the clinic. UCAs are 
composed of encapsulated gas microbubbles (MBs; 1 – 10 μm in diameter) that oscillate 
volumetrically in response to US pressure variations, a phenomenon known as acoustic 
cavitation36. Cavitation of MBs has been shown to enhance US-induced bioeffects, which 
include drug delivery, cell death, and dissolution of thrombi (sonothrombolysis), by 
mechanisms such as enhanced fluid transport, sonoporation, and stimulated 
endocytosis36,37,245,360. Other investigators have tested the use of US in combination with 
MBs for enhancing biofilm degradation62,65,112,124. However, these studies have not 
evaluated the potential to enhance treatment of IE biofilms either by US, or US with 
UCAs. 
 
In this paper, we report the results of a translatable, proof-of-principle study for treating 
S. aureus IE biofilms in an in vitro flow model. This treatment strategy that we have 
termed sonobactericide, combines US exposure and an UCA, with or without antibiotics 
or other therapeutics, to treat IE infections. A therapeutic of interest could be 
recombinant tissue plasminogen activator (rt-PA), a thrombolytic agent, because 
successful treatment of paediatric patients with IE has been reported previously361-364. 
We hypothesized that combination treatment with an antibiotic and a thrombolytic, in 
the presence of US and UCAs, will enhance the efficacy of S. aureus IE biofilm treatment. 
To test this hypothesis in vitro, we developed an infected clot model using S. aureus from 
an IE patient and human whole blood to replicate the in vivo early pathogenesis of IE. 
Infected clots were treated over a 30-minute period using an in vitro flow model equipped 
with time-lapse microscopy152,365. Infected clots were exposed to continuous human 
plasma flow either alone or with different combinations of the following: oxacillin (the 
antibiotic used clinically for the treatment of staphylococcal IE infections101,102), rt-PA, 
UCA Definity, and intermittent continuous-wave US. The cavitation activity nucleated 
by UCA was monitored using a passive detector. Treatment efficacy was assessed by 
measuring the infected clot width loss by bright-field microscopy. In addition, the 
particle size profile of the effluent produced by treatment was characterized to assess 






Materials and Methods 
Bacterial isolate  
 
The S. aureus (JC01-2016) used in this study was an anonymized, de-identified strain 
isolated from an IE patient at Cincinnati Children’s Hospital Medical Center, collected 
in accordance with guidance from the Institutional Review Board. According to 
institutional review board policy, anonymized, de-identified bacterial isolates such as 
JC01-2016 are considered Non-Human Subject Research and do not require informed 
consent. All experimental protocols in this study were approved by the University of 
Cincinnati institutional review board, and all methods were carried out in accordance 
with relevant guidelines and regulations. Overnight cultures of the isolate in tryptic soy 
broth (MP Biomedicals, USA) were added to DMSO (15%; Fisher Chemical, USA) and 
stored at -80°C. All overnight cultures from frozen stocks were streaked on tryptic soy 
agar (TSA; MP Biomedicals, USA) and incubated at 37°C. 
 
Bacterial chromosomal DNA was isolated from a single colony using DNeasy Ultraclean 
Microbial kit (MoBio Laboratories, California, USA). Amplification and sequencing of 
the polymorphic X region of the Protein A gene was performed using spa1095F (5’-
AGACGATCCTTCGGTGAGC-3’) and spa1517R (5’-GCTTTTGCAATGTCATTTACTG-
3’) (Integrated DNA Technologies Inc., Iowa, USA)366-368. Amplification and sequencing 
was verified using primers spa1113F (5’-TAAAGACGATCCTTCGGTGAGC-3’) and 
spa1514R (5’-CAGCAGTAGTGCCGTTTGCTT-3’)366. PCR amplification (Mastercycler 
pro S, Eppendorf, New York, USA) was accomplished using 22 µl of sterile water, 1 µl 
of forward primer, 1 µl of reverse primer, 2 µl of isolated chromosomal DNA, and 24 µl 
of MidSci Taq Plus Mastermix with red tracer dye (Midsci, Missouri, USA). 
Thermocycler parameters were set as previously described368. Sequences were analysed 
for polymorphic X region repeats and matched to repeat succession sequences provided 
by Ridom SpaServer Database (http://spa.ridom.de) to determine the spa-type367. 
 
Antibiotic susceptibility testing and growth curve assessment      
 
Oxacillin (28221; Sigma-Aldrich, Missouri, USA) susceptibility was determined (n=3) 
using the agar dilution method on Mueller-Hinton agar (Sigma-Aldrich, Missouri, USA),  






a quality control for antibiotic susceptibility testing. Bacterial growth curves (n=3) with 
an initial OD600nm of 0.05 were produced as described by Harris et al.370 with the 
exceptions of IMDM (containing no phenol red; Gibco, USA) instead of brain heart 
infusion medium, and samples of 3 mL were measured every 30 min for 9 h and a final 
sample measured at 24 h. 
 
S. aureus inoculum preparation for infected blood clot formation 
 
To prepare the S. aureus isolate for inoculation of blood clots, early exponential growth 
phase grown bacteria were generated following the same protocol for determining 
growth curves. Cultures with a starting OD600nm of 0.05 were incubated at 37°C in 
IMDM. After 3.5 - 4 h of growth the S. aureus isolate was in the mid-exponential growth 
phase, and a 1.5 mL sample at an OD600nm of 1 (approximately 1 x 109 CFU/mL) was 
obtained. The bacteria were grown to mid-exponential phase because this is when the 
expression of surface-associated adhesins generally occurs to facilitate initial 
colonization371. This bacterial suspension was kept at 37°C and subsequently used for 
inoculation within fifteen minutes of preparation.  
 
Infected clot formation as model for IE 
 
To produce the infected clots to resemble the in vivo early pathogenesis of IE, first human 
whole blood clots were created around silk sutures as previously described by Bader et 
al.152 with the exceptions of complete experimental sterility and suture brand and size. 
Specifically, 9 cm sections of 6-0 silk sutures (1639G; PERMA-HAND, Ethicon Inc., 
USA) were threaded into 2.5 cm long borosilicate glass capillaries (1.12 mm inner 
diameter, World Precision Instruments Inc., USA). These capillaries were subsequently 
placed inside borosilicate glass culture tubes (10 mm diameter x 75 mm height, VWR 
International, USA). With University of Cincinnati institutional review board approval 
and written informed consent, venous whole blood was drawn from five healthy 
volunteers. Five hundred μL aliquots were transferred into each tube, and by capillary 
action blood was drawn into the capillaries. The glass tubes were incubated for 3 h at 
37°C to allow the blood to clot around the suture, followed by refrigeration at 4°C for a 
minimum of three days to promote clot retraction. These retracted clots are stable and 






After retraction, the clots were incubated at 37°C for 30 min. Aliquots of 30 minutes 
pre-warmed sterile human fresh-frozen plasma (3.325 mL; hFFP; Hoxworth Blood 
Centre, Cincinnati, Ohio, USA) were placed into borosilicate glass culture tubes, and 
inoculated with 175 μL of the prepared bacterial inoculum. The retracted clots were 
removed from the glass capillaries and carefully placed in the inoculated hFFP. To ensure 
the bacterial inoculate had reached all surfaces of the clot, the glass tubes were gently 
inverted approximately 8 times. Subsequently, the glass tubes were incubated for 24-30 
h at 37°C, and reinverted every hour for approximately the first five hours.  
 
Before placement in the in vitro flow system, infected clots were washed three times with 
PBS to remove any planktonic bacteria. Additionally, for histological analysis, two 
additional clot controls were used: sterile retracted clots alone; and sterile retracted clots 
following the infected clot protocol, with the exception of using no bacteria and thus 




Clots were fixated in 10% neutral buffered formalin. Following fixation, clots were 
transferred to a tissue cassette containing a foam biopsy pad (first set specimens), or 
without a foam pad (2nd set specimens). These specimens were processed, embedded in 
paraffin, sliced (4 μm), mounted on a microscopy slide, and stained with either H&E or 
CV for cross-sectional analysis. Images were either captured using a camera (Digital 
Sight DS-Ri1, Nikon, Japan) mounted on a microscope (BX51, Olympus Inc., USA) with 
imaging software (NIS-Elements Basic Research, Nikon) for the first set of clot 
specimens, or with a virtual microscope digital slide scanner (C9600; NanoZoomer 
2.0HT, Hamamatsu Photonics, Japan) and corresponding digital pathology viewing 





Individual infected clots were placed in a sterile chambered #1.5 polymer coverslip 
(80286; μ-slide 2 Well, ibiTreat, ibidi GmbH, Germany). Following the manufacturer’s 
instructions, the LIVE/DEAD BacLight bacterial viability fluorescence kit (L7012, 






with PBS, and then placed in the CLSM holder, where it was observed with an upright 
Nikon FN1 microscope attached to a Nikon A1R confocal system. A 25× long working 




An in vitro flow model, depicted in Supplementary Fig. S7.1 online was used, which has 
been described in detail previously152. Using a syringe pump in withdrawal mode (Model 
44, Harvard Apparatus, Massachusetts, USA), the perfusate flow rate was maintained at 
0.65 mL/min (0.3 cm/s), consistent with previously reported sonothrombolysis studies 
using the same in vitro flow set-up152 and coinciding with slow blood flow eddies 
experienced by IE biofilms373,374.  
 
The infected clots, along with the perfusate, were insonated with a custom-designed, 
unfocused, 120-kHz US transducer (60 mm diameter aperture; 5 cm distance to clot; 
Sonic Concepts, Washinton, USA). Distances for both the passive cavitation detector 
and the 120-kHz transducers to the clot was 5 cm375. Using a function generator 
(33250A; Agilent Technologies Inc., California, USA) and power amplifier (1040L; ENI, 
New York, USA), the transducer was excited at its resonant frequency (120-kHz). A 
custom-built impedance matching network (Sonic Concepts Inc., Washington, USA) 
was used to maximize power transfer to the transducer152. The acoustic field was 
measured and in situ acoustic pressure calibrated along the clot using a 0.5 mm 
hydrophone (TC 4038; Teledyne Reason Inc, California, USA) mounted on a computer-
controlled three-axis positioner (NF-90; Velmex Inc., New York, USA)152.  
 
A single element acoustic passive cavitation detector (PCD; circular aperture diameter 
19 mm; 5 cm distance to clot; 2.25-MHz centre frequency; -6 dB two-way bandwidth of 
0.98-MHz; 595516 C; Picker Roentgen GmbH, Espelkamp, Germany) was aligned with 
the infected clot and used to monitor cavitation activity. As reported previously, 
ultraharmonic (UH) and broadband (BB) emissions were employed to detect stable and 
inertial cavitation, respectively152. To remove any noise from radiofrequency 
interference, the received signal from the PCD was filtered by a 10-MHz low-pass filter 
(J73 E, TTE, California, USA), and amplified with a wideband low-noise amplifier 





duration, 31.25-MHz sampling frequency), and the power spectrum computed in 
MATLAB (The Mathworks, Massachusetts, USA). To compute the UH energy, UH 
bands of the power spectrum between 250-kHz and 1-MHz were summed over a 2-kHz 
bandwidth centred around each UH frequency152. The BB energy was computed by 
summing BB emissions between 250-kHz and 1-MHz in 4-kHz bands centred at each 




For each in vitro flow experiment, 30 mL of hFFP was placed in a 500 mL beaker for 2 h 
to reach gas equilibrium at 37°C. An infected clot was carefully mounted inside the glass 
capillary, connected to the flow system, and placed at the bottom of the 37°C water tank 
over the microscope objective. The focus of the PCD was aligned with the capillary and 
the 120-kHz therapeutic acoustic beam, and infected clots were treated for 30 min, 
which is the half-life of oxacillin in the body376. This time has also been reported for 
sonothrombolysis experiments152,377. A pulsed US exposure scheme, shown to promote 
UH emissions, was used as described by Bader et al.152. Definity and perfusate were 
insonated for a period of 50 s at a peak-to-peak pressure of 0.44 MPa. This was directly 
followed by a 30 s quiescent period to allow a fresh influx of UCA to fill the glass 
capillary. Acoustic emissions recorded by the PCD were acquired at a rate of 2.33-Hz 
(0.43 s inter-frame time)152. This scheme was repeated in intermittent fashion over the 
30 min treatment time.  
 
For infected clots, 9 different experimental flow exposures were included: (1) plasma 
alone; (2) plasma and the US exposure scheme; (3) plasma, US exposure, and Definity; 
(4) plasma and rt-PA; (5) plasma, rt-PA, and US exposure; and (6) plasma, rt-PA, US 
exposure, and Definity; (7) plasma, oxacillin, and rt-PA; (8) plasma, oxacillin, rt-PA, 
and US exposure; and (9) plasma, oxacillin, rt-PA, US exposure, and Definity. Definity 
(Lantheus Medical Imaging, North Billerica, Massachusetts, USA)378 vials were activated 
according to the instructions of the manufacture and diluted to a concentration of 2 
μL/mL (2 × 106 MBs/mL), the infusion dose previously used for sonothrombolysis152. 
For oxacillin, 172 μg/mL was chosen because this is the peak serum concentration of 
the antibiotic therapeutic dose in humans treated with IE379,380. For all experiments 






thrombolysis interventions381,382. At least 9 experiments were performed for a given 
treatment, using blood from 5 donors (total of 82 experimental infected clots).  
 
Calculations of infected clot degradation metrics 
 
To quantify instantaneous infected clot degradation from the images recorded with the 
CCD camera, an edge-detection and tracking analysis script in MATLAB was used as 
described previously152,377. Briefly, the initial infected clot width (ICWi) at 0 min and the 
final infected clot width (ICWf) at the completion of the 30 min experiment were used 







The width of the infected clot was defined as the distance between the edges for each 
row of the image, minus the width of the suture. 
 
Post-experiment bright-field light microscopy 
 
Following in vitro flow experiments of plasma alone and the combination of plasma, 
thrombolytic, and antibiotic, the flow system was left intact and placed on top of an 
inverted microscope (IX71, Olympus Inc.). Images were obtained using a 12-bit CCD 
camera (Retiga-EXi, Q-imaging, British Columbia, Canada) equipped to the microscope 
in order to obtain additional qualitative information (e.g. colour, larger field-of-view) 
about clots than that inferred from time-lapse imaging. 
 
Calculations of infected clot degradation metrics 
 
Effluent samples from the in vitro flow experiments were measured directly following 
the 30 min protocol using a Coulter Counter (Multisizer 4, 30-μm aperture, Beckman 
Coulter, California, USA) to quantify the size distribution (600 nm – 18 μm) of debris, 
cells, and cell aggregates. This measurement was completed three times for each 








Data were statistically analysed using GraphPad Prism 7 (GraphPad Software Inc, 
California, USA) with a significance level of p < 0.05. To analyse the FICL difference of 
means among the experimental exposures for infected clots, the Kruskal-Wallis test was 
used. Additionally, post-hoc testing was performed using Dunn’s non-parametric 
pairwise multiple comparison test. The UH and BB cavitation energy difference of means 
was analysed using a two-way ANOVA with post-hoc analysis using Tukey’s multiple 
comparisons test. For both the cavitation energy and FICL analyses, the Tukey method 




The data generated during and/or analysed during the current study are available from 





Bacteria isolate characterization 
 
The S. aureus IE clinical isolate used in this study was found to have the spa-type t021. 
Oxacillin susceptibility was determined to be less than 2 ug/mL, thereby classifying it 
as methicillin-susceptible. The S. epidermidis quality control strain was resistant to all 
oxacillin concentrations, which is in accordance to its already well-known methicillin-
resistant status. A growth curve indicating the lag, exponential, and stationary phase 
was completed for the S. aureus IE isolate in Iscove’s Modified Dulbecco’s Medium 
(IMDM). Based on this curve, all inoculums were prepared for experiments when 
bacteria were in the mid-exponential growth phase, around an optical density at 600 nm 









Histological analysis and confocal viability assay of infected clots 
 
Close inspection of the infected clots at high magnification showed a biofilm outer layer 
consisting of fibrin-embedded Staphylococci (Fig. 7.1a, b). Directly below the dense 
matrix of large quantities of bacteria within the fibrin mesh was a layer of fibrin. The 
inner portions of the clots were comprised of fibrin, sporadic immune cells, and 
predominately erythrocytes. Additionally, locations further from the clot core contained 
fewer erythrocytes, and an increasing amount of fibrin, seen in both the haematoxylin-
eosin (H&E) and crystal violet (CV) staining (Fig. 7.1a, b). CV staining confirmed the 
location and presence of staphylococcal bacteria, because on a cellular level only gram-
positive bacteria are stained purple (Fig. 7.1b). Of additional note, the iodine in the CV 




Figure. 7.1. Cross-sectional histological staining and confocal laser scanning microscopy of the 
infected clot model. Both A and B are each composed of two combined microscope images acquired 
at 40x magnification. (a) Image of H&E staining of an infected clot cross-section. The arrowhead 
indicates bacteria (purple), the arrow points at fibrin (pink), and a dashed-line arrow at 
erythrocytes (red). (b) Crystal violet staining, where an arrowhead indicates bacteria (purple), an 
arrow for fibrin (yellow), and a dashed-line arrow for erythrocytes (brown). (c) Image J maximum 
intensity projection of live (green, SYTO 9 stained) and dead (red, PI stained) S. aureus comprising 









The interpretation of the living status of the infected clot bacteria could not be obtained 
from H&E and CV histological staining. Therefore, confocal laser scanning microscopy 
(CLSM) with two fluorescent markers was used to determine if bacteria were viable before 
flow experiments. In each case, the biofilms lining the clots were made up of 
predominately viable bacteria of 0.5-1 μm spheres (-cocci) (see Fig. 7.1c; fluorescently 
labelled green by Syto 9). Dead bacteria (fluorescently labelled red by propidium iodide) 
were present, however at substantially lower numbers than viable bacteria. Corresponding 
to the histology, the thickness of the biofilms was not homogeneous. Additionally, the 
biofilm structure did not appear completely intact in some places (e.g. bottom left 
corner, Fig. 7.1c). Occasionally observed, most likely due to green auto-fluorescence, 
were rod-shaped fibre-like chains, suggesting fibrin, and round objects larger than 
bacteria, suggesting erythrocytes, immune cells, or possibly platelets. 
 
Histological comparison of infected and control clots 
 
When examining the H&E staining that was performed at the same time for all infected 
and control clots, the infected clots, though from a different batch, had similar 
morphology (Fig. 7.2a1-a3) to the previous stained specimens (Fig. 7.1a). Briefly, a 
biofilm composed of bacteria encased the fibrin mesh on the outer layer of the clots. 
Directly below the biofilm was a thick fibrin layer; and below the biofilm layer, the 
number of erythrocytes present increased towards the predominately erythrocyte core 
(Fig. 7.2). The suture (top right in Fig. 7.2a1 and 7.2a3) supporting the infected clot 
was also lined in a fibrin layer and biofilm (Fig. 7.2a3). The biofilm was heterogeneous 
with varying thickness. The control clots (Fig. 7.2b1, 7.2c1) were structurally and 
morphologically different from the infected clots. The sterile retracted clots consisted of 
a porous perimeter surrounding a dense erythrocyte core (Fig. 7.2b1). The outer most 
layer of the perimeter appears to be less porous than the rest of the inner region (Fig. 
7.2b2). This less porous outer layer is more prominent in the sterile retracted clots 
incubated 24 h in human fresh-frozen plasma (hFFP; Fig. 7.2c2). This clot was also 
devoid of the dense core seen in the sterile retracted clot not incubated with plasma. 
The sutures are eccentric in the infected clot compared to the controls (Fig. 7.2a3-c3). 
Additionally, both the infected clot core and the sterile, retracted clot have tear streaks; 
with multiple found in the infected clot core (Fig. 7.2a1) and two streaks, one from the 
left side of the suture to the outside and the other to the right of the suture, of the sterile 








Figure 7.2 H&E histology of infected and control clot cross-sections. (a1-3) Infected clot, (b1-3) 
sterile, retracted clot, and (c1-3) sterile, retracted clot incubated 24 hr in sterile hFFP. The boxes 
with a solid black line in a1, b1, c1, represent the border region of zoomed-in focus for the images 
to the right (a2, b2, c2). The dashed line boxes represent the zoomed-in area of the clot by the 
suture for the corresponding images to the far right (a3, b3, c3). Black arrows indicate a suture 
thread (light grey). Images (a1, b1, c1) are at 10x magnification, and the rest (a2-3, b2-3, c2-3) are 
at 40x magnification. 
 
 
Infected clot degradation as determined by width loss 
 
In this study, infected clots were subjected to different combinations of therapeutics 
(oxacillin, rt-PA, intermittent continuous-wave 120-kHz US, and UCA Definity), while 
subjected to plasma flow under controlled conditions. The infected clots had an average 
diameter of 442.2 µm ± 47.6 SD with no significant differences between the treatment 
groups. The fractional infected clot width loss (FICL) over 30 min treatment was used 
to quantify the extent of degradation, and was computed using custom automated 
computer image analysis of the time-lapse microscopy images. As seen in Figure 7.3, 





at 30 min. A perfusate flow rate of 0.65 mL/min provided minimal degradation of 
infected clots due to mechanical shear stress and endogenous tissue plasminogen 
activator from plasma flow alone, thus providing us with a stable, reproducible control. 
When rt-PA and oxacillin were added to the plasma, infected clot width loss appeared 
highly variable, ranging from minimal (6.2%) to full clot width loss, i.e. 100% FICL. 
Similar amounts of degradation as the plasma alone group were seen when US alone 
under plasma flow was used as treatment. The addition of rt-PA and oxacillin to the 
perfusate of the US group demonstrated a high level of variability (-14.8 – 99.9%), 
similar to the rt-PA and oxacillin without US treatment. The addition of Definity to the 
plasma and US did not result in large amounts of infected clot degradation (< 20%). 
However, Definity added to the plasma, rt-PA, oxacillin, and US perfusate treatment 
group resulted in an almost complete loss for all infected clots (99.3 ± 1.7%). This was 
statistically significantly different than the plasma, US, and Definity treated clots 
without the rt-PA and oxacillin addition. 
 
Post-experimental light microscopy 
 
In addition to the transverse visualization of the clots during the 30 min time-lapse 
imaging, a longitudinal perspective was also obtained directly after experiments using 
light microscopy and a colour camera. Following experiments with plasma alone, the 
structure of the infected clots appeared intact and adherent to the suture (Fig. 7.4a). At 
a higher magnification, the biofilm was visible and observed to be surrounding both the 
clot (red) and suture (horizontal black line) (Fig. 7.4b). The images of infected clots 
treated with plasma alone were consistent with histological findings. Infected clots were 
composed of a somewhat dense core becoming less dense towards the outer perimeter, 
and the biofilm as the outermost layer. When infected clots were treated with rt-PA and 
oxacillin in combination with the plasma, the border of the clot was no longer smooth, 
but irregular in shape and also appeared less dense (Fig. 7.4c). This border was also 
observed with the monochromatic camera during time-lapse imaging appearing as a 
rolling-adhesion type motion of fibrin degradation products down the length of the clot. 
However, the camera and experimental set-up did not allow for capturing the complete 
length of the clot. After treatment with all therapeutics combined, US exposure, 


































Figure 7.3. Fractional infected clot loss following different treatments. Boxes represent the 
interquartile range. The lines within the boxes represent the median and the whiskers indicate 1.5 
times the interquartile range. The dot depicts an outlier as determined using the Tukey method. 
A single asterisk (p<0.05) or three asterisks (p<0.001) with a solid line above the boxes represent 
a statistically significant difference with the plasma alone, the plasma with ultrasound, and the 
plasma, ultrasound, and Definity treatment groups. The different treatment conditions are given 
in the table below the graph. N=9 for all treatments, with the exception of the plasma and 
ultrasound treated group (n=10). 
 
 
 Cavitation detection 
 
Two different types of cavitation energies, ultraharmonic (UH) and broadband (BB), 
were detected with the passive cavitation detector (PCD), demonstrating the presence 





groups, very low levels of cavitation were detected for both types of energy (Fig. 5a, 5b). 
The addition of Definity resulted in significant higher levels of UH energy (Fig. 5a), 
indicating stable cavitation. Additionally, these three treatment groups with Definity 
exhibited significantly higher UH energy than BB (Fig 5a, 5b), which indicates more 
stable than inertial cavitation. Both UH and BB cavitation was observed to be higher in 
the Definity, rt-PA and oxacillin treated infected clots, albeit not a significant difference 







Figure 7.4. Bright-field light microscopy imaging of infected clots acquired directly following 
treatment. Infected clot treated only with plasma at 4x (a) and at 10x magnification (b). The black 
arrow in image b points out the biofilm (beige). (c) A plasma, rt-PA, and oxacillin treated infected 
clot at 4x magnification. (d) A plasma, rt-PA, oxacillin, ultrasound, and Definity treated infected 
clot at 4x magnification. The sutures (black line) are situated at the bottom of the clots, which can 








Effluent particle size detection 
 
The number-weighted size distribution of effluent particles, measured directly following 
treatment, is shown in Figure 6. The largest particle size detected was 10.4 μm, and 
99.6% of the particles were smaller than 5 μm. The plasma treatment alone had the 
lowest number of particle counts, and the infected clots treated with US, Definity, rt-
PA, and oxacillin had the largest amount of counts. Note that the smallest particle-sizing 





Figure 7.5. The ultraharmonic (a) and broadband (b) cavitation energy detected by the passive 
cavitation detector in response to 120-kHZ ultrasound insonification. Boxes represent the 
interquartile range. The lines within the boxes represent the median and the whiskers indicate 1.5 
times the interquartile range. Black circles depict outliers as determined using the Tukey method. 
A single asterisk (p<0.05) above a dashed line represents a statistically significant difference 
between the ultraharmonic and broadband energies of the same treatment group. Two asterisks 
(p<0.01) represent a statistically significant difference of ultraharmonic energy between the group 
and the ultrasound without Definity groups. The different treatment conditions are given in the 









his proof-of-principle study reports the potential efficacy of sonobactericide, 
combined with antibiotics and rt-PA, to enhance the treatment of bacterial 
infected clots in an in vitro flow model. In addition, this study also reports on the 
methods used to create a translatable in vitro infected clot model using human and 
bacterial products, on the basis of the IE isolate, methodology of infected clot, histology, 






















Figure 7.6. Effluent characterization using particle size measurement with the Coulter counter. 
Colours and line style represent different treatment groups with yellow indicating no rt-PA or 
oxacillin, red indicating rt-PA without oxacillin, and blue indicating oxacillin addition (n=3 per 
group; line represents the average). Dashed lines indicate treatment with ultrasound; dotted lines 
indicate treatment with ultrasound and Definity. The number-weighted particle size distribution 
is shown with the background subtracted. US = ultrasound and OXA = oxacillin. 
 
 
To model the in vivo situation, a methicillin-susceptible S. aureus isolate that originated 
from an IE patient was used. A clinical IE isolate was chosen for translatability by 








originating isolates may lack the bacterial characteristics necessary for proper adherence 
(e.g. adhesins, fibronectin-, and fibrinogen-binding proteins) to host micro-thrombi to 
induce IE383,384. The isolate’s spa-type t021 has previously been isolated from IE385. 
Although we did not directly perform an in-depth virulence factor analysis of this isolate, 
it has been demonstrated previously that isolates (N=105) originating from IE patients 
from different countries all contained the same surface-associated adhesins shown to be 
important for the invasiveness and development of IE (clfA, clfB, fnbA, and sdrC)386,387. 
Additionally, these factors important for IE development are highly conserved388. S. 
aureus is a known producer of coagulase, an enzyme that converts soluble fibrinogen into 
fibrin349. This fibrin scaffold allows the bacteria to encase themselves in a protective 
structure, consisting of bacterial and host components389,390. A marked presence of gram-
positive bacterial colonies encapsulated in fibrin is seen in our histology (Fig. 7.1 and 
7.2), which is consistent with that of IE in in vivo animal models and human surgically 
excised valves334,348,390-393. 
 
The progression of the presence of microthrombi on heart valves into IE biofilms is 
dependent on bacterial adherence to these initial clots352,390. Two previous studies 
developed infected clots as an in vitro model of IE, using a mix of human, animal, and 
synthetic products394,395. McGarth et al.394 suspended bacteria in an eppendorf tube with 
a fibrin glue recipe consisting of human cryoprecipitate, bovine thrombin, monofilament 
line, and calcium chloride to create infected clots. Another study reported by Palmer, 
et al.395 modified the previous method to include platelets and aprotinin (bovine) 
solution. Our study used infected retracted human blood clots, and the only synthetic 
media used was IMDM, which both may allow for bacterial adherence that better mimics 
the human situation in vivo. Additionally, this methodology resembles the early 
pathogenesis of IE, in which micro-thrombi are formed on heart valves first and then 
bacteria adhere and subsequently grow into an IE biofilm43,334,352. Human cell culture 
media for growing bacteria have previously been used396,397. IMDM was chosen because 
it emulates the iron-restricted environment in vivo. Iron restriction leads to the 
upregulation of virulence factors which would not be present if grown in a traditional 
iron rich bacterial growth media398.  
 
Histology and live cell imaging revealed that the morphology of infected clots reported 





and resembled the structure of IE biofilms found in animal and patient samples334. 
Though limited polymorphonuclear (PMN) leukocytes are seen in our histology, 
neutrophilic inflammation is commonly mentioned in histopathologic findings in vivo. 
However, this inflammation is seen with regards to the valve tissue itself, resulting from 
endocardial injury43. Furthermore, it is well established in vivo that biofilm in IE 
represents a zone of localized agranulocytosis and that it would be rare that PMNs would 
be able to come into direct contact with the fibrin embedded bacteria392,393. This is 
supported by the clear separation of bacterial colonies and PMNs seen in histologic 
studies of animal and human IE biofilms334,348,390,391. Heterogeneous accumulation of 
bacteria is evident in the confocal microscopy images of the biofilm (e.g. bottom left 
corner, Fig. 7.1c) which is not contiguous in some places. This irregularity could also be 
due to the friable nature of infected clots after thin sample preparation, which could 
have been damaged during transport from fluorescent staining to the CLSM system or 
during the image capturing process.  
 
It is widely known that the efficiency of a drug given intravenously can be affected by 
binding of the drug to plasma proteins399. Our flow model included the interaction of 
oxacillin with plasma proteins and inhibition of fibrinolysis with plasminogen activator 
inhibitor (e.g. PAI-1) and antiplasmin400 since we used human plasma as our flow media. 
Additionally, MB oscillations can be affected by the viscosity of the surrounding medium, 
with damping occurring with increased viscosity401. Thus, inclusion of human plasma 
in our flow studies provided a test of the therapeutic effect of sonobactericide in the 
presence of a higher viscosity fluid approximating whole blood. 
 
It has been demonstrated that IE biofilms in vivo form and generally exist on the low-
pressure chamber side of valves373. This side of the valves are exposed to normal and 
regurgitant jet flow, however early IE biofilms are located beside the jet flows where low 
velocities exist374. Additionally, a range of velocities (0 to 45 cm/s over one cardiac cycle) 
have been reported across the mitral valve402, which is a common site of IE. We chose 
0.3 cm/s for all experiments in the in vitro set-up because 1) this is within range of flow 
speeds experienced by IE biofilms; and 2) this presents the worst-case scenario for the 
therapeutic outcome403-405. Additionally, the rate of penetration of therapeutics (both rt-
PA and the antibiotic), replenishment of microbubbles as cavitation nuclei, and the 






meaning the rate is slow under low flow conditions and fast under high flow conditions. 
 
In this study, US and Definity alone did not enhance infected clot size reduction (Fig. 
7.3). There were some clots that showed negative values for infected clot width loss. 
The response of clots to the thrombolytic and antibiotic may appear as growth, when 
the infected clot is in the early stages of degradation (Fig. 7.4c). It is likely that these 
infected clots could have been effectively lysed provided the treatment time was longer 
than the 30 min period employed in this study.  
 
Sustained stable cavitation was harnessed in this study, monitored using a PCD 
detecting UH and BB emissions during 30 min flow experiments. In all cases, we 
observed significantly more UH than BB cavitation (Fig. 7.5), indicating more stable 
than inertial cavitation152, which suggests that unwanted bioeffects may be minimized358. 
Paradoxically, stable cavitation, which occurs at a lower acoustic pressure amplitude, 
has been reported to correlate with enhanced thrombolysis to a greater degree than 
inertial cavitation in the presence of rt-PA360. Although UH was observed when Definity 
was combined with US, the addition of oxacillin and rt-PA was necessary to achieve 
infected clot width loss.  
 
The inclusion of rt-PA in combination with oxacillin in our treatment regime likely 
benefited from this particular lytic’s ability to target fibrin, which is the backbone of IE 
biofilm334,406,407. The absence of large fibrin degradation products liberated during 
treatment in our study (Fig. 7.6) suggests minimal risk of embolization from 
sonobactericide. Nonetheless, filters such as those deployed in vessels downstream of 
the heart valve during transcatheter aortic valve replacement procedures408 could be used 
with sonobactericide to prevent embolism.  
 
In this study, a 120-kHz frequency was chosen considering that the majority of previous 
studies for treating bacterial biofilms and clots in the presence of rt-PA have been 
performed with low frequency US32,62,65,112,124,128,354-357. The intermittent exposure scheme 
has been reported previously for sonothrombolysis152,377. However, diagnostic cardiac 
imaging is typically performed using a 2-MHz centre frequency409. Further studies 
should investigate the feasibility of using dual diagnostic and therapeutic 2-MHz cardiac 





are closer to resonance at 2-MHz than at 120-kHz, therefore lower acoustic pressures 
could be used to produce sustained stable cavitation, and therefore reduce the likelihood 
for any negative bioeffects to surrounding tissues.  
 
The host immune system response, which includes inflammatory processes, is not 
adequately represented in our in vitro IE biofilm model. Another limitation is that 
dynamic flow was not present during the formation of the infected clot. Biofilms 
developed in a mostly static condition vs. a dynamic condition can lack robustness410. 
Additionally, only one isolate was tested in this study. More isolates must be tested in 
future studies to determine the ability of sonobactericide to treat other species or other 
isolates of S. aureus causing IE. Finally, this study did not investigate the direct 
bactericidal capability of sonobactericide in combination with antibiotics and 
thrombolytics, which is important in understanding the true potential of this treatment. 
However, it is known that bacteria released from mature biofilms become metabolically 
active and are thus susceptible to antibiotic treatment in the blood stream7,353. Freed 
bacteria as a result of sonobactericide should be evaluated in future studies. 
 
Traditionally, IE is considered a contraindication for thrombolytic treatment in 
adults101,102. However, it has been shown to be effective in paediatric patients361-364. 
Unlike other thrombolytics, rt-PA has a high affinity to fibrin and thus provides a more 
local activation of fibrin-bound plasminogen, therefore decreasing the risk of negative 
effects due to systemic plasminogen cleavage406,407. Localized delivery of rt-PA to IE 
biofilms using echogenic liposomes loaded with rt-PA in combination with an antibiotic 
could also be a promising strategy to reduce off-target effects377. 
 
Lastly, studies in an IE animal model will be necessary to assess the efficacy of 
sonobactericide in vivo. Nonetheless, the work reported in this paper represents the first 
time that sonobactericide has been investigated as a possible therapeutic option for 
infective endocarditis. Accordingly, our primary goal was to determine suitable 
treatment conditions and to understand if this approach has potential in a tightly 
controlled setting. The rationale for using the in vitro model was to allow for precise 
cavitation monitoring, complete dose control, and to minimize human and 
microbiological variability in the infected clot. Further advantage of an in vitro model 






lapse microscopy. Nevertheless, it has been previously demonstrated that the results of 
in vitro simulated endocarditis biofilms (infected clots) are comparable to the in vivo 






n this proof-of-principle study, infected clots were developed as a translatable 
model of IE biofilm and the efficacy of sonobactericide, the use of US and an UCA 
in combination with or without an antibiotic and thrombolytic was evaluated in vitro 
under flow. Histology and confocal imaging revealed that the infected clot model 
resembled a clinical IE biofilm, especially for early pathogenesis. Infected clots exposed 
to the combination of oxacillin, rt-PA, ultrasound, and Definity achieved 99.3±1.7% 
fractional infected clot loss, which was greater than the other treatment arms. These 
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Figure S7.1. Experimental set-up. (a) Illustration of the infected clot model (442.2 μm  ± 47.6 SD 
in width), where the infected clot composed of bacteria (yellow) and clot (red) is produced on a 
suture (black). (b) Schematic depicting the combined time-lapse microscopy, acoustical field set-
up, and flow system to study the treatment of infected clot on a suture in vitro (not drawn to scale). 
For clarity purposes, only the bottom wall of the tank in the schematic is lined with acoustic 
absorber, while in reality all walls were lined. Distances for both the passive cavitation detector 
and the 120-kHz transducers to the clot was 5 cm. The perfusate reservoir contained plasma alone, 








“ Our lives begin to end the day 
we become silent about things  
that matter.  
  
- Martin Luther King, Jr. 
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One of the main challenges for ultrasound molecular imaging is acoustically 
distinguishing non-bound microbubbles from those bound to their molecular target. In 
this in vitro study, we compared two types of in-house produced targeted lipid-coated 
microbubbles, either consisting of DPPC or DSPC lipid as the main lipid, using the 
Brandaris 128 ultra-high-speed camera to determine vibrational response differences 
between bound and non-bound biotinylated microbubbles. In contrast to previous 
studies that studied vibrational differences upon binding, we used a covalently bound 
model biomarker (i.e., streptavidin) rather than physisorption, to ensure binding of the 
biomarker to the membrane. The microbubbles were insonified at frequencies between 
1 and 4 MHz at pressures of 50 and 150 kPa. This study shows lower acoustic stability 
of bound microbubbles, of which DPPC-based microbubbles deflated most. For DPPC 
microbubbles with diameters between 2 and 4 μm driven at 50 kPa, resonance 
frequencies of bound microbubbles were all higher than 1.8 MHz, whereas those of non-
bound microbubbles were significantly lower. In addition, the relative radial excursions 
at resonance were also higher for bound DPPC microbubbles. These differences did not 
persist when the pressure was increased to 150 kPa, except for the acoustic stability 
which further decreased. No differences in resonance frequencies were observed 
between bound and non-bound DSPC microbubbles. Nonlinear responses in terms of 
emissions at the subharmonic and second harmonic frequencies were similar for bound 
and non-bound microbubbles at both pressures. In conclusion, we identified differences 
in vibrational responses of bound DPPC microbubbles with diameters between 2 and 4 
















ltrasound contrast agents that consist of targeted microbubbles are emerging in 
their applications for ultrasound molecular imaging412-414. These microbubbles 
have a ligand attached to their shell by which they can be targeted to a specific 
biomarker, for example αvβ3 that is expressed on the cellular membrane of endothelial 
cells in neovasculature415,416. For successful translation of ultrasound molecular imaging 
to the clinic, two major problems still need to be tackled: 1) producing microbubbles of 
the same size that also behave identical in an ultrasound field, and 2) distinguishing the 
response of a single targeted microbubble bound to a specific biomarker from a non-
bound targeted microbubble. Since microbubbles of the same size can still have different 
acoustic properties237,243,417-419, producing monodisperse microbubbles may not 
necessarily result in microbubbles that have, for example, the same resonance frequency. 
But if it is possible to determine the acoustic parameters that are specific for bound 
targeted microbubbles, they may be distinguished from non-bound targeted 
microbubbles based on their acoustic signal. Several studies investigated the difference 
in acoustic properties of bound and non-bound microbubbles, but these studies reported 
conflicting results. In the low frequency range (2 - 4 MHz) a shift in resonance frequency 
was found for microbubbles after binding55,420, whereas at 11 MHz and 25 MHz no shift 
was observed421. For the responses at the subharmonic frequency either a change in 
frequency421 or no change in amplitude and frequency422 was reported upon binding. In 
contrast, for the response at the second harmonic frequency the results reported by Zhao 
et al.422 and Casey et al.423 were in agreement with each other: the amplitude increased 
for bound microbubbles. Finally, both Zhao et al. and Overvelde et al. found a decrease 
in the vibrational response at the fundamental frequency for bound microbubbles55,422. 
 
All acoustic studies on bound versus non-bound targeted microbubbles used either 
physisorption as a method to attach a model biomarker to an artificial surface 
(membrane or capillary)55,420,422,423 or had the model biomarker embedded in agarose421. 
Physisorption of a model biomarker can result in detachment of the biomarker from the 
membrane or capillary which then can cover the whole targeted microbubble, including 
the area that is not directly in contact with the membrane. This was reported by  







membrane424. Functionalization of lipid-coated microbubbles with streptavidin changes 
the properties, such as elasticity35,425,426 and acoustic stability35. Consequently, the 
comparisons made in previous studies between bound microbubbles and non-bound 
microbubbles are in fact a comparison between bound lipid-coated microbubbles 
covered by streptavidin and non-bound lipid-coated microbubbles, which did not have 
streptavidin on their shell. In addition, both physisorption and embedding a model 
biomarker in agarose are far from the in vivo situation, where biomarkers are 
incorporated into the cellular membrane.  
 
We covalently linked a model biomarker to an artificial surface to study the vibrational 
responses of single bound targeted microbubbles and non-bound targeted microbubbles 
aiming to find parameters to discriminate them acoustically. Super-resolution confocal 
laser scanning fluorescence microscopy showed that covalent coupling of the model 
biomarker streptavidin to a hydrogel prevented the streptavidin to bind to the 
biotinylated lipid-shell of the microbubble outside the binding area241. That study 
compared the lipid distribution and binding area of two types of targeted lipid-coated 
microbubbles that were either coated with mainly DPPC (1,2-dipalmitoyl-sn-glycero-3-
phosphocholine, C16:0) which is the main shell component of Definity® (Lantheus 
Medical Imaging, North Billerica, MA, USA) or mainly DSPC (1,2-distearoyl-sn-glycero-
3-phosphocholine, C18:0) which is the main lipid component of SonoVue, Lumason, 
and BR14 (Bracco Imaging  S.p.A., Milan, Italy)133,241,378,419,427,428. It was shown that the 
lipid distribution was more homogeneous for DPPC-based microbubbles than for DSPC-
based microbubbles and that the binding area for DPPC-based microbubbles was 
significantly larger than for DSPC-based microbubbles241. We previously determined the 
acoustic properties of these DPPC and DSPC-based microbubbles in a set-up where the 
microbubbles were floating against an OptiCell wall (non-bound)419 and hypothesized 
that the difference in ligand-distribution and binding area could alter the acoustic 
response after adherence of the microbubble to its molecular target. In the present study 
we investigated the vibrational response of in-house produced targeted DPPC-based and 
DSPC-based microbubbles using the Brandaris 128 ultra-high-speed optical camera222 
when they had bound to a streptavidin-coated hydrogel and  compared their responses 
to those of non-bound microbubbles floating against the hydrogel. We aimed to identify 
differences in vibrational responses that may be used to discriminate bound from non-
bound microbubbles.   
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Materials and Methods 
Microbubble preparation 
 
Biotinylated lipid-coated microbubbles with a C4F10 gas core (F2 Chemicals Ltd, Preston, 
UK) were made as previously described241,314 by sonication for 1 min. The coating was 
composed of 84.8 mol% DSPC (P6517, Sigma-Aldrich, Zwijndrecht, the Netherlands) 
or DPPC (850355, Avanti Polar Lipids, Alabaster, AL, USA), 8.2 mol% polyoxyethylene-
40-stearate (PEG-40 stearate, P3440, Sigma-Aldrich), 5.9 mol% 1,2-distearoyl-sn-
glycero-3-phosphoethanolamine-N-[carboxy(polyethylene glycol)-2000] (DSPE-
PEG(2000), 880125, Avanti Polar Lipids); and  1.1 mol% 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[biotinyl(polyethylene glycol)-2000] (DSPE-PEG(2000)-
biotin, 880129,  Avanti Polar Lipids).  
 
A 25 μm thick polyester membrane was mounted on a custom-made rectangular 
polyvinylchloride holder (same size as a microscope objective glass) and was custom 
coated with a 1-2 μm thick polycarboxylate hydrogel (XanTec bioanalytics GmbH, 
Düsseldorf, Germany). For the bound targeted microbubbles, the hydrogel was activated 
and streptavidin (S4762, Sigma-Aldrich) was subsequently covalently attached to the 
hydrogel using the amine coupling kit (K AN-50, XanTec bioanalytics GmbH) according 
to the instructions of the manufacturer as previously described241. Briefly, streptavidin 
was dissolved in acetate buffer (2 mM, pH 5.4) (1 mg/mL). After desalting the 
streptavidin by use of a PD-10 desalting column (GE Healthcare Bio-Sciences), the 
concentration was determined spectrophotometrically at 570 nm using a PierceTM BCA 
Protein Assay kit (Thermo Scientific) and Thermo Multiskan EX. Three polyester 
membranes were placed in a 5-Slidemailer (Heathrow Scientific, Northgate, UK) with 
18 mL of 1 M NaCl + 0.1 M NaB (pH 10) elution buffer (K AN-50, XanTec bioanalytics 
GmbH), followed by an incubation with 18 mL of 1.6 % (w/v) EDC·HCL (K AN-50, 
XanTec bioanalytics GmbH) in activation NHS/MES buffer (K AN-50, XanTec 
bioanalytics GmbH), and 18 mL of 33 μg/mL desalted streptavidin in 2 mM acetate 
buffer at pH 5.2-5.4. Finally, 18 mL of 1 M ethanolamine hydrochloride (pH 8.5) 
quenching buffer (K AN-50, XanTec bioanalytics GmbH) was used to terminate the 
reaction. The targeted microbubbles were allowed to adhere to the streptavidin-coated 
membrane in air-equilibrated phosphate buffered saline (PBS) containing calcium   





Netherlands) by flotation for 5 min. Then, the membrane was gently washed with air-
equilibrated PBS containing calcium and magnesium three times using a 3 mL plastic 
Pasteur pipet. For the non-bound targeted microbubbles the hydrogel was treated in the 
same way, except for the addition of streptavidin. The targeted microbubbles were added 
below the hydrogel-coated polyester membrane of the custom-made holder and floated 
up due to buoyancy. The hydrogels with the non-bound targeted microbubbles and 




























Figure 8.1. Configuration and composition of non-bound targeted microbubbles (top) floating 
against a streptavidin-coated membrane and targeted microbubbles bound to this membrane in 
the experimental set up (not to scale). 
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The vibrational responses of the bound and non-bound targeted microbubbles were 
captured using the Brandaris 128 ultra-high-speed camera operated at ~15 million 
frames per second222. Single microbubbles were investigated in ROI mode242 using the 
microbubble spectroscopy technique243 in combination with the exact same set-up as in 
our previous study419, except for a higher magnification microscope objective (60×, NA 
= 0.9, Olympus, Tokyo, Japan). Briefly, a broadband single element polyvinyl difluoride 
(PVDF) transducer (25 mm focal distance, f-number 1.1, center frequency 5 MHz, 
PA275, Precision Acoustics Ltd, Dorchester, UK) transmitted a Gaussian tapered 8-cycle 
sine wave burst at transmit frequencies swept from 1 to 4 MHz (increment steps of 200 
kHz) at a peak-negative pressure (PA) of 50 or 150 kPa at the focus. The pressures were 
calibrated with two calibrated PVDF needle hydrophones in a separate measurement 
beforehand (0.2-mm diameter PA2030 and 1-mm-diameter PA1875, Precision 
Acoustics). The optic focus was aligned with the acoustic focus, to ensure that the 
microbubble received the intended pressure. The ultrasound was triggered on the 
second recording of each microbubble to obtain the initial resting diameter and the noise 
level with our contour tracking algorithm in the first recording. The experiments were 
conducted at room temperature and the sample was submersed in air-equilibrated PBS 
containing calcium and magnesium. All microbubbles were exposed to ultrasound 




Diameter-time (D-t) curves were obtained using custom-designed image analysis 
software243 that determines the vibrational responses as described elsewhere [10]. 
Briefly, the acoustic stability of the microbubbles was quantified as the difference 
between the mean diameter of the microbubble in the initial D-t curve (D0) and the final 
D-t curve (Dend). Next, the asymmetry of the D-t curves was measured as the ratio E/C 
between the relative expansion E, defined as (D#$% − D') D'⁄ , and the relative 
compression C, defined as (D' − D#*+) D'⁄ , of the microbubble. Where Dmax is the 
maximum diameter, Dmin the minimum diameter in the D-t curve, and D0 the resting 
diameter before vibration. The E/C ratios were used to classify the asymmetry as: 
compression-only behavior (E/C < 0.5); normal excursion (0.5 ≤  E/C  ≤ 2); or 





Using the fast Fourier transformation (FFT) the frequency content of the D-t curves was 
analyzed in terms of the amplitude at the transmit frequency (fT). These amplitudes 
were fitted to a resonance curve of a linear oscillator by a least-mean-squares 
method243,419 to determine the resonance frequency (fres) of the microbubble. At fres, the 
diameter of the microbubble is referred to as Dres. The maximum relative radial 
excursions (i.e. at fres) were defined as the maximum amplitude of the FFT divided by 
the corresponding resting diameter of the microbubble419. The same approach was used 
to determine the subharmonic resonance frequencies (fsub) and the second harmonic 
resonance frequencies and the corresponding maximum relative radial excursions. Next, 
the maximum relative radial excursions were transformed into pressures as described 
by Emmer et al.237,419. All calculations were performed in MATLAB (The MathWorks 




Shapiro-Wilk tests for normality showed that the data was not normally distributed, so 
we used nonparametric testing. For comparing the acoustic stability of the microbubbles 
we used Wilcoxon signed-rank tests. When comparing groups, e.g. bound DSPC and 
non-bound DSPC, we used Mann-Whitney U tests. Medians and interquartile ranges 
(IQR) are reported and were calculated using Tukey’s Hinges method. Statistical 
analyses were performed using SPSS (Statistics 21, IBM Corp., Armonk, NY, USA) and 









n total, 143 single microbubbles having a D0 between 1.5 and 10 μm were analyzed. 
At 50 kPa, 46 bound DPPC microbubbles were insonified; 18 of which were also 
insonified at 150 kPa. For bound DSPC microbubbles, 43 were insonified at 50 kPa; 15 
of which were also insonified at 150 kPa. None of the bound microbubbles detached 
during the experiments since every microbubble remained within the optic focus. For 
the non-bound microbubbles we included 26 DPPC and 28 DSPC microbubbles, which 




At PA = 50 kPa, both bound DPPC and DSPC-based microbubbles deflated significantly 
more than when they were non-bound (p = 0.0001), as shown in Figure 8.2. The median 
size for the bound DPPC microbubbles after insonification was 83% of D0, while this 
was 98% for the non-bound DPPC microbubbles. The median size of bound DSPC 
microbubbles was 93% of D0 after insonification, whereas non-bound DSPC 
microbubbles maintained their original size (100% of D0). At a pressure of 150 kPa, the 
size difference between bound DPPC and non-bound DPPC microbubbles was not 
significant. The median diameter after insonification decreased to 53% of D0 for bound 
DPPC microbubbles and to 56% for non-bound DPPC microbubbles. In case of DSPC 
microbubbles those that had bound deflated more than those that had not (p = 0.004). 
For the DSPC microbubbles this was 76% for the bound ones and hardly any shrinkage 
(98% of their initial size) for the non-bound ones. In addition, for both bound and non-
bound microbubbles, those based on DPPC deflated more than those based on DSPC at 
50 kPa (bound: p = 0.001, non-bound: p = 0.031) and also at 150 kPa (both p = 
0.0001). 
 
Linear oscillation behavior 
 
The resonance frequencies in relation to Dres are shown in Figure 8.3. First of all, at a 
pressure of 50 kPa the resonance frequencies of bound DSPC microbubbles were similar 
to those of non-bound DSPC microbubbles. For DPPC-based microbubbles, the 
resonance frequencies of bound microbubbles were significantly higher than for non-








Figure 8.2. Diameter change during ultrasound exposure expressed as D0/Dend for bound DPPC 
(50 kPa: n = 46, 150 kPa: n = 18), non-bound DPPC (50 kPa: n = 28, 150 kPa: n = 28), bound 
DSPC (50 kPa: n = 43, 150 kPa: n = 15) and non-bound DSPC microbubbles (50 kPa: n = 26, 150 
kPa: n = 26). The filled black circles are outliers. 
 
 
frequencies between bound and non-bound DPPC microbubbles, we compared the 
resonance frequencies of those having Dres < 4 μm. For larger microbubbles all resonance 
frequencies were similar, but for microbubbles having a Dres < 4 μm, the resonance 
frequencies of bound DPPC microbubbles were significantly higher than for non-bound 
DPPC microbubbles (p = 0.002). In addition, no overlap was found between the median 
(IQR) resonance frequencies of bound DPPC microbubbles and non-bound DPPC 
microbubbles: 1.94 (1.83 – 2.25) versus 1.59 (1.40 – 1.77). In contrast, the resonance 
frequencies of bound and non-bound DSPC microbubbles were similar for all studied 
sizes (p = 0.494). Median (IQR) resonance frequencies were 2.39 (1.98 – 2.78) for 
bound DSPC and 2.63 (2.25 – 3.11) for non-bound DSPC microbubbles. The resonance 
frequencies of bound DSPC microbubbles were significantly higher than those of bound 
DPPC-based microbubbles at PA = 50 kPa (p = 0.001), for the non-bound DSPC and 
DPPC microbubbles no difference was found. The resonance frequencies at a pressure 
of 150 kPa were all similar. The number of microbubbles included in these graphs is 
lower than the total number of studied microbubbles, since some resonance peaks were 
below or above the measuring range (< 1 MHz or > 4 MHz); the resonance frequency 
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Figure 8.3. Resonance frequencies (fres) of bound DPPC (filled red circles), non-bound DPPC (red 
crosses), bound DSPC (blue open circles), and non-bound DSPC (blue crosses) microbubbles 
plotted versus the diameter at resonance (Dres) at PA = 50 kPa (top panel) and PA = 150 kPa 
(bottom panel).  
 
 
For bound DPPC microbubbles, the median maximum relative radial excursions 
(median (IQR) of 0.14 (0.11 – 0.18)) at the resonance frequency at a pressure of 50 kPa 
was significantly higher than for the non-bound DPPC microbubbles (0.09 (0.06 – 0.13), 
p = 0.002, Fig. 8.4,). Although the median maximum relative radial excursions of bound 
DSPC microbubbles 0.11 (0.08 – 0.12) were not significantly different from non-bound 
DSPC microbubbles 0.05 (0.03 – 0.13, p = 0.157) over the whole resonance frequency 
range, the maximum relative radial excursions for bound DSPC microbubbles were 
significantly higher for resonance frequencies > 2 MHz (bound: 0.11 (0.08 – 0.12), non-
bound: 0.03 (0.02 – 0.04), p = 0.001). In addition, the maximum relative radial 
excursions of bound DSPC microbubbles were significantly lower than of bound DPPC 
microbubbles (p = 0.0001), but similar for the non-bound DSPC and DPPC 
microbubbles. At a driving pressure of 150 kPa the median maximum relative radial 
excursions of bound and non-bound DPPC microbubbles at fres were similar, but 
significantly higher for bound DSPC than non-bound DSPC microbubbles (p = 0.001). 
The median (IQR) of the maximum relative radial excursions was similar for the bound 





microbubbles (Fig. 8.4). For non-bound microbubbles the maximum relative radial 
excursions were significantly higher (p = 0.03) for DPPC microbubbles than for DSPC 




Figure 8.4. Maximum relative radial excursions at the resonance frequency of bound DPPC (filled 
red circles) non-bound DPPC (red crosses), bound DSPC (blue open circles), and non-bound DSPC 
(blue crosses) microbubbles plotted versus the resonance frequency (fres) at PA = 50 kPa (top 
panel) and PA = 150 kPa (bottom panel).  
 
 
Nonlinear oscillation behavior 
 
The asymmetry of the radial excursions at each transmit frequency was expressed as the 
ratio between the relative expansion E and relative compression C. At 50 kPa the median 
of the radial excursions was compression-dominated with 0.5 < E/C < 1 for bound 
targeted microbubbles of both types (Fig. 8.5) at all frequencies. For the non-bound 
microbubbles the oscillations were mostly symmetric, except for the frequencies 
between 1 and 1.6 MHz for which the radial excursions of DPPC microbubbles were 
compression-dominated. At PA = 150 kPa the excursion behavior of bound 
microbubbles at frequencies between 1 and 1.8 MHz ranged from symmetric to 
expansion-dominated, whereas at higher frequencies the behavior of both microbubble 
types was compression-dominated. The non-bound microbubbles showed mostly 
symmetric oscillations.  
 
182 


































Figure 8.5. Median (IQR) ratio between the relative expansion E and the relative compression C 
of bound DPPC (50 kPa: n = 37, 150 kPa: n = 18) and bound DSPC (50 kPa: n = 43, 150 kPa: n 
= 15) microbubbles, and non-bound DPPC (50 kPa: n = 28, 150 kPa: n = 28) and non-bound 
DSPC (50 kPa: n = 26, 150 kPa: n = 26) microbubbles plotted versus the transmit frequency at 






Responses at the subharmonic frequency at a driving pressure of 50 kPa were present in 
22 out of 46 (48%) bound DPPC microbubbles and in 7 out of 43 (16%) bound DSPC 
microbubbles. For both non-bound DPPC and DSPC microbubbles only one (4%) 
responded at the subharmonic frequency. At the higher pressure of 150 kPa, the number 
of bound DPPC microbubbles responsive at the subharmonic frequency was similar to 
that at 50 kPa: 8 out of 18 (44%), but increased to 9 out of 15 (60%) for DSPC-based 
microbubbles. The number of non-bound microbubbles that responded at the 
subharmonic frequency increased to 12 out of 28 (43%) for DPPC and 6 out of 26 (23%) 
















Figure 8.6. Absolute pressures emitted at the subharmonic frequency of bound DPPC (50 kPa: 
n = 17, 150 kPa: n = 8), bound DSPC microbubbles (50 kPa: n = 7, 150 kPa: n = 7), non-bound 
DPPC (50 kPa: n = 0, 150 kPa: n = 10), and non-bound DSPC microbubbles (50 kPa: n = 1, 150 




Although quite some microbubbles had a response at the subharmonic frequency, only 
for the ones shown in Figure 8.6 a subharmonic resonance curve could be determined. 
Reasons for not being able to determine the subharmonic resonance curve were not 
enough points for a fit or the peak was below or above the measuring range. Emitted  
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subharmonic pressures were similar irrespective of binding and the type of lipid coating 
at each acoustic pressure (Fig. 8.6). At 50 kPa, of the 17 bound DPPC microbubbles 
shown in Figure 8.6, nine had a response at T2R (transmit at twice the resonance 
frequency with fsub = fres)430,431 and four at TR (transmit at the resonance frequency, fsub 
= ½fres)418,430. Of the seven bound DSPC microbubbles, three had a clear response at T2R 
and none had a response at TR. At 150 kPa, of the eight bound DPPC microbubbles 
seven had a response at T2R and one at TR. Of the seven bound DSPC microbubbles 
four had a response at T2R and none at TR. In the case of non-bound microbubbles at 
50 kPa the only microbubble responsive at fsub was a DSPC microbubble with a response 
at T2R. At 150 kPa, one out of the ten DPPC microbubbles had a response at T2R and 
two out of ten at TR. For the four non-bound DSPC microbubbles two had a response 
at T2R and none at TR. For the other microbubbles responding at fsub, the relation 
between TR or T2R could not be determined; either because no clear relation was found 
between the subharmonic and fundamental frequency, or because the fundamental 
frequency had not been determined since the peak was located outside the measuring 
range. We assumed a detection limit of 1 Pa (black dashed line in Fig. 8.6) for diagnostic 
ultrasound scanners, achievable with a typical high-quality transducer for harm 
harmonic imaging432. The emitted pressures of the subharmonic responses will therefore 
be difficult to detect. 
 
At PA = 50 kPa, about half of both bound DPPC (53%) and bound DSPC (57%) 
microbubbles responded at the second harmonic frequency. The number of responding 
non-bound microbubbles based on DPPC was similar (50%), but for non-bound DSPC 
microbubbles only 1 out of 26 (4%) was responsive at the second harmonic frequency. 
The number of responsive microbubbles at a driving pressure of 150 kPa increased in all 
cases: to 14 out of 15 (93%) for bound DPPC microbubbles, 13 out of 18 (72%) for 
bound DSPC microbubbles, 17 out of 28 (61%) for non-bound DPPC microbubbles, and 
8 out of 26 (31%) for non-bound DSPC microbubbles. The median (IQR) pressures 
emitted at the second harmonic frequency when insonified at 50 kPa were 2.0 (1.0 – 
2.6) Pa for bound DSPC microbubbles, hence in the same order as the only non-bound 
DSPC microbubble (3.1 Pa, Fig. 8.7). For bound DPPC microbubbles, the emitted 
pressures were 4.1 (2.1 – 12.9) Pa and 2.4 (2.0 – 2.8) Pa for non-bound DPPC 






pressures at the second harmonic frequency of bound DPPC microbubbles were higher 
than those of bound DSPC microbubbles (p = 0.004). At the higher driving pressure of 
150 kPa, the emitted pressures were significantly higher (p = 0.017) for non-bound than 
bound DSPC microbubbles, with median pressures of 28.5 (14.0 – 38.1) Pa for non-
bound and 3.2 (2.4 – 8.4) Pa for bound DSPC microbubbles. The median pressures of 















Figure 8.7. Absolute pressures emitted at the second harmonic frequency of bound DPPC (50 
kPa: n = 21, 150 kPa: n = 10), bound DSPC microbubbles (50 kPa: n = 19, 150 kPa: n = 8), non-
bound DPPC (50 kPa: n = 6, 150 kPa: n = 6), and non-bound DSPC microbubbles (50 kPa: n = 















his study investigated vibrational responses of bound and non-bound 
microbubbles to identify differences to acoustically discriminate them. For 
DPPC-based microbubbles with diameters between 2 and 4 μm the resonance 
frequencies and relative radial excursions were higher than for non-bound DPPC-based 
microbubbles (PA = 50 kPa). In contrast, at an insonifying pressure of 150 kPa the 
relative radial excursions for bound and non-bound DPPC-based microbubbles were 
similar. Interestingly, at this higher pressure the radial excursions for bound DSPC-
based microbubbles were higher than for non-bound DSPC microbubbles, whereas 
these were similar at 50 kPa. We also found compression-dominated behavior and a 
higher number of responsive microbubbles at the second harmonic frequency for bound 




Bound microbubbles were acoustically less stable than non-bound microbubbles, 
irrespective of their main coating component. Further we found that the acoustic 
stability for DPPC-based microbubbles was lower than that for DSPC-based 
microbubbles. This was previously attributed to the shorter acyl chain length of the 
DPPC lipid than that of the DSPC lipid419. This shorter chain results in lower 
intermolecular van der Waals forces between the different lipids and results in less 
attraction and cohesion of the microbubble shell419,433. The maximum relative radial 
excursions of bound microbubbles were higher at the resonance frequency than those 
of non-bound microbubbles (for DPPC at 50 kPa and DSPC at 150 kPa). This means 
that the radial excursions after binding were more prominent, which resulted in more 
shrinkage and therefore a lower acoustic stability. Others have reported lower radial 
excursions after binding for DSPC-based microbubbles55,422, but those studies had not 
covalently linked their model biomarker to their membrane. As a result, the biomarker 
that attached to the microbubble shell increased the stiffness35 and therefore limits the 
radial oscillations.  
 
Some non-bound DSPC microbubbles appeared to increase in diameter after 
insonification at 150 kPa. The microbubbles in which this was observed were all 






optical focus due to radiation forces, in combination with the error in the tracking 
algorithm which was previously estimated to be approximately 10%243. 
 
Linear oscillation behavior 
 
The resonance frequencies for bound DPPC microbubbles were higher than for non-
bound DPPC microbubbles at a pressure of 50 kPa for microbubbles with diameters 
between 2 and 4 μm at resonance. Based on the IQRs, the resonance frequencies of most 
bound DPPC microbubbles of this size were higher than 1.8 MHz, whereas those of non-
bound DPPC microbubbles were lower than 1.8 MHz. In terms of shell properties, a 
higher resonance frequency is related to an increase in elasticity (i.e., a stiffer shell) by 
the Marmottant model434. It is not likely that the elasticity changes upon binding, but 
the apparent stiffness may increase due to binding of the microbubble to the biomarker. 
We may not have found a change in apparent stiffness for DSPC-based microbubbles, 
because their surface binding area is smaller than for DPPC-based microbubbles as 
previously determined by our group for the same type of microbubbles and same 
streptavidin biomarker241. Next, the initial elasticity of DSPC microbubbles is already 
higher than for DPPC microbubbles419, and it has been shown that the resonance 
frequencies for DSPC microbubbles did not change after conjugating  the relatively 
heavy molecule streptavidin to the lipid shell, whereas for DPPC microbubbles the 
resonance frequencies increased35. In addition, the resonance frequency exponentially 
decreases for increasing microbubble size435. As a consequence, the difference in 
resonance frequencies for microbubbles with diameters between 2 and 4 μm is larger 
than for microbubbles with diameters between 5 and 7 μm419. An increase in resonance 
frequency for bound microbubbles will therefore be more pronounced for smaller than 
for larger microbubbles. This may explain why the apparent increase in stiffness was 
only present for bound DPPC microbubbles having diameters between 2 and 4, and not 
for DSPC microbubbles or larger DPPC microbubbles. At 150 kPa, however, all 
resonance frequencies appeared the same. The microbubble oscillations at this pressure 
start of very violently in the first insonifications between 1 and 1.5 MHz, thereby largely 
decreasing the microbubble size and shifting its original resonance frequency towards 
higher frequencies. Since the mechanical index (MI) was ~2× lower for the 
insonifications at the end of the frequency sweep, the resulting relative radial excursions 
were lower at the new resonant microbubble size. Therefore, the oscillations of the first 
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insonifcations dominated the resonance behavior, leading to an apparent resonance 
frequency between 1 and 1.5 MHz before shrinkage. 
 
Others have also reported differences in resonance frequencies between bound and non-
bound microbubbles. Casey et al.423 reported an increase in resonance frequency for their 
bound in-house produced biotinylated microbubbles, but for DSPC microbubbles (C3F8 
gas core and same components as our DSPC-based microbubbles, but unknown ratios) 
instead of for DPPC-based microbubbles as we report here. Overvelde et al.55 found 30% 
lower frequencies of maximum response for targeted BG-6438 microbubbles bound to 
an OptiCell wall than for non-targeted BG-6437 microbubbles floating against the wall 
at pressures < 40 kPa (both bubble types are from Bracco Research S.A., Geneva, 
Switzerland). The BG-6438 microbubbles were targeted to FITC-BSA using an anti-FITC 
antibody attached to the microbubble shell using streptavidin-biotin bridging. The main 
limitation of both studies is the method of attaching the model biomarker streptavidin 
to the cellulose tube423 or FITC-BSA to the OptiCell wall55, namely by physisorption. As 
mentioned before, this physisorbed biomarker is likely to bind to the microbubble shell 
creating a lipid-coated microbubble covered with the model biomarker. These very large 
and heavy complexes are expected to behave completely different in an ultrasound field 
than a bare lipid-coated targeted microbubble, as has been shown for microbubbles that 
were functionalized with streptavidin depending on the initial stiffness of the 
microbubble coating35. In addition to this, Overvelde et al.55 did not block the OptiCells 
to prevent unspecific binding in their experiments that compared free BG-6437 
microbubbles and BG-6437 microbubbles close to the wall: the latter may have actually 
bound to the wall. Next to that, the BG-6437 microbubbles did not have anti-FITC 
antibody attached to their shell, which is not a fair comparison between microbubbles 
that have bound to the wall and that are floating against the wall. In our present study 
the covalent coupling of streptavidin to the hydrogel, and thus the membrane, was 
established and it was confirmed that no streptavidin was present on the microbubble 
shell241.  
 
Nonlinear oscillation behavior 
 
For nonlinear contrast-enhanced ultrasound imaging the responses at the subharmonic 






non-bound microbubbles responded at the subharmonic frequency, for both the DPPC 
and DSPC-based coatings. At 150 kPa more microbubbles—both bound and non-
bound—were responsive at the subharmonic frequency, but the emitted pressures were 
close to or below the assumed detection limit for clinical use of 1 Pa432. The subharmonic 
emissions seem therefore of limited use for nonlinear contrast-enhanced imaging and 
discrimination of bound from non-bound microbubble based on our experimental 
conditions.  
 
We found similar amplitudes at the subharmonic frequency for bound and non-bound 
microbubbles, in line with findings of Zhao et al.422 for microbubbles with a coating of 
82 mol% DSPC, 9 mol% DSPEPEG2000, and 9 mol% DSPE-PEG2000-biotin437. Helfield 
et al.421 reported similar amounts of bound and non-bound Target-Ready MicroMarker 
microbubbles that were responsive at the subharmonic frequency, whereas we found 
more bound microbubbles that responded. The different composition and gas core of 
Target-Ready MicroMarker likely contributed to these differences. As suggested by 
Helfield et al.421, the membrane material could have frequency-dependent effects and 
their results might be biased due to aggregation of microbubbles that may have changed 
the echogenicity438. We previously performed the exact same experiments as described 
here for non-bound microbubbles in an OptiCell439. Indeed, a membrane dependent 
effect was observed, but was not found to be frequency related. The maximum relative 
radial excursions of non-bound microbubbles in an OptiCell (both DPPC and DSPC) 
were 2-2.5 times higher than for non-bound microbubbles floating against the hydrogel. 
Because the microbubbles may be partly embedded in the polymer-based hydrogel, this 
can damp the microbubble oscillations and therefore result in lower maximum relative 
radial excursions.   
 
Another difference between our study and that of Helfield et al.421, is that they coated 
their cellulose tube with streptavidin using physisorption, with the disadvantage of 
streptavidin covering the microbubble shell, which may have influenced the amplitude 
of the subharmonic signal. Indeed, their acoustic measurements showed a 20% higher 
subharmonic signal of Target-ready MicroMarker, a streptavidin-functionalized lipid-
coated microbubble, when bound to a biotinylated agarose phantom. The difference 
between the results of Helfield et al. and our results presented in this study might         
also be due to the used techniques: ultra-high-speed optical imaging versus acoustic  
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measurements. In our set-up we were only able to image the top-view of the 
microbubble oscillations, whereas acoustic measurements can detect out-of-plane 
signals as well. If a larger portion of the subharmonic excursions were generated in the 
perpendicular plane, we might have missed those vibrations with our set-up. 
 
Numerical simulations have shown that the subharmonic signal is optimal when the 
microbubble is insonified at T2R440. Experimental validation showed that the threshold 
for generating TR subharmonic responses is higher than that for T2R subharmonic 
responses in lipid-coated microbubbles430,441. The absence of DSPC responders at TR 
may suggest that the threshold for generating TR subharmonic responses is lower for 
DPPC microbubbles than for DSPC microbubbles, irrespective of them being bound or 
not. On the other hand, due to the applied frequency range and studied microbubble 
sizes the majority of the resonance frequencies were between 1.5 and 3.5 MHz, which 
limits the possibility to insonify microbubbles at T2R within the frequency range we 
applied. 
 
The higher second harmonic amplitudes we measured for non-bound DSPC-based 
microbubbles at 150 kPa are in contrast with results reported by others420,423. The study 
by Casey et al.423 used microbubbles similar to our DSPC microbubbles, but with a C3F8 
core and attachment to a capillary wall using the physisorbed streptavidin as biomarker 
(fT = 2 MHz, PA = 90 kPa). The study by Zhao et al.420 also used DSPC-based 
microbubbles, with a set-up and parameters comparable to those of Casey et al.423. Both 
studies used somewhat lower pressures, but may also have effectively studied bound 
targeted DSPC-based microbubbles coated with a streptavidin layer, which may explain 
the different findings. In our study, the emitted pressure amplitudes of bound 
microbubbles were similar or lower than for non-bound microbubbles and acoustic 
discrimination based on the second harmonic pressures does therefore not seem 
feasible. 
 
DSPC vs DPPC for ultrasound molecular imaging applications 
 
The differences between bound targeted DPPC and DSPC-based microbubbles were not 
as pronounced as we expected from the differences in shape change upon adherence and 






microbubbles and same streptavidin biomarker241. The most prominent differences we 
did find were higher acoustic stability for non-bound microbubbles, higher resonance 
frequencies (for DPPC microbubbles with diameters between 2 and 4 μm) and radial 
excursions for bound DPPC microbubbles at 50 kPa, and higher amplitudes at the 
second harmonic frequency for non-bound DSPC microbubbles than for bound DSPC 
microbubbles at 150 kPa. The lower resonance frequencies for DPPC microbubbles than 
for DSPC microbubbles were already observed for non-bound DPPC microbubbles419, 
and were thus maintained upon binding. 
 
For in vivo ultrasound molecular imaging the ideal targeted microbubble: 1) can 
effectively bind to the biomarker of interest; 2) persists binding to the biomarker after 
initial binding, i.e. the binding strength is larger than the shear stress induced by the 
flowing blood; 3) is stable during the course of the ultrasound examination; 4) 
nonlinearly scatters ultrasound that is microbubble specific; 5) can be discriminated 
acoustically from non-bound microbubbles; 6) has the same resonance frequency as the 
other microbubbles that are injected, i.e., all microbubbles in the population respond in 
the same way to ultrasound. Concerning the first two points, Kooiman et al.241 favored 
targeted DPPC microbubbles over DSPC microbubbles because of their larger surface 
binding area to a streptavidin-coated membrane, their dome shape after binding, and a 
more homogeneous distribution of fluorescently labeled ligands attached to DSPE-
PEG(2000). The more homogeneous lipid distribution might aid the initial attachment, 
whereas the larger binding area and difference in shape might be able to better sustain 
blood shear forces. However, binding of the microbubbles was performed under static 
conditions and experiments in the presence of flow are needed to verify which of the 
two microbubble types binds best under flow. Based on the acoustic stability (point 3), 
DSPC-based microbubbles are favored over DPPC-based microbubbles. This also means 
that the size is better maintained during insonification and the resonance frequency will 
therefore be more consistent throughout the investigation. In terms of nonlinear 
scattering of ultrasound (point 4), the maximum relative radial excursions at the 
subharmonic frequency for both our DPPC and DSPC microbubbles resulted in ~20 dB 
lower scattered pressures than the second harmonic responses. The subharmonic 
responses were too low and unpredictable to discriminate bound from non-bound 
microbubbles. In contrast, the responses at the second harmonic frequency were 
sufficiently high to be detected, but amplitudes were similar for bound and non-bound  
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microbubbles, or higher for the non-bound ones in terms of DSPC-based microbubbles 
(point 5). At 50 kPa, bound and non-bound DPPC microbubbles with diameters 
between 2 and 4 μm at resonance could be separated based on their resonance 
frequencies: bound DPPC microbubbles had resonance frequencies above 1.8 MHz, 
whereas those were significantly lower for non-bound DPPC microbubbles. Lastly (point 
6), as mentioned in the introduction one of the main challenges for successful 
translation of ultrasound molecular imaging to the clinic is the production of 
microbubble populations that have the same acoustic signature. Both the DPPC and 
DSPC-based microbubbles can have different resonance frequencies and radial 
excursions although their sizes are similar. Several studies showed that monodisperse 
lipid-coated microbubble distributions can be produced using flow-focusing 
devices150,442-444. Talu et al.444 and Kaya et al.442 studied the difference between echo 
amplitudes of these monodisperse single microbubbles when insonified at a frequency 
close to resonance, and found a lower standard deviation than for polydisperse 
microbubbles. Segers and Versluis445 developed an acoustic sorting chip that separated 
monodisperse microbubbles based on the radiation force they experienced, which 
resulted in an overall contrast enrichment of more than 10 dB. This is an important step 
towards improving the quality of in vivo ultrasound molecular imaging, especially if 
microbubbles with low shell elasticity and a diameter between 2 and 4 μm can be 
produced to distinguish bound from non-bound microbubbles, as shown in our study. 
However, this approach is still limited to specific microbubble compositions that can be 
produced monodispersely by means of flow-focusing devices.   
 
Summing up all the aforementioned similarities, differences, advantages, and 
disadvantages of DPPC and DSPC-based microbubbles, this results in a favor for DSPC-
based microbubbles for ultrasound molecular imaging solely based on a higher acoustic 
stability. Studying the adherence of the microbubbles under flow should reveal whether 
the heterogeneous lipid distribution in the DSPC shell hinders binding. On the other 
hand, bound DPPC microbubbles (diameters between 2 and 4 μm) at 50 kPa had 
resonance frequencies higher than 1.8 MHz, whereas those of non-bound DPPC 
microbubbles were lower than 1.8 MHz. In addition, the relative radial excursions of 
bound DPPC microbubbles were also higher. When monodisperse DPPC microbubbles 
with a diameter between 2 and 4 μm are produced, these could acoustically be 





Limitations and outlook 
 
Although we aimed to create a more in vivo-like set-up using covalent biomarker binding 
versus physisorption, the membrane we used in our experiments was still artificial. The 
1-2 μm thick hydrogel created a softer layer between the microbubble and the polyester 
membrane, but to have a real in vivo-like membrane one would need to develop a 
material with exactly the same stiffness, viscosity, etc. to an actual cell layer or perform 
in vivo experiments. In addition, in vivo one can also study microbubble vibration when 
microbubbles are in contact with cells and under flow, for which the chorioallantoic 
membrane model could be used. This model has proven to be useful to study non-
targeted microbubble vibration using ultra-high-speed imaging and targeted-
microbubble mediated drug delivery446,447. 
 
For in vivo ultrasound molecular imaging multiple microbubbles may bind in closer 
range with each other than investigated in the present study. However, the binding 
range actually depends on the availability of the biomarker on the cell surface, which 
depends both on the cell type and the biomarker of interest. When the interbubble 
distance is ≤ 10 μm, this will cause interaction of the bubbles in terms of secondary 
Bjerknes forces, and due to the secondary Bjerknes forces a bubble will deform in the 
direction of their neighboring bubble448. Next to that, two similar sized bubbles that are 
close to each other result in a shift in resonance frequency and therefore a decrease in 
maximum relative radial excursions449. As a consequence, for abundant biomarkers on 
the cell membrane these observations may counteract the increase in resonance 
frequency and maximum relative radial excursions we observed for DPPC microbubbles 
between 2 and 4 μm at 50 kPa. This, however, should first be experimentally verified 
using a setup comprising of a biomarker distribution that is comparable to the in vivo 










his study shows that binding of in-house produced DPPC-based microbubbles to 
a streptavidin-coated surface increased the resonance frequencies (for 
microbubbles with diameters between 2 and 4 μm) and the corresponding relative radial 
excursions at relatively low pressure (50 kPa). At this pressure, the bound 2 to 4 μm 
microbubbles resonated above 1.8 MHz, whereas the non-bound 2 to 4 μm DPPC 
microbubbles were resonant below this frequency. At higher pressure (150 kPa) this 
difference did not persist. No differences in resonance frequency were observed between 
bound and non-bound DSPC microbubbles. In terms of non-linear responses, only the 
responses at the second harmonic frequency of bound DSPC microbubbles at 150 kPa 
were lower than of non-bound DSPC microbubbles. Our in-house produced DPPC-
based microbubbles were acoustically less stable than our DSPC-based microbubbles, 
which is the major advantage of this type of microbubble for ultrasound molecular 




The authors thank Robert Beurskens, Frits Mastik, Michiel Manten, and Geert 
Springeling for technical assistance, Dr. Tom Kokhuis for valuable discussions (all from 
the Dept. of Biomedical Engineering, Thorax Center, Erasmus MC), and Dr. Jason L. 
Raymond for experimental assistance (visiting fellow Whitaker program). We also 
thank Ihsan Chrifi from the Dept. of Experimental Cardiology, Thorax Center, Erasmus 
MC, for the spectrophotometer measurements, and Dr. E. Gedig from XanTec 
bioanalytics GmbH, Germany, for discussions about the covalent coating of streptavidin 
to the polyester membranes. The authors are grateful to Prof. Dr. A.L. Klibanov from 
the University of Virginia, Cardiovascular Division, Charlottesville, Virginia, USA for 











- Abraham Lincoln 
            
In the end, it’s not the years  
in your life that count.  





































Journal of Controlled Release, vol. 238, pp. 197-211, 2016 
 
Viability of...               
endothelial cells.. 
after ultrasound-..           
mediated….  
    sonoporation ..    
Tom van Rooij, Ilya Skachkov,  
Inés Beekers, Kirby R. Lattwein,  
Jason D. Voorneveld, Tom J.A.  
Kokhuis, Deep Bera, Ying Laun,  
Antonius F.W. van der Steen,  






Microbubbles (MBs) have been shown to create transient or lethal pores in cell 
membranes under the influence of ultrasound, known as ultrasound-mediated 
sonoporation. Several studies have reported enhanced drug delivery or local cell death 
induced by MBs that are either targeted to a specific biomarker (targeted microbubbles, 
tMBs) or that are not targeted (non-targeted microbubbles, ntMBs). However, both the 
exact mechanism and the optimal acoustic settings for sonoporation are still unknown. 
In this study we used real-time uptake patterns of propidium iodide, a fluorescent cell 
impermeable model drug, as a measure for sonoporation. Combined with high-speed 
optical recordings of MB displacement and ultra-high-speed recordings of MB 
oscillation, we aimed to identify differences in MB behavior responsible for either viable 
sonoporation or cell death. We compared ntMBs and tMBs with identical shell 
compositions exposed to long acoustic pulses (500-50,000 cycles) at various pressures 
(150-500 kPa). Propidium iodide uptake highly correlated with cell viability; when the 
fluorescence intensity still increased 120 s after opening of the pore, this resulted in cell 
death. Higher acoustic pressures and longer cycles resulted in more displacing MBs and 
enhanced sonoporation. Non-displacing MBs were found to be the main contributor to 
cell death, while displacement of tMBs enhanced reversible sonoporation and preserved 
cell viability. Consequently, each therapeutic application requires different settings: 
non-displacing ntMBs or tMBs are advantageous for therapies requiring cell death, 
especially at 500 kPa and 50,000 cycles, whereas short acoustic pulses causing limited 

















icrobubbles (MBs) are ultrasound (US) contrast agents that consist of gas 
bubbles with diameters between 1 and 10 μm, which are encapsulated by a 
stabilizing coating. Non-targeted microbubbles (ntMBs) are clinically used as blood pool 
agents for contrast-enhanced US imaging in cardiology and radiology450,451 and also have 
therapeutic potential36,37. Targeted microbubbles (tMBs) are promising agents for US 
molecular imaging and therapy; in particular for diseases that can alter the endothelium, 
such as cancer and inflammation. The tMBs can adhere to specific disease-associated 
intravascular biomarkers by the addition of targeting ligands to the MB coating35,452. 
 
When MBs are insonified by US, they oscillate due to the acoustic pressure wave36. 
Oscillating MBs can increase cell membrane permeability to facilitate intracellular drug 
uptake (sonoporation), stimulate endocytosis, and open cell-cell junctions36,220. 
Although the exact mechanisms of MB-mediated drug uptake still remain unknown, 
many studies have attempted to pinpoint the US settings that best stimulate 
intracellular drug uptake36,453. So far the key findings are: 1) cell membrane pores 
induced by oscillating MBs can be reversible or irreversible229; 2) a MB has to oscillate 
with sufficient amplitude to induce sonoporation454; 3) tMBs stimulate drug uptake 
better than ntMBs both in vitro455-459 and in vivo460-463. Recently, it has also been shown 
that the cell membrane pore size and pore resealing coefficient can be mathematically 
obtained from real-time observed MB-mediated intracellular drug uptake228. 
 
While reversible sonoporation likely facilitates cellular drug uptake without causing 
lethal damage to the cell, irreversible sonoporation is thought to lead to significant cell 
damage and eventually cell death. Different therapeutic approaches may require 
reversible or irreversible sonoporation, and a balance is expected between therapeutic 
effectiveness and cell damage. Hu et al.229 revealed the size of the created cell membrane 
pore to be a predictor for reversible or irreversible sonoporation: pores < 30 μm2 
successfully resealed within 1 min after insonification, while pores > 100 μm2 had not 
resealed within 30 min. An established method to study drug uptake by sonoporation 
relies on the intracellular uptake of the model drug propidium iodide (PI)227,228,447,454,464, 
because this molecule can only pass the cell membrane of a live cell when it has been  







Fan et al.228 showed that intracellular PI fluorescence intensity directly relates to the 
amount of PI-DNA and PI-RNA complexes that have formed in the cell. They proposed 
a model to relate intracellular fluorescence intensity to the size of the created pore and 
its resealing time, which corresponded well with their experimental in vitro results on 
kidney228 and endothelial cells466.  
 
For MB-mediated drug uptake, MB dynamics also have to be considered. The frequency 
generally used for MB-mediated drug delivery is 1 MHz36, which means that the MBs 
oscillate one million times per second. These MB oscillations can only be resolved using 
an ultra-high-speed camera, capable of recording at least two million frames per second 
(Mfps) to satisfy the Nyquist sampling criterion467. While our group used ultra-high-
speed recordings to determine that the relative oscillation amplitude of tMBs had to be 
above 50% to successfully sonoporate a cell454 (6× 10 cycles at 1 MHz and 80-200 kPa 
peak negative acoustic pressure), others used high-speed cameras (in the order of a few 
thousand fps) to reveal that MB displacement is an important contributor to 
sonoporation-mediated cell death (1.25 MHz, 60-600 kPa, pulse repetition frequency 
(PRF) 10-1000 kHz, duty cycles 0.016-20%)468. MBs displace due to acoustic radiation 
forces, especially when longer acoustic pulses are used469,470. Long acoustic pulses have 
sparsely been used in MB-mediated drug delivery studies471-474, even though one of these 
studies reported that 7,000 cycles resulted in significantly more luciferase activity than 
1,000 and 5,000 cycles in endothelial cells in vitro (2.25 MHz, 330 kPa, PRF 20 Hz, 120 
s treatment)474. On the other hand, no significant differences between 1,000, 5,000, and 
10,000 cycles were observed; different US pulse lengths thus affected luciferase activity. 
So far, in depth sonoporation studies on the effect of longer acoustic pulses at different 
acoustic pressures are lacking, as is the relation between MB oscillation and 
sonoporation efficiency. In addition, the effect of the same type of ntMBs and tMBs on 
endothelial cells has never been directly compared in vitro. All prior studies comparing 
ntMBs and tMBs were performed on cancer455,457-459 and smooth muscle cells456, despite 
that MBs are primarily in contact with endothelial cells when injected intravenously36,452. 
 
In this study we used long US pulses (500-50,000 cycles) at various pressures (150-500 
kPa) to investigate how these settings affect US-mediated endothelial cell membrane 
permeability and cell death. In order to properly compare ntMBs and tMBs, we used  
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home-made MBs with identical shell compositions to investigate their effect. The real-
time observed PI uptake patterns were fit to the previously proposed diffusion model of 
Fan et al.228 and additional Principal Component Analysis was used to determine 
whether cells were reversibly or irreversibly damaged. In combination with high-speed 
optical recordings of MB displacement and ultra-high-speed recordings of MB 










Materials and Methods 
Microbubble preparation  
 
Lipid-coated MBs with a C4F10 gas core (F2 Chemicals, Preston, UK) were made by 
sonication as described previously314,447. The coating of the non-targeted MBs (ntMBs) 
consisted of 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC; 84.8 mol%; P6517; 
Sigma-Aldrich, Zwijndrecht, the Netherlands), polyoxyethylene-(40)-stearate (PEG-40 
stearate; 8.2 mol%; P3440; Sigma-Aldrich), and 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-carboxy(polyethylene glycol) (DSPE-PEG(2000); MW 2000; 
7.0 mol%; 880125P; Avanti Polar Lipids, Alabaster, AL, USA). Before the experiment, 
the ntMBs were washed three times using centrifugation for 1 min at 400 g. After 
washing the ntMBs, the size distribution and concentration were measured using a 
Coulter Counter (n = 3; Multisizer 3; Beckman Coulter, Mijdrecht, the Netherlands). 
The mean (± standard deviation, SD) diameter of the ntMB was 2.54 (± 0.02) µm. 
 
The same components were used for the targeted MBs (tMBs), except 1.1% of DSPE-
PEG(2000) was replaced with DSPE-PEG(2000)-biotin (MW2000; 880129C; Avanti 
Polar Lipids). This allows for adding targeting moieties to the MBs via biotin-
streptavidin bridging as previously described447,475. Briefly, after three washing steps by 
centrifugation at 400 g for 1 min, the concentration of the MBs was measured using a 
Coulter Counter (n = 3) and 1 x 109 biotinylated MBs were incubated with 20 μg of 
streptavidin (S4762; Sigma-Aldrich) on ice for 30 min. Following incubation, the 
streptavidin-conjugated MBs were washed once to remove non-bound streptavidin. 
Next, 5 μg of biotinylated anti-human CD31-antibody (BAM3567; R&D Systems, 
Abingdon, United Kingdom) were conjugated to the MB shell, during incubation for 30 
min on ice. Following this, tMBs were washed once to remove non-bound antibodies. 
Directly afterwards the size distribution and concentrations were measured using a 
Coulter Counter (n = 3) and mean (± SD) diameter for the tMBs was 2.82 (± 0.09) 
µm. 
 
Endothelial cell culture  
 
Human umbilical vein endothelial cells (HUVECs; C2519A; Lonza, Verviers, Belgium) 
were cultured in EGM-2 medium (CC-3162; Lonza) in T-75 flasks (353136; BD Falcon  
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Fisher Scientific, Breda, the Netherlands), and maintained in a humidified incubator 
under standard conditions (37°C, 5% CO2). Thereafter the cells were trypsinized using 
trypsin in EDTA (CC-5012; Lonza) and replated on one side of an OptiCellTM (Thermo 
Scientific, NUNC GmbH & Co, Wiesbaden, Germany). Experiments were performed 




For visualization of the MBs and HUVECs, the microscopic set-up consisted of a 
fluorescence microscope (Olympus, Zoeterwoude, the Netherlands) equipped with a 5× 
objective (LMPlanFl 5X, NA 0.13, Olympus) for the sonoporation and cell viability 
assays or a 40× objective (LUMPlanFl 40XW, NA 0.80, water immersion, Olympus) to 
capture MB behavior. For bright-field imaging the sample was illuminated from below 
via a light fiber using a continuous light source and for fluorescence imaging a mercury 
lamp and a suitable set of fluorescent filters were used for the detection of propidium 
iodide (U-MWG2 filter, Olympus), Hoechst 33342 (U-MWU2 filter, Olympus), and 
calcein (U-MWIB2, Olympus). On top of the microscope three different cameras were 
mounted: 1) a high sensitivity CCD camera (AxioCam MRc, Carl Zeiss, Germany) for 
fluorescence imaging, 2) a high-speed Redlake Motion Pro Camera (10K, San Diego, 
CA, USA), and 3) the ultra-high-speed Brandaris 128 camera [36]. The experimental 
set-up is illustrated in Figure 9.1.  
 
For the acoustical set-up, a 1 MHz single-element, focused transducer (focal distance 75 
mm; V303; Panametrics-NDTTM, Olympus NDT, Waltham, MA, USA) was mounted 
in the water bath at a 45° angle below the sample (Fig. 9.1). Each OptiCell was divided 
into eight equally sized, acoustically non-overlapping sections (19 x 33 mm each; for 
schematic see Fig. 9.1), which covered the beam area (-6 dB beam width of 6.5 mm) at 
the focus of the transducer, as verified in advance with a calibrated 0.2 mm PVDF needle 
hydrophone (Precision Acoustics Ltd, Dorchester, UK). The acoustic focus was aligned 
with the optic focus.  
 
During the experiment, the position of the OptiCell was adjusted to place the center of 
each subsection in the focal zone. The sample was insonified by a single Gaussian 






Palo Alto, CA, USA) and amplified using a broadband amplifier (ENI A-500, Electronics 
& Innovation, Rochester, NY, USA). The peak negative acoustic pressure of the US burst 
(150, 300, or 500 kPa) was kept constant for the entire OptiCell, whereas the number 
of cycles in the single US burst (500; 1,000; 2,000; 5,000; 10,000; 20,000; and 50,000) 
varied per OptiCell subsection (Fig. 9.1). For each Opticell one of the subsections was 




Figure 9.1. Experimental set-up. (A) Illustration of the optical imaging systems combined with 
the acoustical set-up. Brandaris 128 is the ultra-high-speed camera, Redlake the high-speed 
camera, and AxioCam the fluorescence and bright-field CCD camera. The enlarged OptiCell shows 
the insonification scheme. (B) Orientation of the microbubbles (MBs) with respect to the cells and 
the direction of ultrasound (US) insonification. Non-targeted MBs (ntMBs) were floating against 
the cells, targeted MBs (tMBs) were adhered on top of the cells, or tMBs adhered below the cells 




Time-lapse sonoporation assay 
 
The time-lapse sonoporation assay was used to monitor sonoporation over time for the 
different US pressures and number of cycles and is illustrated in Figure 9.2. First, 
calcein-AM (C3100MP; Invitrogen; prepared in DMSO (Sigma-Aldrich)) was added to 
the HUVECs in the OptiCell in a final concentration of 0.25 μg/mL. We used calcein-AM  
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as a live-cell stain as it passively crosses into cellular membranes, has high cell retention, 
and is only converted to fluorescent calcein in living cells476. After 30 minutes of 
incubation (37°C, 5% CO2) of the HUVECs with calcein-AM, we added propidium 
iodide (PI; final concentration 25 µg/mL; P-4864; Sigma-Aldrich) and Hoechst 33342 
(final concentration 5 µg/mL; H3570; Invitrogen, Breda, the Netherlands) to the 
OptiCell. PI, which is live cell-impermeable, was used to determine the presence and 
intensity of sonoporation, or disruption of cell membranes, since it only becomes 
fluorescent when bound to DNA and RNA inside cells465. The Hoechst 33342 fluorescent 
dye was used to stain the nuclei of living and dead HUVECs, as it rapidly diffuses into 
all cells, binds specifically and quantitatively to DNA, and has low toxicity to viable 
cells477. Since Hoechst is a non-intercalating dye which binds to the minor groove of 
DNA478 and PI binds to DNA and RNA by intercalating between the bases479, no 





Figure 9.2. Procedural time line (not to scale) for the time-lapse sonoporation and cell viability 
assays. Arrows indicate when fluorescence dyes or MBs were added, or when US was applied. The 
cameras show which imaging system was used and the colored bars indicate the type of imaging: 







At the same time as PI and Hoechst, ~107 MBs were added to the OptiCell to obtain a 
ratio of 1-2 MBs per cell. After mixing, we incubated the OptiCell for 5 minutes at 37°C, 
with the cells on the top membrane. This allowed for the MBs to float up and the tMBs 
to adhere to the cells. The OptiCell was then placed in a 37°C water bath (Fig. 9.1). For 
the experiments using tMBs, the OptiCell was placed with the cells on the bottom 
membrane, so any non-adhered MBs would float away from the cell surface, whereas the 
OptiCell for the ntMB experiments was placed with the cells on the top membrane to 
ensure that the ntMBs were floating against the cell membranes. To investigate whether 
the difference in orientation of tMBs influenced sonoporation outcome, we also 
performed experiments on tMBs located below the cells (tMBB, see Supplementary 
Material). The AxioCam was used to take snapshots in bright-field (indicated by the 
gray bar in Fig. 9.2), and of the fluorescent signals of calcein (green) and Hoechst (blue). 
Just before US exposure, the Redlake camera was started and ran for 60 ms to completely 
cover the full US exposure. Consequently, this camera recorded more frames after 
insonification for the shorter pulses than for the longest pulse. The Redlake camera 
recorded the MB displacement and clustering at 2,000 frames per second (fps). After 
these 60 ms, the AxioCam recorded the fluorescence intensity change over time for 3 
min (1.5 s exposure and 5 s time intervals) caused by cellular PI uptake after US 
application. At the end of the protocol, snapshots in bright-field and of calcein and 
Hoechst signal were taken for comparison with the initial situation. This procedure was 
repeated for each subsection and the experiment was performed in triplicate. 
 
Cell viability assay 
 
For each US setting, cell viability was determined as shown in Figure 9.2. The same 
amount of MBs as described in the previous section (~107) were added to the OptiCell 
and left in the incubator (37°C) for 5 min. Within 3 to 4 min after the US treatment of 
all eight subsections of the OptiCell, HUVECs were incubated at 37°C, 5% CO2. Thirty 
minutes after the US treatment, calcein-AM was added to the OptiCell and incubated 
for another 30 minutes under the same conditions. After the final incubation, PI and 
Hoechst were added to the Opticell. This procedure was followed directly with bright-
field and fluorescent (calcein, Hoechst, and PI) microscopic examination using the AxioCam 
(Fig. 9.2). For each condition, five different fields of view were acquired within a 6 mm 
circle around the center of the insonified area. All experiments were done in triplicate. 
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Oscillatory behavior of microbubbles 
 
To relate MB behavior to sonoporation, high imaging speeds in the range of a few million 
frames per second (Mfps) are required. Since these high speeds cannot be achieved using 
the Redlake camera, we used the Brandaris 128 ultra-high-speed camera [36] in 
segmented mode242. The protocol was similar to the time-lapse sonoporation assay, but 
the Redlake camera was replaced by the Brandaris 128 camera. The segmented mode of 
the Brandaris 128 allows for optical recording of long US pulses by dividing the CCD 
sensor arc into four segments. During each exposure all four segments were illuminated, 
however only one segment was triggered to transfer the data to the buffer channel. These 
triggered transfers from the consecutive segments were equally spaced over the time 
span of the applied US pulse. The start of the acquisition was triggered at a frame rate 
of 3.85 Mfps, resulting in a corresponding intersegment time of ~328 µs. During one 
US pulse a full recording then captured four equally spaced movies of ~8 µs in bright-
field using a Xenon flash source (MVS-7010, Perkin-Elmer Optoelectronics, Wiesbaden, 
Germany). These settings resulted in a total acquisition time of 1017 µs. The recording 
time of the ultra-high-speed movies was a few μs longer than the US pulse to ensure 
that the start and end of the MB oscillations were fully captured. MB behavior was 
recorded for both tMBs and ntMBs, at 1,000 cycles for pressures of 150 and 300 kPa. 
The number of cycles was limited to 1,000 cycles (i.e. 1 ms duration), because the Xenon 
flash duration could not be extended.  
 
Analysis of fluorescence images 
 
All images acquired with the Axiocam (bright-field and fluorescence) were analyzed 
using a custom-built plugin for ImageJ480. To segment the nuclei, first a composite image 
of the Hoechst image after insonification and the final PI image was produced, to ensure 
clear visibility of all nuclei. We chose to use the Hoechst image after insonification, since 
less cell displacement was expected between this image and the first PI image. The 
composite image was thresholded using the method of Otsu481, resulting in a binary 
image with white nuclei on a black background. A mask of this image was created and 
watershedding was applied to separate overlapping nuclei. The watershedding algorithm 
calculates the centers of the nuclei and dilates them until touching another dilated 






Analyze Particles function, the nuclei and the area of the nuclei were located and stored 
in the ROI manager. The center of the nuclei was found using the Find Maxima function, 
added to the ROI manager, and copied to a blank image. Next, the cell borders were 
automatically segmented using Voronoi tessellation482 which is a built-in option in the 
Find Maxima function. Voronoi tessellation is based on the theory that every point p has 
a distance to another point q that is less than or equal to its distance to any other point 
r. The lines in a Voronoi diagram are thus equidistant to two points in space (i.e., the 
cell nuclei) and correspond to the most likely position of the cell boundaries. The 
resulting Voronoi segmentation was transformed into a mask and stored in the ROI 
manager. The ROI manager now contained the center of each nucleus, the area of each 
nucleus, and the cell borders.  
 
For assessing cell death using the cell viability assay, the number of cells that showed 
PI uptake on the images without the application of US was analyzed as described above. 
Next, the number of cells that had taken up PI after receiving US was normalized to the 
number of cells that had taken up PI in the control sections, to correct for cells that were 
already dead when the experiment started. 
 
For assessing the dynamic uptake of PI after sonoporation the segmented nuclei and cell 
borders were overlaid on every frame of the PI fluorescence time-lapse recording after 
the application of US. The mean signal intensity of PI for each nucleus and each cell was 
obtained frame by frame. The nuclear PI uptake was used for further analysis because 
the segmentation of the nuclei was based on intensity thresholding of Hoechst stained 
nuclei, which is more accurate than the segmentation of cell borders that is based on 
the highest probability of a cell border being present.  
 
PI model fit and data classification 
 
The temporal PI intensity values in the nuclei were loaded into RStudio (RStudio, Inc., 
Boston, MA, USA) for further quantification of sonoporation. Fan et al.228 derived an 
equation (Eq. 1) to model sonoporation dynamics of a single cell, based on the resealing 
of the created pore and the diffusion rate of PI into the cell. 
  (9.1) ( ) ( )0 1 1 toF t DC r e ba p b
-× × -×=
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In Equation (9.1), F(t) is the fluorescence intensity as a function of time, α is a coefficient 
that relates the amount of PI molecules to the fluorescence intensity of PI-DNA and PI-
RNA. This coefficient is determined by the sensitivity of the fluorescence imaging 
system. The other parameters are the diffusion coefficient of PI, D, the extracellular PI 
concentration, C0, the initial radius of the pore, r0, the pore resealing coefficient, 𝛽, and 
time, t. The pore size coefficient, α·π·D·C0·r0, determines the initial slope of the PI uptake 
pattern and is the scaling factor for the exponential increase. Therefore, a steep initial 
slope corresponds to a larger pore size. The overall slope follows 𝐹(𝑡) = 	 (𝛼 ∙ 𝜋𝐷𝐶- ∙ 𝑟/) 	 ∙
𝑒123, in which the pore resealing coefficient 𝛽 is the time constant that determines the 
time to reach the asymptotic value of the maximum PI intensity. This asymptotic 
maximal PI intensity value is given by the inverse relationship between the pore size 
and pore resealing coefficients (Eq. (9.2)). Therefore a cell with a high pore resealing 
coefficient quickly reaches the asymptotic value, resulting from quick resealing of the 
pore. 
 
   (9.2) 
 
To obtain the pore size coefficient, α·π·D·C0·r0, and the pore resealing coefficient, 𝛽, the 
PI intensities recorded in the time-lapse sonoporation assay were fit to Equation (9.1) 
using a nonlinear least-squares approach. Classification, based on the distributions of 
both coefficients, was performed using Principal Component Analysis (PCA) [45, 46] 
on the complete data set (all settings, both ntMB and tMB). We chose PCA because this 
method captures as much of the variation in the data as possible by computing 
eigenvectors (for determining the direction in which the data has largest variance) and 
corresponding eigenvalues (to determine how much variance there is in the data in that 
direction). The principal components (PCs) are uncorrelated with each other since the 
eigenvectors are perpendicular to each other. In this data set we chose two PCs because 
we only used the pore size coefficients and pore resealing coefficients to fit the data to 
Equation (9.1). Classification thresholding was applied on the PC with the largest 
variance, separating the complete data set in two groups. Using these PCs, the cell 
populations at each different setting were classified. Based on Equation (9.1), two 
additional thresholds were chosen to classify the cells that were most likely irreversibly 
damaged based on very low pore resealing coefficients. In these cells, PI intensities still  










increased at the end of the time-lapse sonoporation assay (i.e. at 180 s), or > 120 s. 
Because pores remaining open for more than 1 min would not close229, we assumed these 
pores to most likely result in cell death.  
 
Displacement of microbubbles 
 
Tracking of displacing MBs was implemented in Python™ (v2.7, Python Software 
Foundation). The recordings on which the tracking was performed were obtained with 
the Redlake camera and had an isotropic spatial resolution of 0.63 µm/pixel. Gaussian 
Mixture-based background subtraction485 was applied to remove all but the displacing 
MBs from each frame. This was required to correct for illumination fluctuations among 
the frames and in different regions of the image, which hindered accurate MB tracking. 
The remaining MBs were tracked using Trackpy486, an open source blob tracking 
algorithm, to obtain the trajectory of each displacing MB. 
 
To differentiate between sonoporation due to displacing or non-displacing MBs, the 
latter were segmented from the AxioCam bright-field images before US application. 
Since the FOV of the Redlake camera was smaller than that of the AxioCam, only the 
part of the FOV that overlapped was analyzed. We used the Laplacian of Gaussian (LoG) 
blob detection algorithm (scikit-image487); this algorithm convolves Gaussian kernels of 
a range of standard deviations with an image. In this way it determines the centroid and 
diameter of non-displacing MBs, approximated by the standard deviation of the 
corresponding Gaussian kernel. In order to detect most MBs, their diameters were 
limited to a range between 1.7 and 5.0 µm, and a 20% overlap was allowed to properly 
deal with clusters and focal differences.  
 
After locating the displacing and non-displacing MBs, their effect on cellular PI uptake 
was assessed. For segmentation of the nuclei from the Hoechst images, we also used the 
LoG blob detection algorithm, which performed best when the range to detect nuclei 
was limited between 5.0 and 6.7 µm in diameter, and overlapping at most 20%, to 
separate nuclei with seemingly overlapping borders. Centroids of the segmented cell 
nuclei were used as seeding points for cell border segmentation using Voronoi 
tessellation. For segmenting regions with PI uptake in the initial and final frame of the 
PI stained image sequences, the LoG blob detection algorithm was limited to diameters  
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between 5.0 and 8.3 µm, and allowed 25% overlap. More overlap and larger regions were 
allowed than for nuclei segmentation since PI can also stain the cytoplasm by binding 
to RNA. Regions in which PI uptake was detected in both the first and last frame were 
neglected, because these cells had already taken up PI before US application. Cells were 
defined as sonoporated when 70% of their equivalent circular diameter overlapped with 
a region showing PI uptake. This percentage was used to compensate for the 
overestimation of cellular diameters due to odd shaped cells, e.g. rectangular shaped 
cells. If a cell’s equivalent diameter intersected with 1.25 times a MB diameter (to 
account for MB expansion) it was considered to be in contact with a non-displacing MB. 
Similarly, contact with displacing MBs occurred when the cell’s full equivalent diameter 
intersected with a MB’s trajectory (the lines connecting a MB between frames, as 
determined by Trackpy). 
 
The relations between MB displacement and sonoporation outcome at all acoustic 
settings were visualized using scatter plots and linear fits through these data using a 




To compare the various acoustical settings, we performed statistical testing using 
Student’s t-tests to identify significantly different outcomes. All statistics were 
performed using Student’s t-tests for independent samples, where a p-value of 0.05 was 
regarded as significant. 
 
For both sonoporation and cell death, different insonifying pressures were compared at 
the same number of cycles for both ntMBs and tMBs. One-sided t-tests were used to 
reveal whether higher pressures at the same number of cycles resulted in more 
sonoporation and cell death. The same t-tests were performed to verify whether the 
experimental acoustic settings resulted in more sonoporation than in the control 
experiments. For comparing sonoporation with cell death, we used 2-sided t-tests to 
verify whether the percentage of sonoporated cells was different from the percentage of 
cell death. The effect of ntMBs, tMBs, and tMBB on the amount of sonoporated cells and 







The cells that were classified as non-resealing within 120 s were compared to the cells 
that were determined as dead by the cell viability assay. We used 2-sided t-tests to verify 








Sonoporation and cell-death 
 
The influence of various acoustic settings on cellular responses, for both ntMBs and 
tMBs, was evaluated by the amount of sonoporated cells and cell death, as illustrated in 
Figure 9.3. The sonoporation and cell death data are presented as the mean of three 
experiments at the same settings, with a mean (± SD) of 1,727 (± 338) cells in the FOV 
for ntMBs and 3,104 (± 130) cells for tMBs. The amount of injected microbubbles was 
adjusted accordingly, resulting in 1.9 (± 0.8) ntMBs per cell and 1.6 (± 0.3) tMBs per 
cell. No controls are shown for the cell death data, since these were already subtracted 
at all settings to correct for natural, non-US related, cell death (6.7 ± 1.1%). 
 
The data show that applying higher acoustic pressures and more cycles increased both 
the number of sonoporated cells (Fig. 9.3A, C) and the number of dead cells (Fig. 9.3B, 
D). This trend was seen for both ntMBs (Fig. 9.3A, B) and tMBs (Fig. 9.3C, D). However, 
when statistically comparing the same number of cycles at increasing pressures, the 
increase in sonoporation at higher acoustic pressure was only significant (p < 0.05) for 
ntMBs with at least 2,000 cycles. For tMBs sonoporation at 500 kPa was always higher 
than at 300 kPa, whereas at 300 kPa at least 10,000 cycles had to be applied to 
sonoporate more cells than at 150 kPa. Cell death for the same number of cycles at 
increasing pressures was significantly higher when using ntMBs, in all cases. For tMBs, 
cell death at 500 kPa was always significantly higher than at 300 kPa. Conversely, when 
comparing 300 kPa and 150 kPa, cell death was not significantly different between 1,000 
and 5,000 cycles. 
 
The amount of sonoporated cells, in the presence of ntMBs at 150 kPa, only resulted in 
significantly more sonoporation than in control experiments (0.4% sonoporation) when 
applying 10,000 or 50,000 cycles (2.0% or 4.7%, respectively). At 300 kPa, at least 2,000 
cycles were required to significantly yield more PI uptake than in the control 
experiments, whereas at 500 kPa pressure, 1,000 cycles were already sufficient. For 
tMBs, 150 kPa did not result in significantly more sonoporation than in the experiments 
without US. However, application of 300 or 500 kPa sonoporated significantly more cells 









Figure 9.3. Targeted and non-targeted microbubble-mediated sonoporation and cell death after 
ultrasound exposure at different acoustic pressures (150, 300, and 500 kPa) and number of cycles 
(500 – 50,000). (A) Mean (± SD) percentage of sonoporated cells and (B) cell death after 
insonification of ntMBs.  (C) Mean (± SD) percentage of sonoporated cells and (D) cell death after 
insonification of tMBs. Results were based on n = 3 repetitions of each experiment. Significant 
differences (p < 0.05) between sonoporation and cell death after US insonification in the presence 
of ntMB or tMB are indicated by (*). Significantly more sonoporation than cell death is indicated 
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The amount of sonoporated cells was expected to be higher than the amount of dead 
cells, because cells that are sonoporated can also remain viable. However, for most of 
the settings we applied, cell death was similar to the amount of sonoporated cells. The 
settings for which the difference between cell death and sonoporation was significant 
are indicated by (o) in Figure 9.3A and C. Since cell death was assessed from the viability 
assays—which were performed separately from the sonoporation assays—cell death 
could even be higher than the amount of sonoporated cells. This was the case for the 
150 kPa experiments in the presence of tMBs.  
 
To validate whether ntMBs or tMBs were more efficient in inducing sonoporation and 
cell death, we statistically compared them for significance. The asterisks (*) in Figure 
9.3 indicate significant differences between ntMB and tMB for sonoporation (A) and cell 
death (B). Although Figure 9.3A and C may suggest that ntMB more efficiently 
sonoporated cells than tMB at 500 kPa using long US pulses, this difference was not 
significant, probably due to the high standard deviations in the tMB sonoporation 
experiments. Cell death due to ntMBs was significantly higher for almost all number of 
cycles at a pressure of 300 kPa, and comparable for all settings at 150 kPa and for most 
settings at 500 kPa. 
 
Sonoporation-induced PI uptake over time  
 
Before US exposure, bright field imaging was used to discern MB locations (Fig. 9.4A); 
the black dots in this figure are the MBs, examples indicated by white arrows. The grey 
background of the image shows spherical structures; these are the nuclei of the 
endothelial cells in the monolayer. Fluorescence microscopy established individual cell 
nuclei locations by Hoechst staining (Fig. 9.4B), cell membrane integrity by the absence 
of PI fluorescence (Fig. 9.4C), and live cells by the presence of calcein (Fig. 9.4D). After 
US insonification, less MBs were present because they had dissolved, coalesced, or 
displaced (Fig. 9.4E). Intracellular PI uptake was observed by increase of fluorescence 
signal, thus indicating sonoporation (Fig. 9.4G). 
 
Interestingly, when increasing PI signal was observed, Hoechst signal decreased 
(Fig. 9.4F). Because the segmentation was done on the image after US application, the 









Figure 9.4. Optical recordings of microbubbles and the HUVEC monolayer. (A) Bright-field image of 
ntMB locations (black dots) before US exposure; an example of a single ntMB and a ntMB cluster are 
indicated by a white arrow. Yellow circles indicate highlighted sonoporated cells. (B) Hoechst 
fluorescence imaging of HUVEC nuclei before US application. (C) Fluorescence image of PI uptake 
before insonification; no uptake was present in the field of view. (D) Calcein stained image of live cells 
before US application. (E) Bright-field image after US treatment; ntMBs dissolved, displaced, and 
clustered. (F) Hoechst stained image of nuclei after US application; signal in sonoporated cells was lower 
than before US application. (G) Fluorescence image of PI signal after US application; red stained nuclei 
indicate sonoporated cells. (H) Calcein stained image after US application; calcein leaked out of some 
sonoporated cells. (I) PI fluorescence intensity as a function of time up to 180 s after US treatment 
(colored circles) and fit to the Fan model (Eq. 1, solid lines); black circles indicate 90% of theoretical 
maximum PI intensity that could be reached with the fit parameters. Cells 1 to 4 are marked with yellow 
circles in panels A-H, and the numbers correspond to those in panel A. US settings: 500 kPa acoustic 
pressure, 10,000 cycles. Scale bar 30 μm. 
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before US (compare panel B and F). In between the recording of these images, there can 
be small displacements of cells due to the radiation force of the applied US, movement 
of the MBs, or retraction of cells because of cell-cell contact opening. In cells that had 
taken up PI, calcein signal was found to decrease (Fig. 9.4H), which has previously been 





Figure 9.5. PI fluorescence intensity as a function of time up to 180 s after US treatment (colored 
circles) and fit to the Fan model (Eq. 1, solid lines); black circles indicate 90% of theoretical 
maximum PI intensity that could be reached with the fit parameters. Cells 1 to 4 are marked with 
yellow circles in Fig. 9.4A-H, and the numbers correspond to those in Fig 9.4A. US settings: 500 
kPa acoustic pressure, 10,000 cycles. Scale bar 30 μm. 
 
 
The PI time-lapse images (example shown in Fig. 9.4G) were analyzed for all acoustic 
settings, resulting in time-intensity curves showing the dynamic PI uptake from just 
after US application, up to 180 s later. The time-intensity curves were fit to the Fan 
model (Eq. 1) and revealed a variety of uptake dynamics. Because PI signal intensity 
could fluctuate between frames, we chose a robust method that only considered cells as 
actually sonoporated when the time-intensity curve could be fit to the model with an R2 
> 0.8. For R2 < 0.8 the fit was regarded as less reliable, because already dead cells at 
the start of the experiment without clear increase in PI uptake would also be marked as 






to the numbered cells in Figure 9.4A. The curves obtained for ntMB insonified at 500 
kPa for 10,000 cycles illustrate the general differences in PI uptake rates found at all 
other acoustic settings. The red and blue curve reach 90% of the maximum intensity 
value predicted by the model within 50 s, whereas the green curve reached this 90% 



















Figure 9.6. Classification of cell populations based on pore size and pore resealing coefficients. 
This graph originates from the same data set as Fig. 4 and shows cells with high PI uptake (red), 
low PI uptake (blue), cells with pores that resealed within 120 – 180 s (green), and cells with pores 
that did not reseal within 180 s (black). US settings: 500 kPa acoustic pressure, 10,000 cycles. 
 
 
PI uptake as a function of pore size and pore resealing coefficients 
 
The pore size and pore resealing coefficients of the cells that resulted in a reliable fit to 
Equation (9.1) (R2 > 0.8) were used to classify those cells into groups using PCA. This 
approach divided the total population of cells into two groups: one with relatively high 
pore resealing coefficients and relatively low pore size coefficients (Fig. 9.6, blue), and 
one with relatively low pore resealing coefficient and relatively large pore size coefficients  
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(Fig. 9.6, red). The cells in the blue population had low PI uptake suggesting small pores 
that sealed quickly, whereas the cells classified as red had high PI uptake suggestive of 
large pores that sealed slower, but within 120 s. By applying the additional thresholds 
(based on Eq. 1, as described in the Materials and Methods section), the cells that were 
likely to be irreversibly damaged were identified and classified into two separate 
populations: cells with pores that did reseal, but only after 120 s (Fig. 9.6, green), and 
cell with pores that did not reseal within 180 s (Fig. 9.6, black). 
 
Influence of acoustic settings on sonoporation-induced uptake and cell death 
 
 
The impact of the acoustic pressure and the number of cycles in a single burst sine wave 
on sonoporation-induced PI uptake is illustrated in Figure 9.7. These graphs show the 
populations of the time-lapse sonoporation assays classified as high PI uptake cells 
(red), low PI uptake cells (blue), cells with pores that had not resealed within 120 s 
(grey, this is the sum of the cells previously classified as green or black), and cell death 
(yellow) determined from the cell viability assays for each corresponding treatment. The 
cells with pores that did not reseal within 120 s were expected to be dead, and statistical 
comparison with cell death indeed confirmed that these two populations were not 
significantly different except for a few settings, mainly those with very low amounts of 
sonoporated cells (indicated by (*) in Fig. 9.7). The proportion of cells with low and 
high PI uptake (blue and red, respectively) significantly increased with increasing 
pressure, but did not significantly increase when only more cycles were applied. These 
cells were determined to be reversibly sonoporated and viable. On the other hand, the 
amount of cells with slow resealing pores (> 120 s, grey) and cell death (yellow), 
continued to increase with increasing pressure and cycles. Only increasing the number 
of cycles resulted in more cell death, but not necessarily in more cells that were viably 
sonoporated. 
 
Oscillatory behavior of microbubbles 
 
The ultra-high-speed movies recorded by the Brandaris 128 camera were qualitatively 
analyzed per segment. For each segment the number of single MBs and the number of 
MB clusters were counted and classified into four categories: 1) non-oscillating (white), 
2) oscillating (dark grey), 3) oscillating with coalescence of MBs (black), and 4) 









Figure 9.7. Percentage of cell death and cells classified per category by PCA and additional 
thresholding under various experimental acoustic pressures and cycles. The amount of cells with 
pores that did not reseal within 120 s (grey line) correlated well with cell death (yellow line) and 












Figure 9.8. Ultra-high-speed imaging of microbubble oscillation behavior. Top: illustration of the 
segments at which microbubble oscillation was captured and still frames of a recording of tMBs 
insonified at 300 kPa and 1,000 cycles. Bottom: ntMBs and tMBs oscillation behavior categorized 
into single MBs and clusters at 150 and 300 kPa insonifying pressure.  
 
 
The time line shows the US signal (for visualization purposes, only 20 cycles are shown 
in the schematic instead of the 1,000 cycles that were actually applied) and the segments 






Brandaris is smaller than that of the AxioCam or Redlake camera, therefore we could 
only study oscillatory behavior of a subset of MBs.  
 
When ntMBs were insonified at 150 kPa and 1,000 cycles, more single MBs were 
counted than MB clusters. In the first segment about 60% of single MBs oscillated, 
whereas > 90% of MB clusters were oscillating. Towards the end of the US burst, only 
25% of single MBs and 60% of MB clusters were still oscillating. From segment a to 
segment b most coalescence occurred (black). At a pressure of 300 kPa, more ntMBs 
oscillated: 75% of single MBs and all MB clusters (see Supplemental Video 1). The 
higher pressure ensured that MBs below resonance, i.e. smaller MBs, also started 
oscillating. In segment a and b, most clusters coalesced into larger clusters that kept 
oscillating until the end of the US pulse. This higher degree of clustering was probably 
caused by more displacement of MBs, due to higher acoustic radiation forces. At the end 
of the pulse, in segment 4, the large clusters split into smaller clusters or single MBs.  
 
At 150 kPa less tMBs coalesced than ntMBs. This was hypothesized to be due to less 
displacement of tMBs, as tMBs were attached and higher forces are needed to dislocate 
them [50]. Fewer clusters were present for tMBs, but more of them were oscillating 
(~75% in all segments). At a higher pressure of 300 kPa, the overall trend of oscillating 
single tMBs and clusters was not very different than that at 150 kPa. This has already 
been shown in Figures 9.3 and 9.7 in terms of sonoporation efficiency. However, at 300 
kPa more clusters were present and more coalescence occurred. 
 
Displacement of microbubbles 
 
As described in the previous section, more coalescence and clustering were observed for 
ntMBs, which was hypothesized to be caused by more displacing ntMBs. For each 
sonoporated cell, in a subset of the original image (ntMB: ~1100 cells, tMB: ~ 1700 
cells), we determined it to be either in contact with: 1) both non-displacing and 
displacing MBs (dark grey), 2) a MB that displaced (black), 3) a MB that had not 
displaced (light grey), or 4) when no MB could be detected nearby the cell (white), as 
shown by the stacked bars in Figure 9.9 as percentages of the total amount of 
sonoporated cells. The red solid line illustrates the amount of sonoporated cells as a 
percentage of the total amount of cells in the FOV. This amount was, on average, 2.7%  
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higher than the amount of sonoporated cells shown in Figures 9.3 and 9.7. This was 
expected, since the data for those figures only accounted for the cells that fitted properly 
to the model. Both methods showed the same trends, thus the determination of PI 
uptake was performed on a representative subset of the full-size AxioCam images. 
 
 
Figure 9.9. Displacement of ntMBs and tMBs under varying experimental acoustic pressures and 
cycles. For each acoustic setting, the stacked bar graph indicates the percentage of sonoporation 
caused by displacing MBs, non-displacing MBs, both, or when no MB could be detected. The red 
line shows the percentage of cells that were sonoporated.  
 
 
Most sonoporation was induced by non-displacing MBs (light grey, Fig. 9.9), whereas for 
ntMBs at 500 kPa and 50,000 cycles both displacing and non-displacing MBs accounted 
for similar amounts of sonoporation. The use of ntMBs resulted in the highest amount of 
displacing MBs, which supports the previously stated hypothesis that the higher degree of 
clustering was due to more displacing MBs. Overall, when comparing the contribution of 






line in Fig. 9.9), they followed the same trend.  
 
To relate MB displacement to sonoporation outcome, we compared the two cell classifications: 
1) reversibly sonoporated cells that had resealing pores < 120 s (Fig. 9.7, blue and red lines) 
and 2) irreversibly sonoporated cells (Fig. 9.7, grey line) with A) cells that were sonoporated 
by displacing MBs (Fig. 9.9, dark grey and black) and B) those that were sonoporated by non-
displacing MBs (Fig. 9.9, dark grey and light grey as shown in Fig. 9.10). The slope of the linear 
fit shows the ratio of increase between two groups; a ratio of 1 implies that the values are 
identical and increase proportionally (data follows the line y = x). 
 
A proportional increase was found for the amount of irreversibly sonoporated cells and 
the amount of cells that were sonoporated by non-displacing MBs (slope 1.0 for ntMB in 
Fig. 9.10A; slope 1.1 for tMB in Fig. 9.10B, both R2 = 0.99). In addition, the amount of 
sonoporated cells that was in contact with non-displacing MBs (Fig. 9.10C and D) 
increased four times faster than the amount of reversibly sonoporated cells (slope of 3.7 
and 4.1, respectively). This strongly suggest that cells in contact with non-displacing MBs 
were irreversibly damaged.  
 
On the other hand, the amount of sonoporation for cells in contact with displacing ntMBs 
increased twice as fast as the amount of reversibly sonoporated cells (Fig. 9.10G, slope of 
2.1), while still contributing to irreversible sonoporation (Fig. 9.10E, slope of 0.57). This 
suggest that displacing ntMBs can both induce reversible and irreversible sonoporation. 
For cells in contact with displacing tMBs the amount of reversibly sonoporated cells 
increased proportionally (Fig. 9.10H, slope of 1.0). Further, displacing tMBs minimally 
contributed to irreversible sonoporation (Fig. 9.10F, slope of 0.27). This suggests that 
displacing tMBs mainly resulted in reversible sonoporation.  
 
The relation between the presence of displacing and non-displacing MBs and the 
classification of cells was confirmed on a single cell basis, as shown in Figure 9.11 and Figure 
9.5. Cells 1 and 2 were both reversibly sonoporated due to MBs displacing over their cell 
membranes, of which cell 1 had high PI uptake and cell 2 low uptake. Cell 1 also had non-
displacing MBs in its vicinity, which might be the reason for the higher uptake o PI. Cells 3 
and 4 had slow resealing pores (> 120 s) and only non-displacing MBs nearby their cell 
membranes.  
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Figure 9.10. Scatter plots visualizing the relation between MB displacement and sonoporation 
outcome. The slope of the linear fit shows the ratio of increase between each two groups. Blue 
circles are the experimental data points at all 21 acoustic settings, the black dashed line the linear 
fit. Irreversible sonoporation is the grey data set from Fig. 6; reversible sonoporation is the sum of 








Figure 9.11. Microbubble displacement. White arrows indicate displacing ntMBs and blue filled 
circles indicate non-displacing ntMBs, overlaid on the same PI stained image as shown in Fig. 4G. 
Cells 1-4 (yellow lines) are the same ones as shown in Fig. 4. MB displacement was not correlated 
to the direction of US application. US settings: 500 kPa acoustic pressure, 10,000 cycles. Scale bar 
indicates 30 μm. 
 
 
Orientation of targeted microbubbles 
For all experiments concerning ntMBs, the cells were on the upper membrane of the 
OptiCell with the MBs floating against the cells. For the tMB experiments described so 
far, the cells were on the bottom membrane with the tMBs adhered on top of the cells. 
In addition to the comparison between ntMBs and tMBs, we also investigated the effect 
of the orientation of tMBs with respect to the cells and US application. We therefore 
placed the OptiCell containing tMBs in the same orientation as the experiments on 
ntMBs, so the cells were on the upper membrane with the tMBs below the cells (tMBB). 
These experiments were repeated two times at 500 kPa for all investigated number of 
cycles with on average 3,106 (± 139) cells in the FOV.  
 
The amount of US-induced sonoporated cells with tMBB was higher than for the control 
experiments for the four settings with the smallest error bars: 1,000; 2,000; 10,000; and 
50,000 cycles. Although, especially for the longer pulses, tMBB seemed to more 
efficiently sonoporate cells than both tMBs and ntMBs, this was not statistically 
significant for most cycles. Only with 10,000 cycles were tMBB more efficient than ntMBs 
(*); and only with 500 cycles were tMBB more efficient than tMB (o) (Fig. 9.12A, p < 0.05).  
226
Viability of endothelial cells after sonoporation 
 
  
Cell death for tMBB was significantly higher than for the tMBB controls after applying 
2,000; 5,000; 20,000; and 50,000 cycles. In addition, cell death and the total amount of 
sonoporated cells were significantly different for all experimental settings. For most 
settings cell death of tMBB was similar to ntMBs or tMBs, except for 1,000 cycles with 
ntMBs (*) and 1,000 and 2,000 cycles with tMBs (o) as shown in Figure. 9.12B. Cell 
death controls are not shown, since these were subtracted from cell death at the other 
settings to correct for natural cell death. 
 
Cell classification based on PI uptake patterns showed similar trends for tMBB as for 
ntMBs and tMBs, in terms of the amount of cells in each group. However, the cells with 
non-resealing pores within 120 s (Fig. 9.12C, grey) did not correlate with the amount 
of cell death (Fig. 9.12C, yellow), since they were significantly different for all applied 
settings, possibly of lower statistical power (only n = 2). As expected, displacement of 
tMBB was very similar to the displacement of tMBs (Fig. 9.12D and Fig. 9.9), since the 
binding strength that has to be overcome to displace them is identical.  
 
Discussion 
his is the first study that directly compares ntMB and tMB-mediated sonoporation 
in primary endothelial cells in vitro using long acoustic pulses (500 – 50,000 
cycles). At 1 MHz and three different acoustic pressures (150-500 kPa), we aimed to 
identify differences in MB behavior responsible for either viable sonoporation or cell 
death. The real-time observed uptake of PI upon sonoporation was fit using a previously 
reported diffusion model228 and subsequently classified using PCA. Cell viability highly 
correlated with the four different PI uptake patterns derived from this classification. 
Further, displacing tMBs resulted in viably sonoporated cells, whereas non-displacing 
tMBs and ntMBs accounted for more cell death.  
 
Cellular response dynamics 
Four cell populations with different PI uptake profiles were found for ntMB and tMB-
mediated sonoporation at each US setting. The cells that had non-resealing pores within 
120 s after US application were irreversibly damaged (Fig. 9.7, grey) as this correlated 
well with cell death (Fig. 9.7, yellow). Further, cells having low PI uptake (Fig. 9.7, blue) 









Figure 9.12. tMBs adhered below the cells (tMBB) insonified at 500 kPa. (A) Mean (± SD) 
percentage of sonoporated cells and (B) cell death after insonification of tMBB. Asterisks (*) 
indicate significant differences between tMBB and ntMBs, and (o) between tMBB and tMBs. (C) 
Classification of cells based on their pore size and pore resealing coefficient. The amount of cells 
with non-resealing pores within 120 s (grey) was significantly different from the amount of dead 
cells (yellow) for all settings. (D) Displacement of tMBB. For each acoustic setting, the bar graph 
indicates the percentage of cells that were sonoporated by displacing MBs, non-displacing MBs, 
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have shown that cells remained viable when pores resealed within a few seconds up to 
60 s227,229,488. However, these studies were not performed on human endothelial cells, 
but on human fibroblasts229, bovine endothelial cell227, and Xenopus oocytes488. 
Enhanced drug uptake up to several hours has also been reported489,490, but cells having 
non-resealed pores for such long periods are not expected to be viable. We therefore 
believe that the route of model drug uptake in their experiments was most likely not 
due to pore formation, but possibly stimulated endocytosis. Our results suggest that 
human endothelial cells showing increasing nuclear PI signal up to 120 s were also viably 
sonoporated. This may imply that pores open for longer than 60 s can still result in 
viably sonoporated cells.  
 
Cells that had taken up PI also showed an efflux of calcein, which is another indicator 
of sonoporation228. Next to calcein efflux, those cells also revealed lower Hoechst signals 
in the fluorescence images taken after US treatment than in those taken before (Fig. 
9.4). Since the literature agrees upon non-competitive binding of PI and Hoechst478,479, 
we believe this decrease in signal was caused by Förster resonance energy transfer 
(also known as FRET)491. The emission spectrum of Hoechst (maximum intensity at 461 
nm) overlaps with the excitation spectrum of PI (491 - 495 nm); the presence of PI can 
therefore result in considerable quenching of the Hoechst signal492. Hoechst signal 
intensity was therefore lower in cells that had taken up PI. In addition, the amount of 
PI uptake was found to be related to the level of quenching; cells 1, 3, and 4 had high PI 
uptake (Fig. 9.4G) and Hoechst signal was almost completely quenched (Fig. 9.4F), 
whereas cell 2 had low PI uptake and less quenching of Hoechst signal. 
 
Influence of oscillation and displacement of microbubbles 
Quantitative assessment of the displacement of MBs revealed more PI uptake when 
more tMBs or ntMBs displaced (Fig. 9.9). We studied the relation between MB 
displacement and reversibility of sonoporation and found a clear relation between non-
displacing MBs and irreversible sonoporation (Fig. 9.10A and 9.10B); an increase in 
sonoporation by non-displacing MBs coincides with a similar increase in irreversible 
sonoporation. We therefore concluded that irreversible sonoporation was mainly caused 
by non-displacing MBs, explained by prolonged MB oscillation at the same location on 
the cell membrane. The relation between displacing MBs and sonoporation is less 






ntMBs increased twice as fast as those that were reversibly sonoporated (slope of 2.1), 
which implies that displacing ntMBs did not only induce reversible sonoporation, but 
also irreversible sonoporation (Fig. 9.10E). Because longer pulses at higher acoustic 
pressure cause more displacement, the ntMBs can affect multiple cells or multiple 
displacing ntMBs can affect a single cell.  
 
For tMBs we found an increase in reversible sonoporation that coincides with a similar 
increase in sonoporation caused by displacing tMBs (Fig. 9.10H). We therefore conclude 
that displacing tMBs mainly resulted in reversible sonoporation. The amount of 
irreversibly sonoporated cells by displacing tMBs is much smaller than for ntMBs 
(compare Fig. 9.10E and 9.10F). When tMBs detach and displace, they float away from 
the cells and will not contribute to more sonoporation.  
 
Displacing tMBs resulted mainly in reversible sonoporation, whereas the much larger 
amount of displacing ntMBs also induced irreversible sonoporation. This may imply that 
reversibility is only achieved with limited displacement of MBs. Fan et al.466,468 concluded 
that displacement of both ntMBs and tMBs correlated with irreversible sonoporation, 
while we related displacement to reversibility. This difference may be explained by larger 
MB displacements in their study because they used pulsed US (1.25 MHz, 60-600 kPa, 
PRF 10-1,000 Hz, duty cycles 0.016-20%), whereas the single US burst we used resulted 
in less and slower displacement for the second half of the pulse (Fig. 9.8).  
 
In the high-speed and ultra-high-speed recordings we observed clustering of MBs. 
Higher pressures enhanced cluster formation, and ntMBs formed more clusters because 
they displaced more than tMBs. Since the amount of sonoporated cells was similar for 
ntMBs and tMBs (Fig. 9.3), clustering did thus not result in more sonoporation. 
 
Mannaris and Averkiou123 were the first to show acoustically that MBs remained 
oscillating during 1,000 acoustic cycles at 100 kPa. Our ultra-high-speed recordings 
revealed the presence and oscillation of both single MBs and MB clusters at the end of 
the 1,000-cycle US burst at 150 and 300 kPa, albeit that we observed more oscillating 
MB clusters at the end of the US pulse than single MBs. Chen et al.493 reported 
contrasting observations. After 1,000 cycles their ultra-high-speed recordings only 
showed oscillating clusters; no single MBs were present anymore. The most likely cause  
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for these different findings is the high pressure (up to 1.5 MPa) they applied, which 
resulted in more displacement due to acoustic radiation force437,469 and more clustering.  
 
Sonoporation efficiency: ntMB versus tMB 
The sonoporation efficiency of ntMB and tMB showed the same trend: higher pressures 
and more cycles resulted in more sonoporation (Fig. 9.3), as also shown by others230,474. 
However, for tMBs the amounts of sonoporated and dead cells at 300 kPa were lower 
than for ntMBs, which is most likely caused by MB displacement or oscillation behavior. 
Increasing the pressure from 150 to 300 kPa resulted in more displacing ntMBs, but the 
number of displacing tMBs did not increase (Fig. 9.9). In addition, the ultra-high-speed 
recordings showed more oscillating ntMBs for increasing pressure, while no change was 
observed for tMBs (Fig. 9.8). This is caused by functionalization of our tMBs with CD31 
antibodies via streptavidin-biotin binding, but we did not add streptavidin nor control-
antibodies to our ntMBs, as clinical ntMBs would not have this either. Functionalization 
of MBs alters shell properties35 and therefore oscillation behavior419. Since our tMBs and 
ntMBs had identical lipid shells with DSPC as the main lipid, the targeting moieties 
would result in a higher elasticity and thus a stiffer shell of our tMBs35. As a 
consequence, higher pressures are required for tMBs to obtain the same oscillation 
amplitude as for ntMBs36, which likely influences sonoporation efficiency.  
 
The sonoporation experiments with tMBs at 500 kPa and 10,000 to 50,000 cycles 
showed very large error bars (Fig. 9.3C). Two of the OptiCells in which the experiments 
were done showed similar uptake percentages, but the amount of sonoporated cells in 
the third OptiCell was almost twice as high. The underlying cause for this observation 
is unclear; all cell layers were confluent, the total amount of cells and MB concentration 
was similar, as well as the average number of MBs per cell. Hence, we can only conclude 
that sonoporation caused by tMBs is less predictable than by ntMBs.  
 
Our findings, that in general tMBs did not induce higher PI uptake than ntMBs, 
contradict other in vitro studies that report tMBs to be more efficient for drug delivery 
than ntMBs in a direct comparison. The five reported in vitro studies455-459 all show that  
the lipid-shell tMBs are 1.1459 to 7.7455 fold more efficient for drug delivery than ntMBs. 







DNA), the other one describes co-administration of PI458. A direct comparison between 
our study and the five reported studies is difficult, due to the differences in experimental 
conditions. None of these studies assessed MB-mediated drug delivery in endothelial 
cells. Instead, smooth muscle456 or cancer cells were used. The study that reported the 
largest difference between ntMBs and tMBs, rinsed the cells to remove free MBs that 
had not adhered455. As a result, the ntMBs would almost all have been washed away, 
which could explain the large difference. Another study treated cancer cells in 
suspension457, whereas we treated a fully confluent monolayer of endothelial cells. Two 
studies457,459 used ntMBs with a different shell composition and smaller mean diameter 
than their tMBs, which without doubt results in differences in MB behavior36,238,419. In 
addition, one study reported that the 5.5 fold higher uptake could only be achieved with 
70% confluent cells456. Consequently, our results are not supported by other studies, 
since none directly compared ntMB and tMB-mediated drug delivery in endothelial cells 
in vitro. Several studies reported more efficient drug delivery or transfection in vivo for 
tMBs than for ntMBs460-463. Due to blood flow, ntMBs flow by and thus have shorter 
contact with tissue, thereby making ntMBs less efficient. Inclusion of flow in the in vitro 
experiments is thought to result in more efficient sonoporation for tMB than for ntMB 
and will be subject for future studies. 
 
Microbubble orientation 
We used a different orientation of MBs relative to the cells and US direction for tMBs 
and ntMBs (Fig. 9.1B and Fig. 9.12). Therefore, the ntMBs could have been pushed 
towards the cells by the US, while the tMBs could have been pushed away from the cells. 
To study whether this influenced sonoporation efficiency, we performed experiments 
with tMBs in the same orientation as the ntMBs, which we referred to as tMBB (tMB 
below cells). Because tMBB adhered below the cells, non-adhered tMBB would also be in 
contact with the cells and could have contributed to sonoporation as well. Higher 
amounts of non-adhered tMBB would results in more displacing tMBB and thus enhance 
sonoporation. However, since the amounts of tMBB and tMBs in the FOV were the same 
(~3,100 cells), we can assume that all tMBB had adhered and that non-adhered tMBB 
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Sonoporation efficiency for tMBB seemed higher than for tMBs (compare Fig. 9.3C and 
Fig. 9.12A), possibly caused by MBs that detached during insonification and remained 
in contact with the cells. In contrast, the configuration for tMBs allowed them to float 
away after detachment. The sonoporation efficiency, however, was not significantly 
different to conclude that tMBB were more efficient than tMBs. To the best of our 
knowledge, no previously published studies investigated the orientation of MBs relative 
to the cells and US direction. Others that directly compared the effect of ntMBs and 
tMBs either did not mention the orientation457,459, had the MBs on top of the cells with 




To obtain the amount of sonoporation from the nuclear PI uptake and the associated 
model fit, we used algorithms implemented in ImageJ and RStudio, whereas a different 
algorithm in Python was used to obtain sonoporation from PI uptake in the entire cell 
and its relation to displacing and non-displacing MBs. Although this is not ideal, we 
chose this approach to optimally utilize the strengths of each method: segmentation 
(ImageJ) and tracking of moving particles (Python). Since both methods relied heavily 
on correct detection of cell nuclei, we manually counted the nuclei on the Hoechst 
images and compared this to the outcomes of the ImageJ and Python algorithms: both 
detected, on average, only 6% of the nuclei incorrectly (n = 6 images). Since the errors 
were small, the additional analyses were expected to be comparable as well. Indeed, the 
segmented cell borders by Voronoi tessellation closely overlapped between the two 
methods. As already mentioned, sonoporation was slightly higher (2.7% on average) for 
the tracking method in Python, than for the more robust fitting method using RStudio. 
This was caused by additional detection of cytoplasmic PI uptake and by cells of which 
the model could not be fit (R2 < 0.8) to the nuclear uptake profile.  
 
In contrast to the paper by Fan et al.228, we did not calculate the size of the pores, since 
not all parameters of our system were known. However, if we would have done this, 
possible multiple pores in a single cell could still have been detected as one larger pore. 
In addition, we only included PI uptake in the nucleus because determination of the cell 
borders was based on probability, whereas the nucleus could be more precisely 






On average, 7.4% of sonoporated cells that were found using the tracking algorithm 
were classified as being sonoporated without the presence of a MB nearby (Fig. 9.9, 
white). Since control experiments with only MBs showed sonoporation of < 0.9% of all 
cells, this was not caused by spontaneous uptake of PI, but most likely due to the size 
of the MBs—only  a few pixels in diameter—and the quality of the images. Accurately 
detecting ntMBs was more difficult due to the optical focus in the corresponding bright-
field images; the cells were better in focus, resulting in lower discriminative power 
between cell structures and MBs. The error for ntMB detection was therefore higher. 
Manual counting of the number of MBs that was not counted by the algorithm resulted  
in an average of 9% more MBs per image (n = 9). This is slightly higher than the average 
amount of sonoporated cells without MBs nearby, because MBs that were in contact 
with non-sonoporated cells could have also been missed.  
 
Limitations of this study 
A limitation to our study is the use of CD31 as the ligand on our tMBs, because this is 
a constitutively expressed adhesion molecule on endothelial cells494. It can therefore not 
be used in vivo, since CD31-tMBs would adhere to the entire vasculature. Also, the MBs 
circulate within the vasculature in vivo, while we performed our studies under static 
conditions. Flow is expected to have an influence on the sonoporation efficiency, as 
ntMBs will be taken away by the flow, while tMBs will still adhere to the cells under 
flow495. A higher sonoporation efficiency for tMBs is therefore expected and 
shown460,461,463 under flow and in vivo conditions.  
 
Therapeutic applications 
Based on our results, ntMBs exposed to an acoustic pressure of 500 kPa and a pulse 
length of 1,000 cycles would be most beneficial for drug delivery. These settings resulted 
in relatively high amounts of viably sonoporated cells (Fig. 9.7, blue) and minimal cell 
death (Fig. 9.7, grey/yellow). For drug delivery, high drug uptake would be most 
beneficial since higher doses of therapeutics can be delivered (Fig. 9.7, red). 
Nevertheless, we always observed equal or lower red uptake patterns in comparison to 
the blue uptake patterns of lower PI uptake, implying there is not one US setting that 
favors one over the other. On the other hand, for therapeutic applications where high 
cell death is desired, e.g. cancer therapies, high pressures and long pulses should be  
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applied (e.g., 500 kPa and 50,000 cycles). Both tMBs and ntMBs were shown to 
effectively kill cells, but ntMBs were more efficient. For therapies requiring 
sonoporation of specific cells under flow, ntMBs would need to be replaced with tMBs. 
ntMBs could sonoporate cells as they move along the cells, or when pressed against a 
thrombus occluding a blood vessel, as in the case of sonothrombolysis37,496.  On the other 
hand, for locally enhanced drug delivery in tumors tMBs are required, since the MBs 
need to be close to the cell membrane227,497. Hence, the choice of using either ntMBs or 




n depth sonoporation studies on the effect of longer acoustic pulses at 1 MHz at 
different acoustic pressures revealed a clear relation between sonoporation 
efficiency and MB behavior. Different patterns of PI uptake derived from the diffusion 
model and subsequent classification using PCA highly correlated with cell viability. 
Limited displacement of the MBs enhanced drug delivery and preserved cell viability, 
while non-displacing MBs were the main contributor to cell death. Longer pulses 
resulted in more dead cells, but did not result in significant increase in viably 
sonoporated cells. In addition, the effect of the same type of ntMBs and tMBs to 
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 A.A. Milne 
            
What day is it?” asked Pooh. 
“It’s today,” squeaked Piglet. 
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Ultrasound insonification of microbubbles can locally increase vascular permeability to 
enhance drug delivery. To control and optimize the therapeutic potential, we need to 
better understand the underlying biological mechanisms of the drug delivery pathways. 
The aim of this in vitro study was to elucidate the microbubble-endothelial cell 
interaction using the Brandaris 128 ultra-high-speed camera (up to 25 Mfps) coupled to 
a custom-built Nikon confocal microscope, to visualize both microbubble oscillation and 
the cellular response. Sonoporation and opening of cell-cell contacts by single αVβ3-
targeted microbubbles (n = 152) was monitored up to 4 min after ultrasound 
insonification (2 MHz, 100–400 kPa, 10 cycles). Sonoporation occurred when 
microbubble excursion amplitudes exceeded 0.7 μm. Quantification of the influx of the 
fluorescent model drug propidium iodide upon sonoporation showed that the size of the 
created pore increased for larger microbubble excursion amplitudes. Microbubble-
mediated opening of cell-cell contacts occurred as a cellular response upon sonoporation 
and did not correlate with the microbubble excursion amplitude itself. The initial 
integrity of the cell-cell contacts affected the susceptibly to drug delivery, since cell-cell 
contacts opened more often when cells were only partially attached to their neighbors 
(48%) than when fully attached (14%). The drug delivery outcomes were independent 
of nonlinear microbubble behavior, microbubble location, and cell size. In conclusion, 
by studying the microbubble–cell interaction at nanosecond and nanometer resolution 
the relationship between drug delivery pathways and their underlying mechanisms was 
further unraveled. These novel insights will aid the development of safe and efficient 












ife-threatening diseased tissue often lies beyond the vasculature. This means that 
intravenously administered drugs need to extravasate from the vasculature to 
reach their intracellular and extravascular targets. The endothelial cells that line the 
vessel wall are barriers that severely limit local and effective drug delivery necessary for 
successful treatment. To overcome the challenges these barriers present, drug delivery 
can be locally enhanced using lipid-coated gas microbubbles (1–10 μm) in combination 
with ultrasound36,220. These microbubbles are widely used in the clinic to improve 
contrast in diagnostic ultrasound imaging. When ultrasound is applied, microbubbles 
will oscillate, which can permeabilize cell membranes (sonoporation), open cell-cell 
contacts, and stimulate endocytosis36,220,307. However, the underlying physical and 
biological mechanisms of the microbubble–cell interaction need to be elucidated. If we 
can control and predict the different drug delivery pathways, microbubble-mediated 
drug delivery can be tuned to the requirements of a therapeutic application. 
 
To unravel the underlying mechanisms of the microbubble–cell interaction, one needs 
to know which microbubble behavior is responsible for which cellular response. 
Therefore, we need to image both the microbubble oscillation at nanosecond temporal 
resolution and the ensuing detailed cellular response at nanometer spatial resolution. 
Until now, concurrent visualization of microbubble oscillation and endothelial cell 
response has only been possible using an ultra-high-speed camera coupled to a widefield 
microscope224,225,226,227. In these studies, focusing on sonoporation, the microbubble 
behavior was known but the cellular response was imaged at low resolution and 
sensitivity. Helfield et al.224 performed an additional experiment in which they only used 
confocal microscopy to show sonoporation and opening of cell-cell contacts in a single 
example. Confocal microscopy has also been used by others to visualize the cellular 
response at high spatial resolution and detector sensitivity. They investigated 
sonoporation229,230,231,235,501, membrane perforation and recovery dynamics229, 
endocytosis230, sonoprinting501,234, lipoplex delivery231, and cytoskeleton reorganization235. 
However, the studies using confocal microscopy lacked information on the microbubble 
oscillation behavior that was responsible for the cellular effect. Since single microbubble 
response to ultrasound is variable237,239 even for known acoustic pressures, the 







Sonoporation has been investigated in vitro and in real-time, demonstrating the 
capability of an oscillating microbubble to create a pore in the endothelial cell 
membrane224,226,227,245,502. The transient behavior of pore formation and recovery dynamics 
have been studied with live cell microscopy228,229. Reversible sonoporation can 
temporarily enhance intracellular drug delivery without cell death. However, when cell 
membrane integrity is not restored after pore formation, sonoporation is irreversible 
and will eventually lead to cell death. Pore resealing times from a few seconds up to 120 
s have been reported229,245,488,502. Fan et al.228 showed that upon sonoporation, the amount 
of fluorescent marker propidium iodide (PI) uptake can be related to the size of the pore 
and its resealing time. This has been used to quantify the pore dynamics of kidney228 and 
endothelial cells245,466. Nevertheless, it remained unknown how microbubble oscillation 
behavior correlates with the severity of sonoporation, in terms of the pore size and its 
resealing characteristics. When the microbubble excursion amplitude required for 
sonoporation was investigated, the cellular response could only be studied at low 
sensitivity and spatial resolution using widefield microscopy224,226. 
 
Opening of cell-cell contacts has been previously observed using live cell microscopy 
within minutes after ultrasound insonification of a non-targeted microbubble for a 
single example224. The opened cell-cell contacts remained open for tens of minutes, 
suggesting a prolonged enhanced drug delivery effect of this pathway. In addition, 
extravasation of drug compounds from the vasculature has been shown, for instance to 
overcome the blood-brain barrier503,504. It is hypothesized that this cellular response of 
opening the intercellular junctions is caused by the shear stress from the oscillating 
microbubbles, the microbubble forces on the cytoskeleton of the cell, and/or the changes 
in cell morphology due to sonoporation221. However, there is still a lack of understanding 
on how microbubble oscillation behavior causes the opening of cell-cell contacts and 
whether this is an independent drug delivery pathway or induced upon sonoporation221. 
 
In this study we aimed to elucidate the missing link between microbubble oscillation 
behavior and the occurrence of sonoporation and opening of cell-cell contacts in cultured 
endothelial cells. Microbubbles were targeted to the integrin αvβ3 (alpha-v-beta-3), also 
known as CD51/61, expressed by endothelial cells during angiogenesis505, which is 
clinically relevant for cancer and atherosclerosis therapy. Ultrasound at a 2 MHz frequency 
was applied, commonly used in transthoracic ultrasound409. A unique optical imaging  
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system was used consisting of the Brandaris 128 ultra-high-speed camera, to record the 
microbubble oscillation, coupled to a custom-built Nikon A1R+ confocal microscope, 
to visualize the cellular response. The cellular response upon insonification of a single 
targeted microbubble was studied by monitoring uptake of the model drug PI and by 
assessing opening of cell-cell contacts between adjacent cells. As a result, the 
microbubble–cell interaction was studied at both nanosecond and nanometer resolution 




Materials and Methods 
Endothelial cell culture 
 
Primary human umbilical vein endothelial cells (HUVECs) from pooled donors 
(C2519A, LOT 437550, Lonza, Verviers, Belgium) were cultured in MV2 medium 
(C22121, PromoCell, Heidelberg, Germany), supplemented with 1% Penicillin-
Streptomycin (15140122, Gibco, Thermo Fisher Scientific, Waltham, MA, USA). The 
HUVECs were grown (at 37 °C and 5% CO2) in a humidified incubator to full confluency 
in T75 flasks. Next, they were detached using Accutase solution (A6964, Sigma-Aldrich, 
St. Louis, MO, USA) and replated on the bottom membrane of a CLINIcell 
(CLINIcell25–50-T, REF 00106, MABIO, Tourcoing, France) in 12 mL MV2. The 
CLINIcell is an acoustic compatible cell culture chamber with two gas permeable parallel 
membranes (thickness 50 μm, surface area 25 cm2)506. The CLINIcells were incubated 
(at 37 °C and 5% CO2) for two days to achieve a fully confluent cell monolayer. The 
HUVECs used in the experiments were between passage numbers 4 and 6. 
 
Targeted microbubble preparation 
 
For lipid-coated microbubbles with a C4F10 gas core were produced in-house by probe 
sonication for 1 min, as previously described241,314,419. The coating consisted of 1,2-
distearoyl-sn-glycero-3-phosphocholine (DSPC; 84.8 mol%; P6517, Sigma-Aldrich), 
polyoxyethylene-40-stearate (PEG-40 stearate; 8.2 mol%; P3440, Sigma-Aldrich), 1,2-
distearoylsn-glycero-3-phosphoethanolamine-N-[carboxy(polyethylene glycol)-2000] 







(DSPE-PEG(2000)-biotin; 1.1 mol%; 880129C, Avanti Polar Lipids). Finally, to 
fluorescently label the microbubble coating, the lipid dye DiD (1,1′-dioctadecyl-3,3,3′,3′-
tetramethylindodicarbocyanine perchlorate; D307, Thermo Fisher Scientific) was added 
before sonication. The microbubbles were targeted to the αvβ3 integrin using 
biotinstreptavidin bridging, as previously described by others447,454,475,507-509 with the 
exception of the type of ligand. Briefly, after washing three times by centrifugation 
(400g, 1 min) using PBS saturated with C4F10, the microbubble concentration was 
determined with a Coulter Counter Multisizer 3 (n = 3) (20 μm aperture tube, Beckman 
Coulter, Mijdrecht, the Netherlands). Next, 6 × 108 microbubbles were incubated on 
ice for 30 min with 60 μg of streptavidin (2 mg/mL stock concentration in PBS, S4762, 
Sigma-Aldrich) and washed. These streptavidin-conjugated microbubbles were 
incubated on ice for 30 min with 6 μg of biotinylated anti-human CD51/61 antibody 




To study the microbubble-cell interaction, a unique optical imaging system was used 
consisting of the Brandaris 128 ultra-high-speed camera (up to 25 million frames per 
second, Mfps)222 coupled to a custom-built Nikon A1R+ confocal microscope (Fig. 
10.1A)273. With this system high temporal and spatial resolutions can be achieved, 
required to resolve the microbubble oscillation and cellular response, as explained in 
more detail by Beekers et al.273. For simultaneous imaging and ultrasound insonification, 
the CLINIcell was inserted into a 37 °C water tank positioned beneath the microscope. 
A single element focused transducer (a 2.25 MHz center frequency used at 2 MHz; 76.2 
mm focal length; −6 dB beam width of 3 mm at 2 MHz; V305; Panametrics-NDT, 
Olympus, Waltham, MA, USA) was mounted in the water tank at a 45° angle, after 
having been calibrated using a needle hydrophone. The ultrasound and optical foci were 
aligned such that the cells in the CLINIcell could be both imaged and insonified (Fig. 
1A). A single 2 MHz and 10-cycle burst was generated by an arbitrary waveform 
generator (33220A, Agilent, Palo Alto, CA, USA). A broadband amplifier (ENI A-500, 
Electronics & Innovation, Rochester, NY, USA) was used to obtain peak negative 
pressures (PNP) of 100, 200, 250, 300, and 400 kPa at the focus. 
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Figure 10.1. Schematic representation of the experimental procedure (not drawn to scale). (A) 
Experimental setup to insonify a CLINIcell under a 45° angle. The optical imaging system combines 
an A1R+ confocal scan head (Nikon Instruments), with a DS-Fi3 colour camera (Nikon 
Instruments) for widefield imaging, and the Brandaris 128 ultra-high-speed camera. (B) Timeline 
starting with the incubation of HUVECs with fluorescent dyes and targeted microbubbles, 





To The HUVECs were stained with fluorescent dyes for live confocal microscopy 
imaging (Fig. 10.1B). They were incubated with CellMask™ Green Plasma Membrane 
Stain (4 μg/mL final concentration; C37608; Thermo Fisher Scientific) for 10 min inside 
the cell incubator to stain the cell membranes. Next, Hoechst 33342 (5 μg/mL final 
concentration; H3570, Thermo Fisher Scientific) was added to stain the cell nuclei and 
PI (25 μg/mL final concentration; P4864, Sigma-Aldrich) was added as a marker for 
sonoporation. The cell membrane of viable cells is impermeable for PI. When the cell 
membrane is compromised, PI enters the cell, binds to DNA and RNA, and becomes 
fluorescent465. Therefore, PI is often used as a marker for sonoporation to evaluate 
membrane perforation54,224,227,228,510. Additionally, CD51/61 targeted microbubbles (2 × 
105 microbubbles/mL final concentration) were added and the CLINIcell was incubated 
during 5 min inside the cell incubator, while turned upside down to allow the targeted 
microbubbles to float towards the cells to achieve binding (Fig. 10.1B). The CLINIcell 


































the focal plane of the cells. Finally, the top membrane without cells was cut from the 
CLINIcell, making it feasible to image with an objective with a working distance smaller 
than the 5 mm spacing between the CLINIcell membranes. The same incubation 
timeline was used for control CLINIcells without microbubbles. 
 
To monitor the cellular response with confocal microscopy, imaging was performed with the 
following four channels: (1) Hoechst excited at 405 nm, detected at 450/50 nm (center 
wavelength/bandwidth), (2) CellMask Green excited at 488 nm, detected at 525/50 nm, (3) 
PI excited at 561 nm, detected at 595/50 nm, and (4) DiD excited at 640 nm, detected at 
700/70 nm. Channel 1 and 4 were excited and detected simultaneously because there is no 
spectral overlap between Hoechst and DiD. Using a 100× water dipping objective (CFI Plan 
100XC W, 2.5 mm working distance, Nikon Instruments), a field of view (FOV) of 74.2 × 
74.2 μm (256 × 256 pixels) was scanned at 0.65 frames per second (fps). At each location, 
time-lapse imaging was performed for 4 min in total (Fig. 10.1B). This 100× objective has 
a high numerical aperture of 1.10; therefore, we achieve a lateral resolution up to 200 nm 
and an axial resolution up to 600 nm325. To visualize the initial cellular state, confocal 
microscopy time-lapse imaging started before ultrasound. Within the first minute, the light 
path was automatically switched from the confocal scanning head to the Brandaris 128 ultra-
high-speed camera. The microbubble oscillation was then recorded at approximately 17 
Mfps during ultrasound insonification. Once this recording was completed, the light path 
was switched back towards the confocal scanning head to visualize the cellular response. 
Since insonification occurred within the first minute, the cellular response upon 
microbubble vibration was monitored for at least 3 min (Fig. 10.1B). 
 
The area to be imaged was chosen based on the following inclusion criteria: (i) the FOV 
showed fully confluent cells, such that there were no empty spaces in which an extra cell 
could have grown and all cells were at least partially attached to neighboring cells; (ii) 
there was a single targeted microbubble in the FOV; (iii) this targeted microbubble was 
located on a cell that was completely in the FOV; (iv) this cell had a single nucleus; and 
(v) this nucleus did not overlap with that of any neighboring cells. Per CLINIcell, a 
maximum of 15 locations uniformly distributed and spaced by at least 1 cm to avoid 
overlapping insonification were imaged within 120 min. Additional CLINIcells were used 
for two types of control experiments: (i) sham, i.e. without microbubbles or ultrasound; 
and (ii) ultrasound only, i.e. without microbubbles. 
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Analysis of microbubble oscillation 
 
Microbubble oscillation recorded by the Brandaris 128 ultra-high-speed camera was 
quantified using custom-designed image analysis software to determine the change in 
radius as a function of time243. The initial radius (R0) was determined from the first 10 
frames without ultrasound. Microbubble excursion amplitude was defined as the 
difference between the maximum radius (Rmax) and R0. The excursion amplitude 
threshold for sonoporation was determined by linear discriminant analysis and defined 
as the average over the full microbubble size range224. 
 
Nonlinear microbubble behavior was studied by assessing the harmonic response. To 
do so, the frequency spectrum of the radius-time curve was determined using a Fast 
Fourier Transformation (FFT). Amplitudes were determined within a ±300 kHz 
bandwidth centered at the subharmonic (1 MHz) and second harmonic (4 MHz) 
frequencies. The noise levels were defined as the mean amplitude within those 
bandwidths from the FFT of the radius-time curve before and after oscillation. When 
the maximum amplitude of the FFT from the radius-time curve during oscillation was 
at least 6 dB above the mean noise level of all recordings, a microbubble was classified 
as responsive238,247. 
 
Finally, the asymmetry of microbubble oscillation was investigated. This was quantified 
by the amount of expansion (E) relative to the amount of compression (C). As 
previously done by others56,247,419,429,510, the E/C ratio was defined as E/C = (Rmax – R0) / 
(R0 – Rmin). Compression-only behavior is defined by an E/C < 0.5, symmetric oscillation 
ranges from 0.5 ≤ E/C ≤ 2, and expansion-only behavior as an E/C > 2. 
 
Analysis of confocal time-lapse images 
 
The image analysis aimed at studying the microbubble-mediated drug delivery pathways 
induced in the “cell of interest”, i.e. the cell with a single bound targeted microbubble, 
which from now on will be referred to as the cell. From the time-lapse confocal 
microscopy before insonification, the cell was classified based on the initial state of its 
contact with adjacent cells. When the cell edge was fully adjacent to the neighboring 
cells, it was classified as having full junctions, and when partially adjacent it was classified 






determined from the first 30 s of time-lapse confocal microscopy. After ultrasound, the 
cellular response was evaluated by studying two different drug delivery pathways. 
Sonoporation was assessed based on PI uptake within the cell as described in detail below. 
Opening of cell-cell contacts was assessed by changes in the cell border integrity to 
adjacent cells based on CellMask. When a gap, or gaps, formed between the cell and its 
neighbor(s), the cell was classified as retracting. Manual classification was performed by 
two individual users (M.V. and I.B.) for alternating ultrasound settings and experiment days. 
 
To determine the surface area of the cell and the microbubble location, the cell was 
delineated and the microbubble location was registered. The delineation and registration 
were performed manually using a custom-built MATLAB (The Mathworks Inc., Natick, 
MA, USA) routine. After cell delineation, another MATLAB routine was used to 
automatically segment the corresponding nucleus based on the Hoechst images. The 
microbubble location was quantified as the distance from the microbubble to the closest 
cell edge or, alternatively, to the center of the nucleus. The 4 min confocal microscopy 
time-lapse recording was split between before and after insonification by finding the 
period of time when the light path was switched towards the Brandaris 128 camera. The 
resulting sudden loss of CellMask signal in the confocal time-lapse recording was 
automatically detected using MATLAB. The first confocal frame after ultrasound was 
defined as t = 0. 
 
During time-lapse imaging slight vertical displacements of the CLINIcell can occur within 
the water tank, caused by, for instance, thermal expansion of the heating element. These 
small displacements changed the imaging plane, and although the cell was still in the FOV, 
the focus drift could alter the detected fluorescent intensity. Therefore, the PI intensity in 
a sonoporated cell can appear to fluctuate. To correct for PI intensity variations caused by 
focus drift, the CellMask fluorescent intensity was used as a reference. Although CellMask 
stains the membrane while PI is present in the cytoplasm, it is a valid reference since 
endothelial cells are very thin, with a mean height of 0.9 μm at the periphery and up to 
1.6 μm at the nucleus511. Hence, when the membrane is in focus, the cytoplasm is also 
within the same focal plane (600 nm). For each confocal time-lapse recording, a correction 
factor was determined as the ratio between the time-dependent CellMask signal and its 
initial value, both within the delineated cell. Next, the PI intensity detected upon 
sonoporation was corrected by this correction factor. 
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Analysis of PI uptake profiles 
 
Upon sonoporation, the size of the pore created in the cellular membrane is closely 
related to the amount of PI uptake. Fan et al.228 mathematically described this by 
 
   (10.1) 
 
The amount of fluorescent intensity F(t) detected in a cell as a function of time is related 
to the initial pore radius (r0), for a known diffusion coefficient of the PI fluorescent 
molecule (D), extracellular PI concentration (C0), and imaging system dependent 
calibration coefficient (α). The pore size coefficient (απDC0r0) is a measure for the initial 
pore size, defined by the initial slope of the PI uptake profile and independent of cell size. 
The stabilization of the fluorescent intensity is quantified by the pore resealing coefficient 
(β). Since PI molecules bind to both RNA and DNA in the cell cytoplasm and nucleus465, 
we were interested in the amount of PI fluorescence within the delineated cell area. The 
fluorescent intensity F(t) was defined as the sum over the pixels within the cell area after 
ultrasound minus the mean before ultrasound. Thereby, we corrected for any initial 
background noise signal (the mean 12-bit pixel intensity, ranging from 0 to 4095, before 
ultrasound was 150 and increased by an order of magnitude upon sonoporation). 
 
Since the light path towards the confocal microscope was temporarily intercepted during 
insonification, PI uptake could already have started before t = 0, i.e. before the confocal 
light path was restored. In other words, F(0) might not be zero. Therefore, Eq. 10.1 was 
adapted such that PI uptake started at t = t0 and F(t0) = 0. This changes Eq. 10.1 into 
 
   (10.2) 
 
Confocal time-lapse imaging was restored within ~2 s after ultrasound insonification, 
hence t0 ranged from −2 to 0 s. The influx of PI upon pore formation was monitored as a 
function of time and the determined F(t) was fit to Eq. 10.2 using a non-linear least 
squares approach in MATLAB to determine the pore size coefficient (απDC0r0), the pore 
resealing coefficient (β), and the starting time of pore formation (t0).  
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Figure 10.2. Cellular response upon ultrasound insonification of a targeted microbubble imaged 
with combined confocal microscopy and Brandaris 128 ultra-high-speed imaging. Selected frames 
are shown of (i) the initial cellular state with cell delineation and segmentation, (ii) the Brandaris 
128 recording with the determined microbubble radius as a function of time, and (iii) of the 
cellular response. (A) Sonoporation of a cell that initially had full junctions and remained intact. 
(B) Sonoporation and retraction of a cell that initially had partial junctions. Partial junctions are 
indicated by the arrows in (i), and retraction is indicated by the arrowheads in (iii). 
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(i) Confocal microscopy before ultrasound (ii) Brandaris 128 imaging during ultrasound
(iii) Confocal microscopy after ultrasound
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The time t90 at which 90% of the asymptotic value, F(∞) = απDC0r0/β, was reached is 
 
                               (10.3) 
 
When t90 < 120 s it means PI uptake stabilizes, presumably caused by pore resealing245. 
However, in the case of high PI uptake, the detected fluorescent intensity can also 
stabilize due to image saturation or DNA/RNA saturation. Although more PI might be 
entering the cell, this increase can no longer be detected when the pixels are already 
saturated (i.e. when the 12-bit pixels are at their maximum value of 4095) or when there 
is no free DNA or RNA left for PI to bind to. In this study, the imaging settings were 
chosen such that high PI uptake results in image saturation before DNA/RNA 
saturation. The optimal settings were determined such that the pixels in the nucleus 
were image saturated when adding 0.1% Triton X-100 (X100, Sigma-Aldrich), which 
causes non-resealing membrane disruptions leading to DNA/RNA saturation. By doing 
so, we could easily identify when the fluorescent intensity of PI stabilized by image 
saturation, since pixels reached their maximum 4095 value, and we avoided the 
otherwise indiscernible DNA/RNA saturation. Image saturation starts in the cell 
nucleus, since there the fluorescent intensity is highest because there is more DNA for 
PI to bind to. Therefore, when 90% of the pixels in the segmented nucleus reached the 
12-bit value, the cell was classified as saturated. Based on the pore resealing coefficient 
and signal saturation, the PI uptake curves were classified in the following three 
categories: (i) resealing < 120 s, i.e. when PI uptake stabilized with t90 < 120 s without 
saturation; (ii) non-resealing, i.e. when PI uptake did not stabilize within 120 s (i.e. 





The occurrence of a cellular pathway was presented in relative frequencies (%). This 
categorical data was tested for significant differences among groups using a χ2 test. 
Quantitative data were assumed to be not normally distributed, and therefore presented 
in median and interquartile ranges and tested for significance using the Mann-Whitney 
U test. Statistically significant differences were indicated in the graphs with asterisks by  
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using * for p < .05, ** for p < .01, and *** for p < .001. A Spearman's rank-order 
correlation was performed to determine the relationship between the microbubble 






Drug delivery pathways 
 
We evaluated the cellular response of 152 cells to a single targeted microbubble upon 
ultrasound insonification, in 21 different CLINIcells. Additionally, the response of 44 
cells was monitored without microbubbles to assess the effect of ultrasound only 
experiments in four CLINIcells. To control for the experimental procedure, we also 




Table 10.1. Occurrence of cellular effects for sham (i.e. control without microbubbles and 
ultrasound), ultrasound only, and upon treatment with ultrasound and a targeted microbubble. 







 Sham Ultrasound only Ultrasound and targeted microbubble 
 0 kPa 100 kPa 200 kPa 250 kPa 300 kPa 400 kPa 100 kPa 200 kPa 250 kPa 300 kPa 400 kPa 
 n=32 n=8 n=8 n=9 n=9 n=10 n=18 n=43 n=47 n=31 n=13 
No effect 
 
93.8 100 87.5 88.9 100 90 83.3 
62.8 
23.4 32.3 0 
Retraction 
 
6.3 0 12.5 11.1 0 10 16.7 2.3 21.3 3.2 0 
Sonoporation 
 





















Figure 10.3. Microbubble excursion amplitude (Rmax-R0) inducing no cellular effect (light blue), 
retraction (dark blue), sonoporation (pink), or both sonoporation and retraction (red). (A) Rmax-R0 
as a function of the initial microbubble radius (R0) for each cellular response. The dashed line 
indicates the 0.7 μm threshold for sonoporation. (B) Median and interquartile range of excursion 
amplitude for each cellular response. The whiskers range from the minimum to maximum value 
and statistical significance was indicated with ***p < .001. 
 
 
Four distinct cellular responses were observed: no effect, retraction, sonoporation, or 
sonoporation and retraction. A typical example of a sonoporated cell is shown in Fig. 
10.2A, where selected frames of confocal microscopy and Brandaris 128 imaging are 
depicted. The corresponding confocal microscopy recording is shown in Video 1. Before 
ultrasound, in Fig. 10.2A(i) a single microbubble (R0 = 2.00 μm) was located next to 
the nucleus, no PI was observed in the cell, and the cell-cell contacts were fully adjacent 
to the neighboring cells. During ultrasound, the microbubble excursion amplitude was 
determined from the Brandaris 128 recording to be Rmax - R0 = 0.95 μm (Fig. 10.2A(ii)). 
After ultrasound, PI uptake was observed at the location of the microbubble and spread 
throughout the cell over time, meanwhile the cell-cell contacts remained intact (no 
retraction), as shown in Fig. 10.2A(iii). In Fig. 10.2B, a typical example of sonoporation 
and retraction induced by the oscillating microbubble is shown. The corresponding 
confocal microscopy recording is shown in Video 2. Before ultrasound, there was no PI 
observed in the cell and the single microbubble (R0 = 1.91 μm) was located next to the 
nucleus (Fig. 10.2B(i)). The white arrows show the initial cell-cell contacts that were 
classified as partial junctions. During ultrasound, the microbubble excursion amplitude 
was Rmax- R0 = 0.54 μm, as shown in Fig. 10.2B(ii). After ultrasound (Fig. 10.2B(iii)), PI 






cell. After 5 s the cell had already started to retract (white arrowheads in Fig. 10.2B(iii)). 
Retraction became more severe over the following 3 min. After 202 s, retraction was 
even observed on the other side of the cell, although it was fully adjacent at that location 
before ultrasound. In both examples, the PI intensity was brighter in the nucleus than 
in the cytoplasm, since there is more DNA for PI to bind to in the nucleus. 
 
The occurrence of the four different cellular responses is reported in Table 10.1. The 
sham and ultrasound only experiments never induced sonoporation. The vast majority 
(93.4%) of these cells showed no cellular effect at all, independent of acoustic pressure. 
Retraction was only observed in 6.6% of all cells treated without microbubbles (5 out 
of 76 cells for both sham and ultrasound only). When treatment consisted of ultrasound 
insonification of targeted microbubbles, pressure dependence was observed. At 100 kPa 
PNP, there was no sonoporation induced and still only a small subgroup (3 out of 18 
cells) showed retraction. However, for higher pressures the amount of sonoporated cells 
increased. At 400 kPa PNP, an oscillating microbubble always induced sonoporation. 












Figure 10.4. Nonlinear microbubble oscillation behavior. (A) Second harmonic amplitude 
normalized to the fundamental for each cellular response. (B) Asymmetry of microbubble 
oscillation quantified as the ratio of expansion over compression (E/C) for each cellular response. 
The medians and interquartile ranges are overlaid. Statistical significance is indicated with *p < 
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Microbubble oscillation behavior 
 
The microbubble studied had a mean R0 of 2.1 μm, ranging from 1.2 μm to 3.7 μm. 
Insonifying these microbubbles from 100 kPa to 400 kPa PNP resulted in excursion 
amplitudes ranging from 0.1 μm to 2.2 μm (Fig. 10.3A; see Supplementary Fig. 10.1 for 
a separate excursion amplitude graph for each studied PNP). The highest excursion 
amplitudes were observed at R0 of 2.2 μm and corresponded to the expected resonance 
size for DSPC-based microbubbles at 2 MHz419. All microbubbles were still targeted to 
the cell after insonification, and the median shrinkage (with IQR, interquartile range, 
between brackets) of the microbubbles was 92.1% (87.2%–97.3%), defined as the ratio 
between the final and initial radius. The excursion amplitudes inducing sonoporation 
(pink and red) were significantly larger than those where no sonoporation was induced 
(Fig. 10.3B). Using a linear discriminant analysis, the mean threshold for sonoporation 
was found to be Rmax - R0 > 0.7 μm (Fig. 10.3A). However, there was no distinct 
microbubble excursion amplitude associated with retraction. Since microbubble excursion 
can also be quantified by considering the minimum radius during oscillation (Rmin) or 
relative to R0, the statistical comparisons between the different cellular responses were 
also performed for (Rmax - Rmin)/ R0, R0 - Rmin, and Rmax - Rmin. The same statistical differences 
(p < .001) were found between sonoporated and non-sonoporated cells, and the non-
significant differences between retracting and nonretracting cells remained. 
 
To evaluate the effect of nonlinear microbubble behavior on drug delivery, we determined 
if microbubbles exhibited a subharmonic or second harmonic frequency response. The 
FFT amplitude (mean ± standard deviation) of the subharmonic noise level was 21 ± 13 
nm (−18 dB below average fundamental) and that of the second harmonic noise level was 
11 ± 6 nm (−23 dB below average fundamental). Only 6 out of 152 microbubbles (4%) 
had a subharmonic response. The presence of subharmonics did not correlate with a 
higher occurrence of sonoporation and/or retraction. On the other hand, 105 out of 152 
microbubbles (69%) exhibited a second harmonic response, as shown in Fig. 10.4A. 
Significantly (p < .01) more microbubbles responded at the second harmonic frequency 
when sonoporation was induced (49% no effect, 67% retraction only, 84% sonoporation 
only, 89% sonoporation and retraction). However, the second harmonic amplitude 
normalized to the fundamental was not higher for microbubbles inducing sonoporation 






The asymmetry of microbubble oscillation quantified as E/C is shown in Fig. 10.4B. The 
recorded microbubbles presented with a full range of E/C ratios, from compression-only 
behavior (E/C = 0.13) to expansion-only behavior (E/C = 2.15). The E/C resulting in 
sonoporation was significantly larger than that of microbubbles that did not induce 














Figure 10.5. The cellular response of cells with partial or full junctions, classified based on the 
initial integrity of cell-cell contacts. (A) Occurrence of sonoporation, with or without retraction. 
(B) Occurrence of retraction, with or without sonoporation. Statistical significance indicated with 
*p < .05, **p < .01, ***p < .001; US = ultrasound; MB = microbubble. 
 
 
Initial integrity of cell–cell contacts 
 
As described in Section Analysis of confocal time-lapse images, the cells were classified into 
two subcategories based on the integrity of cell-cell contacts before ultrasound: partial 
junctions (n = 88, Fig. 10.2B) and full junctions (n = 64, Fig. 10.2A). The median (with 
IQR between brackets) excursion amplitude of microbubbles attached to a cell with 
partial junctions was 0.65 (0.38–0.94) μm and with full junctions 0.65 (0.42–1.05) μm. 
The cells in the control experiments were also classified using the same criteria.  
 
When treated with ultrasound and microbubbles, the occurrence of sonoporation was 
the same for both cells with partial junctions (48.9%) and with full junctions (48.4%), 
as shown in Fig. 10.5A. In the case of partial junctions, 65.1% of the sonoporated cells  
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also retracted, while this was only 25.8% of the sonoporated cells with full junctions. For 
both cell junction subcategories, the sham and ultrasound only treatments never induced 
sonoporation. In contrast to sonoporation, retraction occurrence was affected by the initial 
integrity of the cell-cell contacts (Fig. 10.5B). After treatment with ultrasound and 
microbubbles, retraction occurred significantly (p < .001) more often when cells initially 
had partial junctions (47.73%) than when they had full junctions (14.1%) (Fig. 10.5B, 
US+MB). Sonoporation was only observed in 66.7% of cells with partial junctions that 
retracted (28 out of 42 cells), whereas almost all cells with full junctions that retracted 
were also sonoporated (88.9%, 8 out of 9 cells). Retraction without sonoporation in cells 
with partial junctions was similar for sham (13.3%), ultrasound only (13.6%), and 
treatment with ultrasound and microbubbles (15.91%). Retraction of cells with full 
junctions was never observed for the sham and ultrasound only treatments. 
 
Cell size and microbubble location 
 
The median (with IQR between brackets) cell area was 908 (725–1093) μm2. There was 
no significant difference in cell area between the four distinct cell responses, as shown 
in Fig. 10.6A. Additionally, there was no significant difference in the location of the 
targeted microbubble on the cell, quantified as the distance from the microbubble to the 
closest cell edge (Fig.10.6B) or, alternatively, as the distance from the microbubble to 















Figure 10.6. Effect of (A) cell area and (B) microbubble location on the cellular response. The 




































Figure 10.7. Different PI uptake categories upon sonoporation imaged with confocal microscopy. 
The initial cellular state is shown (composite image of CellMask Green, Hoechst, and PI) with the 
cell delineation (solid line), nucleus segmentation (dashed line), and microbubble location (white 
circle). During ultrasound insonification, the change in microbubble radius is shown as a function of 
time. All other frames show the PI imaging channel only, before and after ultrasound. (A) PI uptake 
classified as resealing <120 s. (B) PI uptake classified as non-resealing. (C) PI uptake classified as 
saturated. The resulting PI uptake curves of each example are shown in Fig. 10.8. 
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and therefore were significantly (p < .001) larger than cells with full junctions, at 794 
(621–928) μm2. Also, the median distance of the targeted microbubble to the cell edge 
was significantly (p < .001) larger for cells with partial junctions [8.4 (6.4–11.1) μm], 
than for cells with full junctions [6.7 (4.7–8.5) μm]. Within these junction 
subcategories, there was still no significant difference in cell area or distance from the 
microbubble to the edge between the four cellular responses. 
 
Three typical examples of PI uptake profiles upon sonoporation are shown in Fig. 10.7. 
In the first example (Fig. 10.7A), the sonoporated cell had a PI uptake profile (Fig. 10.8, 
blue) that stabilized within 120 s, since 90% of the asymptotic value was reached after 
25 s (i.e. t90 = 25 s). Signal saturation occurred in only 9.9% of the pixels in the nucleus. 
Therefore, this cell was classified as resealing < 120 s. In the second example (Fig. 
10.7B), the PI uptake curve (Fig. 10.8, gray) did not stabilize within 120 s, since t90 = 
170 s. Signal saturation occurred in 16% of the pixels in the nucleus. Therefore, this cell 
was classified as non-resealing. In the third example (Fig. 10.7C), the PI uptake curve 
(Fig. 10.8, red) stabilized within 120 s, since t90 = 81 s. However, 97% of the pixels in 
the nucleus were saturated, so this cell was classified as saturated. 
 
The pore size coefficient (απDC0r0) and pore resealing coefficient (β) of all sonoporated 
cells are shown in Fig. 10.9A. The classification based on the resealing time of the pore 
and the signal saturation in the nucleus separates the cells into three groups. 
Additionally, the pore size coefficients (median and IQR between brackets) of the 
saturated class [0.97 (0.68–1.73)×106] were significantly (p<.001) larger than that of 
the cells classified as resealing <120 s [0.30 (0.14–0.45) × 106] or non-resealing [0.18 
(0.11–0.25) × 106]. As shown in Fig. 10.9B, larger microbubble excursion amplitudes 
correlated with larger pore size coefficients upon sonoporation (Spearman correlation 
coefficient ρ = 0.53, p < .001). Moreover, the excursion amplitudes (median and IQR 
between brackets) of the saturated class [1.22 (1.03–1.45) μm] were significantly (p < 
.001) larger than that of cells classified as resealing <120 s [0.88 (0.77–1.13) μm] or 
non-resealing [0.89 (0.62–1.00) μm]. The microbubble excursion amplitude did not 









Figure 10.8. Cellular PI uptake curves 
shown as the fluorescent intensity as a 
function of time (F(t), circles) and the 
corresponding fit to the mathematical model 
of Eq. (10.2) (solid lines). The three 
examples correspond to those in Fig. 10.7 
for each category: resealing <120 s (blue, 
Fig. 10.7A), non-resealing (gray, Fig. 
10.7B), and saturated (red, Fig. 10.7C). The 
black dots indicate the time t90 at which 90% 
of the asymptotic value was reached (Eq. 
(10.3)). The arrow marks the time at which 
90% of the pixels in the nucleus were 













Figure 10.9. Quantification of PI uptake upon sonoporation (n = 74) and the resulting classification 
as resealing <120 s (blue), non-resealing (gray), and saturated (red). The arrows indicate the data 
points corresponding to the examples in Figs. 10.7 and 10.8. (A) The pore size coefficient as a 
function of the pore resealing coefficient. (B) The microbubble excursion amplitude (Rmax-R0) as a 




onoporation and the opening of cell-cell contacts upon ultrasound insonification of 
a single targeted microbubble were evaluated. Using high temporal and spatial 
resolution, we resolved both the microbubble oscillation and the cellular response. 
Susceptibility to sonoporation and opening of cell-cell contacts clearly depended on 
microbubble oscillation behavior and the initial state of the endothelial cell. Furthermore, 
quantification of sonoporation based on cellular PI uptake correlated with microbubble 
behavior and was used to assess reversibility of sonoporation. 
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Microbubble oscillation behavior 
The ultra-high-speed recordings of microbubble oscillation revealed that sonoporation 
correlated with large excursion amplitudes, while there was no direct relationship 
between microbubble excursion and the opening of cell-cell contacts (Fig. 10.3). 
Sonoporation was induced for absolute excursion amplitudes Rmax - R0 > 0.7 μm, similar 
to the previously found thresholds at 2 MHz of Rmax - R0 > 0.72 μm (using 16 cycles) or 
Rmax - R0 > 1.02 μm (using 8 cycles) by Helfield et al.224. A relative vibration threshold 
of 0.5 at 1 MHz (with 6× 10 cycles) was reported by Kooiman et al.454, which 
corresponds to an absolute threshold of Rmax - R0 > 0.65 μm (for a mean R0 of 2.2 μm 
and symmetric oscillation), similar to our findings. 
 
Microbubbles that induced sonoporation exhibited a second harmonic response more 
often than those that did not result in sonoporation. Since nonlinear behavior increases 
with microbubble excursion amplitude512, this could be inherent to the larger excursions 
that result in sonoporation. We found no differences in the cellular response when the 
second harmonic amplitude was normalized to the fundamental (Fig. 10.4A). The E/C 
ratio was also higher in the case of sonoporation (Fig. 10.4B) only because the expansion 
phase becomes more dominant with increasing acoustic pressures, and thus excursion 
amplitudes434,515. Van Wamel et al.227 hypothesized that cells can better withstand 
compression than elongation forces, thereby suggesting that compression-only (E/C < 
0.5) could be more effective in sonoporation. However, in this study we found that 
nonlinear or asymmetric microbubble behavior itself did not affect the cellular response. 
The occurrence of sonoporation or opening of cell-cell contacts was found to be 
independent of the initial microbubble size for R0 ranging from 1.24 to 3.72 μm, as 
previously found by others who studied similar size distributions224,454. However, to 
achieve high enough excursion amplitudes while insonifying at relatively low acoustic 
pressures, the microbubble size distribution should match the ultrasound frequency 
such that microbubbles are insonified at resonance. In this study, microbubbles were 
insonified at their mean resonance frequency of 2 MHz419. We limited our study to a 
single frequency, since Helfied et al.224 only showed subtle differences between 0.5, 1, 
and 2 MHz. The excursion amplitude, i.e. acoustic pressure, plays a more important role 
than the frequency of oscillation, i.e. the ultrasound frequency (within the clinically 
relevant range 0.5 to 4 MHz). However, the microbubble–cell interaction upon 






For instance, when using low acoustic pressures ≤200 kPa for longer treatment 
duration, the stimulation of the mechanosensory channels could possibly induce 
different drug delivery pathways, such as stimulated endocytosis221. 
 
The susceptibility to sonoporation or opening of cell-cell contacts was independent of 
the microbubble's location on the cell (Fig. 10.6B). This is favorable for the clinical 
applicability, since in vivo it would be impossible to control exact microbubble location 
on the cell membrane. Kooiman et al.454 also found sonoporation to be independent of 
microbubble location, albeit based on a manual classification of microbubble positioning 
for 31 cells. Additionally, drug delivery was also independent of cell area (Fig. 10.6A), 
and thus all cell sizes seem to be equally susceptible to therapy.  
 
Opening of cell–cell contacts due to sonoporation 
Retraction of non-sonoporated cells was observed as often for both the control and 
ultrasound and microbubble experiments, while the enhanced retraction upon 
ultrasound and microbubbles only occurred upon sonoporation (Fig. 5B). From this we 
deduce that microbubble-mediated opening of cell-cell contacts only occurred due to 
sonoporation. Additionally, to open cell-cell contacts the targeted microbubble did not 
have to be near the cell edge (Fig. 10.6B), although that is often hypothesized36,221. 
Therefore, our results suggest that the opening of cell-cell contacts is a biological 
response triggered upon sonoporation, instead of an independent drug delivery pathway 
mechanically induced by microbubble oscillation. The retraction did not directly 
correlate to microbubble oscillation behavior (Fig. 10.3) and was strongly affected by 
the initial cell state (Fig. 10.5B), in contrast to the mechanical induced effect of 
sonoporation. This reinforces our conclusion that opening of cell-cell contacts is a 
cellular response mechanism and not directly caused by a microbubble mechanically 
rupturing the junctions. To the best of our knowledge, this is the first study that 
investigated the relationship between these two microbubble-mediated vascular drug 
delivery pathways in real-time and in the same field of view. Live cell imaging showing 
opening of endothelial cell-cell contacts had only been reported for a single example and 
without studying its correlation with sonoporation224. 
 
The initial cell integrity affected the susceptibility to opening of cell-cell contacts, 
because it occurred significantly more often when cells initially had partial junctions  
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(Fig. 10.5B). About 14% of cells with partial junctions even suffered from retraction in 
sham and in ultrasound only experiments, independent of the acoustic pressures. This 
retraction without treatment could be attributed to, for example, the imaging procedure 
(phototoxicity), the exposure of the CLINIcell to the open air after cutting out the top 
membrane, or the absence of 5% CO2. The different susceptibility to microbubble-
mediated treatment between partial and full junctions could mean that under 
physiological conditions that result in intercellular gaps, ranging from 0.3 to 4.7 μm in 
tumor vasculature514,515 or during inflammation516,517, the drug delivery pathway of 
opening cell-cell contacts is induced more often. At the same time, it emphasizes the 
importance of a realistic model to study the opening of cell-cell contacts. In previous 
studies, endothelial cell confluency varied from ~70% to full confluency so not all cells 
were completely adjacent to their neighbors. Additionally, the integrity of the cell-cell 
contacts before treatment was not assessed in these previous studies224,245,518. The only 
example in literature reporting the opening of endothelial cell-cell contacts was on a not 
fully confluent monolayer of endothelial cells having partial junctions224. In our study, 
the initial cell integrity was assessed using a CellMask cell membrane dye. However, 
this dye does not specifically stain for intercellular junctions and can eventually 
internalize, leading to a poorer co-localization with the plasma membrane. In the current 
study the plasma membrane remained well stained throughout the entire 120 min. Now 
that we observed the importance of the initial integrity of cell-cell contacts, in future 
studies the integrity of intercellular junctions could be more precisely assessed using 
specific fluorescent dyes. 
 
A limitation of our study is that cellular response was only monitored up to 4 min 
after ultrasound insonification. Within that time frame it was not possible to study 
the recovery of cell-cell contacts, since Helfield et al.224 showed that cell-cell contacts 
can remain open for tens of minutes. For long-term effects and recovery studies, the 
experimental conditions would need to be further optimized to reduce spontaneous 
retraction. Finally, when translating to in vivo studies often extravasation is assessed 
as a measure for the opening of intercellular junctions519,520, without monitoring 
sonoporation. If extravasation of a fluorescent compound would also be monitored 
in vitro using a different set-up than the CLINIcell, allowing for measurements on 
the basolateral side of the monolayer, both intracellular delivery by sonoporation 






Additionally, since we found that retraction only occurred upon sonoporation, assessing 
cell membrane permeability and the possible resulting cell death in vivo is of great 
importance. 
 
Transient pore formation 
Based on cellular PI uptake upon sonoporation, the transient behavior of pore formation 
was quantified with the pore size and resealing coefficients, which resulted in three 
distinct classifications. Cells with pores that resealed within 120 s were assumed to be 
reversibly sonoporated, while irreversible sonoporation occurred when there was no 
resealing within 120 s245. We found that microbubble excursion amplitudes above 0.7 
μm induced sonoporation, and the larger the excursion amplitude the bigger the pore 
that was created (Fig. 10.9B). This has never been observed before, since it was not 
possible to image both the microbubble oscillation behavior and detailed cellular 
response. Although intuitively there should be a higher chance for a small pore to reseal 
within 120 s, there was no clear correlation between pores resealing <120 s and the 
pore size coefficient or microbubble excursion amplitude (Fig. 10.9B). Van Rooij et al.245 
also did not find a correlation between smaller pore size and resealing within 120 s. The 
intrinsic variability among cells seems to influence membrane resealing more than the 
microbubble behavior and pore size. Therefore, cellular recovery mechanisms should be 
further unraveled by studying the underlying resealing mechanisms. 
 
The mathematical model described by Fan et al.228 considers any PI uptake plateau to be 
caused by pore resealing. However, we observed that many of the cells that plateau 
within <120 s, thus appearing to reseal, actually suffered from a saturated PI signal 
(Figs. 10.8 and 10.9). Saturation occurred when the pore size was largest. Reversibility 
of sonoporation cannot be assessed for the saturation class since the pore might remain 
open while the corresponding PI increase can no longer be detected. It is unclear if 
previous studies accounted for PI stabilization due to either image saturation or 
DNA/RNA saturation228,245,466. Therefore, it is possible that cells were assumed to be 
reversibly sonoporated when PI uptake plateaued due to PI saturation. Another 
difference with a previous study is that we monitored the PI uptake within the entire 
cell, while van Rooij et al.245 determined the PI uptake profiles only within the nucleus. 
Therefore, small pores that quickly resealed might be missed if their PI uptake profiles 
started in the cytoplasm. In future sonoporation studies the limited dynamic range of an  
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imaging system should be considered. On the one hand, when interested in low uptake, 
i.e. small pores that quickly reseal, PI signal saturation for the larger pores is often 
inevitable. On the other hand, when interested in the high uptake, i.e. larger pores that 
do not or slowly reseal, the imaging settings can be adjusted such that image saturation 
is avoided while missing the initial and lower PI changes. However, in that case the 
fluorescent intensity could reach an equilibrium when there is no free DNA or RNA 
remaining for PI to bind to. Therefore, when avoiding image saturation, one should 
properly account for DNA/RNA saturation. 
 
In this study we chose to have the cells on the bottom membrane of the CLINIcell to 
ensure that a targeted microbubble that did not bind would float up. Since the targeted 
microbubble was located between the objective and the cells, the microbubble gas core 
caused shadowing, impeding the laser to image directly underneath it (see Fig. 10.7A 
for an example). With this orientation it was not possible to directly image the created 
pore. Moreover, the imaging dependent calibration coefficient α (Eqs. (10.1) and (10.2)) 
was not determined in this study. Nevertheless, the pore size coefficient provides us 
with relative sizes because all imaging was performed under the same fluorescent 
imaging conditions, i.e. with the same α, and using the same extracellular PI 
concentration (C0). Another limitation of this study is that reversibility could only be 
derived from the PI uptake profile. Literature has used two separate experiments to 
demonstrate the correlation between the occurrence of pore resealing within 120 s and 
cell viability245. However, if both the pore resealing timeline and cell viability were to be 
studied simultaneously with live cell microscopy, the underlying biological mechanisms 








sing a state-of-the-art optical imaging system allowed for microbubble-mediated 
drug delivery to be studied with high sensitivity at short timescales, while also 
achieving the nanosecond resolution needed to resolve microbubble oscillation. 
Sonoporation and opening of cell-cell contacts by ultrasound insonification of targeted 
microbubbles were investigated. We found that larger microbubble excursion 
amplitudes(Rmax - R0>0.7 μm) correlated with the occurrence and amount of 
sonoporation, while the opening of cell-cell contacts could not be predicted from 
microbubble behavior. Microbubble-mediated opening of cell-cell contacts only occurred 
upon sonoporation and was influenced significantly by the initial cell state. Therefore, 
our results suggest that opening of cell-cell contacts is a biological response as a 
consequence of sonoporation, instead of an independent drug delivery pathway. These 
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Supplemental Figure 10.1. Microbubble excursion amplitude (Rmax - R0) for each acoustic peak 
negative pressure (100 to 400 kPa), inducing no cellular effect (light blue), retraction (dark blue), 
sonoporation (pink), or both sonoporation and retraction (red). 
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- Stephen King 
            
You can, 
you should, 
and if you’re 
brave enough 
to start,  
you will. 
 

























acterial infections are becoming progressively more challenging to manage as 
we stand at the threshold of the antibiotic era. Untreatable infections threaten 
us again, and are only projected to increase with the vulnerable aging population and 
surging use of implantable life-saving technologies that create niches primed for 
colonization. Despite the defenses and unrelenting assaults that antibiotics and our 
immune system can provide, bacteria are able to successfully resist and persist when 
they form communities encased in a protective matrix called a biofilm. Even with the 
multitude of medical advancements over the last decades, mortality rates of biofilm-
associated infections have barely improved and traditional antibiotic development has 
largely stagnated. It is therefore important to investigate alternative and adjunct 
therapeutic and theranostic approaches to successfully overcome life-threatening 
infections associated with biofilm formation, especially for those with higher risk 
caused by Staphylococcus aureus and involving the inner part of the heart called 
infective endocarditis. One potential approach is what we termed Sonobactericide, 
which is the combination of ultrasound and microbubbles, with or without other 
therapeutics, for the treatment of bacterial infections. Microscopic gas bubbles, which 
are about the size of a red blood cell and coated in a layer of lipids, expand and 
contract (i.e. oscillate) when exposed to ultrasonic pressure waves. These oscillations 
can induce various well-studied mammalian cellular responses, e.g. enhanced 
endocytosis, membrane pore formation, and cell death, however little is known 
concerning bacteria/biofilm. The primary aim of this thesis was to investigate the 
potential of sonobactericide as a therapeutic approach for biofilm-associated 
infections. 
 
Chapter 1 begins this thesis by setting the stage for sonobactericide by providing 
background interspersed with historical details on bacterial (biofilm) infection, 
ultrasound, and then leading into microbubbles. Sonobactericide is then extensively 
reviewed (27 publications) and discussed in Chapter 2. It highlights that a large 
heterogeneity and dynamic conditions exist among all aspects of sonobactericide, to 
include bacteria morphology, biofilm structure and inner milieu, ultrasound field in 
relation to disease location, and microbubble composition and behavioral responses. 
All of these, and more, should be taken into consideration as this new research field 
continues towards hopeful clinical translation. 
B 
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In order to reveal the microscopic world of oscillating microbubbles and ensuing 
cellular effects in the same field-of-view, a novel optical imaging platform was 
developed, described, and demonstrated in Chapter 3. The coupling of the Brandaris 
128 ultra-high-speed camera to a custom-built confocal microscope, used either 
together or separately throughout this thesis, allowed for the high spatial and 
temporal resolution necessary to visualize ultrasound-mediated microbubble 
responses. Chapter 4 focuses on biofilm pathogenesis, demonstrating the potential of 
commonly used over-the-counter medications, like paracetamol in this study, to 
induce more resilient biofilm formation. Further genetic background appears to play a 
role. This highlights yet more variability that should be taken into consideration when 
performing biofilm research for clinical translation of not only sonobactericide, but 
also other therapeutic approaches. 
 
In Chapters 5-7, ultrasound-activated non-targeted microbubbles were used to 
determine their sonobactericidal potential on biofilms grown from S. aureus isolated 
from infective endocarditis patients. Chapter 5 studied the oscillating microbubble-
induced effects of dispersion (displacement) and cell membrane permeabilization (i.e. 
sonoporation) on bacteria within biofilms grown in mammalian culture medium. 
Bacterial dispersion was the predominate phenomenon observed, with minimal 
sonoporation overall, and both effects enhanced by increasing the ultrasound pressure 
or cycles. Adding an antibiotic significantly influenced some treatment groups, with 
membrane compromised cells relative to all cells and dispersion increasing, and a less 
variable dispersal response at the highest cycle and pressure settings. In Chapter 6, a 
more cardiovascular representative biofilm with a fibrin mesh was developed by using 
100% human plasma as the culture medium. Both fibrin strand bending and bacterial 
dispersal were observed in the ultrasound with microbubble arms, and were often 
accentuated and more frequent when microbubble clustering occurred. A thrombolytic 
combined with oscillating microbubbles led to observable fibrin strand breaking, and a 
different and faster fibrin dissolution pattern. To better emulate infective endocarditis 
pathophysiology in vitro, an infected human blood clot model was developed in 
Chapter 7 and treated under flow. The addition of a thrombolytic and/or antibiotic to 
microbubbles and ultrasound resulted in almost complete clot loss after 30 minutes, 
and more cavitation was detected in these two groups. The majority of effluent 





Often, the presence of an infection is difficult to confirm until it has grown 
substantially. Targeting microbubbles directly and selectively to biofilms could 
enhance sonobactericide by providing (early-stage) infection detection capability and 
improving effectiveness beyond that of non-targeted bubbles, especially in challenging 
conditions like turbulent blood flow. Chapters 8-9 compared non-targeted and 
targeted microbubbles to better understand their differences. Using various acoustical 
parameters in Chapter 8, distinguishable differences in acoustic stability and 
oscillatory behavior were found between bound and non-bound microbubbles. Further, 
these differing responses also varied depending on the main lipid in the microbubble 
coating. Chapter 9 then examined targeted and non-targeted microbubble responses 
in relation to their influence on endothelial cells. Displacement was a large 
determinant of cell fate for targeted microbubbles, in that displacing resulted in 
reversible sonoporation and non-displacing in irreversible sonoporation, and thus 
death. Overall, non-targeted microbubbles induced more drug uptake than targeted 
microbubbles, however this trend is thought to reverse with flow conditions. 
 
Chapters 10-11 focused solely on targeted microbubbles. Endothelial cell responses 
to ultrasound-activated αVβ3-targeted microbbubles were examined in Chapter 10. A 
minimum excursion amplitude for inducing sonoporation was determined, and larger 
amplitudes resulted in larger membrane pores. Membrane resealing was found to be 
independent of microbubble behavior and cell-cell contact opening occurred as a 
consequence of sonoporation and not mechanical microbubble effects. In Chapter 11, 
a new targeted MB was developed using the antibiotic vancomycin. It successfully 
bound to S. aureus biofilms and continued to under flow. Theranostic potential with 
ultrasound was demonstrated with therapeutic bacterial dispersal.  
 
In the next part of Chapter 12, the main findings central to this thesis are placed into 
a larger context with discussion on several key topics relevant for the future 
perspectives of potential microbubble-mediated clinical applications.  
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This thesis expands upon the limited knowledge that existed on sonobactericide at the 
beginning of my PhD to help pave the way for its clinical translation as an effective 
treatment, diagnostic, or theranostic strategy employed in infectious disease care. 
What becomes quickly apparent is the large heterogenicity in this line of research, 
both on the cellular side and acoustical side. Although a wealth of information already 
exists concerning mammalian cell responses to ultrasound-medicated microbubble 
behavior which can provide an investigative roadmap, it unfortunately cannot all be 
simply translated directly to bacteria and biofilms. This is partly due to the many 
unknowns that still exist regardless of cell type, such as controlling the microbubble 
responses to ultrasound or the complete cellular pathways involved once exposed to 
insonification and cavitating nuclei-induced effects. Nonetheless, the ensuing 
paragraphs will contemplate on future perspectives while touching upon broad cellular 
perspectives, ultrasound-induced microbubble responses, and potential concerns that 
may need to be addressed before clinical approval can be attained. Following this, the 
contributions this thesis provides towards the field of microbubble-mediated therapies 
is presented, thus marking the culmination of my PhD journey entitled, “Sonobactericide”.  
 
All cellular responses, whether mammalian or bacterial, are naturally intricate and 
complex as they strive towards the overall goal of maintaining the delicate balance for 
optimal functioning and survival. Thus, it is already not an easy feat to understand the 
operating pathways for a content cell at rest, nonetheless the ones activated when this 
balance is disrupted, such as by oscillating microbubbles. The development of the 
powerful optical-acoustical imaging system developed in Chapter 3 afforded us the 
opportunity to get one step closer to unraveling these mechanistic minute cellular 
details in the context of responses to microbubbles. Since microbubbles are considered 
a blood pool agent and most commonly used for vascular applications, parts of this 
thesis studied the effects of ultrasound-induced microbubble behavior using the cell 
type that lines the entire circulatory system – the endothelial cell (Chapters 9 and 10). 
These cells are not just simply the gate keepers of the contents within the vasculature, 
but are critically involved in several other important multifaceted processes, such as 
blood flow regulation, angio- and atherogenesis, thrombosis, thrombolysis, and 




   
bacterium Staphylococcus aureus (S.aureus) (Chapters 4-7, and Chapter 11). S.aureus is a 
colonizer of the human skin, where approximately 20% of the population are 
persistent carriers, and 60% intermittently, within their anterior nasal passages546. 
S.aureus can become pathogenic and readily form life-threatening biofilms throughout 
the body (overall mortality rate ~25%)7. These bacteria possess an abundance of 
different virulent factors, physical and chemical, that aid in tissue attachment and 
immune system evasion, such as coagulases to convert fibrinogen into fibrin for 
additional protection, hemolysins to lysis red blood cells for their nutrients, and 
proteases that break down intercellular junctions. In this thesis, these two cells types 
were investigated separately allowing for moderate comparison. Combining the two, 
though potentially challenging, would provide an even better replicate of 
cardiovascular biofilms and insight into how these different cell types together respond. 
 
The understanding of bacterial cell responses to ultrasound-mediated therapies is in 
its infancy when compared to mammalian cells. Even though the number of in vitro 
studies on sonobactericide is limited, already promising in vivo studies have been 
performed for several intended applications as reviewed in Chapter 2. This can 
perhaps be attributed to the knowledge that already exists on microbubble behavior 
from studies with mammalian cells present, and also without cells. However, bacteria 
are extremely different creatures, as well as also considering the vast diversity that 
exists within their own respective Kingdoms. Comparing just the cells in this thesis, 
the endothelial cell is thin/flat outside the central nucleus area and generally 
elongated; dimensions differ, depending on their bodily location,  from 30-50 μm in 
length, 10-30 μm in width, and 0.1-10 μm in thickness; structure consists of a 
phospholipid-bilayer membrane (~10 nm thick) and strengthened by an internal 
microfilament network, junctions to other endothelial cells, and anchoring to a basal 
membrane547. S. aureus are spherical-shaped with a 0.5-1 μm diameter and can divide in 
two planes forming grape-like clusters; layers of peptidoglycan make-up the compact, 
rigid cell wall that is 20-40 nm thick and increases (> 50 nm) with antibiotic 
resistance548,549; and has a cytosolic turgor (internal osmotic pressure) of ~20 atm 
(2,027 kPa)550. It would be of interest to investigate if and how bacterial cell wall 




Summary and Discussion 
 
 
The cellular differences between the two cell types can be seen within this thesis. For 
example, in Chapter 10 microbubbles were insonified with a single ultrasound pulse 
of 2 MHz, 400 kPa (peak negative pressure) and 10 cycles which resulted in 100% 
sonoporation of endothelial cells, whereas in Chapter 5 using the same transducer, 
frequency, and pressure but with 100 cycles and 30 pulses (repeated 10 times) only led 
to sonoporation of around 3% of bacteria overall. Of course this is not a perfect 
comparison because Chapter 10 used targeted microbubbles, and in Chapter 9 non-
displacing microbubbles were associated with more endothelial sonoporation which 
was also irreversible, albeit at different settings. However, even if we look at Chapter 
11, which used targeted microbubbles for bacteria in biofilms, minimal sonoporation 
was observed, although this cannot be definitively certain for all cells as the used 
settings (2 MHz, 250 kPa, 5,000 and 10,000 cycles) led to cell displacement. Bacteria 
are much more easily dispersed as clearly observed in Chapters 5-7 and Chapter 11, 
where in Chapter 9 and 10 this was not observed, even at the highest setting of 500 
kPa, 50,000 cycles. Although these comparisons are imperfect, they provide support 
and allude that the ultrasound parameters and microbubble behavior that induce 
cellular effects in endothelial cells cannot be directly translated to S. aureus, and most 
likely other bacteria. It is possible though that bacteria having a different morphology 
may respond more similarly to endothelial cells, such as the rod-shape, larger size (2 
μm length; up to 1 μm width), thinner cell wall structure (4 nm; monolayered 
peptidoglycan) of a Escherichia coli bacterium with a lower cytosolic turgor of ~5-6 atm 
(506 - 608 kPa)551,552. Regardless, this highlights that further investigations, from 
modeling to in vivo studies, are necessary to determine the best settings for optimal 
microbubble-mediated therapy per the given cellular circumstances. 
 
When developing a novel targeted microbubble, such as the vancomycin-decorated 
microbubbles for binding to bacteria in Chapter 11, many design aspects need to be 
considered in order to obtain the optimal product to best achieve the desired goal. One 
such consideration is the lipid used in the coating, which two were investigated for 
their impact on the vibrational responses of microbubbles in Chapter 8. The main 
finding were that DSPC-based microbubbles were acoustically more stable than DPPC-
based bubbles, including with increasing acoustic pressure. This supported the choice to 
use DSPC for all studies using in-house produced microbubbles in this thesis. In the 





of the increased binding area, homogenous ligand distribution, and the dome-shape 
that is thought to better withstand flow shear over spherical-shaped microbubbles241. 
Unfortunately this means choosing for either lipid is a compromise, and it could be 
that different lipid-coatings may be better suited for some applications than others, 
such as ones involving flow. It is possible that the vancomycin-decorated microbubbles 
developed in Chapter 11, which are DSPC-based but use DSPE-PEG(3400) instead of 
the DSPE-PEG(2000) and have a different ligand-biomarker pair than Chapter 8 and 
Kooiman et al. (2014)241, may have different acoustical responses and binding 
efficiency. Further investigations, such as with acoustical spectroscopy, could help 
determine if there is a more optimal formulation while keeping the intended 
application in mind, as this may already be the most suitable. If using DPPC is found 
to produce less acoustically stable bacteria-targeted microbubbles and ligand 
distribution is the crucial element for binding and sonobactericide efficiency, which 
may be different for environments with and without flow, it is possible other 
production methods could be incorporated that have been shown to induce a more 
homogeneous distribution, such as with lipid handling538 or temperature537 before 
and/or after microbubble production. However, these methods may need to be 
adjusted to ensure vancomycin, or other targeting ligand, is not inactivated in the 
process. Another investigative avenue that may enhance functionality of these and 
other targeted-microbubbles designed for sonobactericide could be found in a dual-
targeting approach, which has been shown to be favorable over a single-targeted 
approach for microbubbles targeted to mammalian cells553.  
 
Endothelial cell work involving the mechanistic study of responses to contrast agents 
largely involves healthy endothelium, including this thesis. While this is important, a 
large cohort exists world-wide with some sort of cardiovascular disease, and this is 
only projected to increase with an aging population and growing prevalence in obesity. 
Many cardiovascular diseases, as well as cancer and bacterial infections, are related to 
endothelial dysfunction, either as the causative agent or a byproduct545. Further, this 
dysfunction also varies depending on the disease, with one or more of the normal 
healthy functions affected. Chapter 10 hints toward cellular response differences, 
since the initial state of cells already leads to variability in susceptibility to ultrasound-
induced microbubble treatment. The endothelial cells used in this thesis that exhibited 
partial junctions better represent the endothelium encased in biofilm than those with full  
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junctions due to the cellular dysfunction caused by biofilm presence and the bacterial 
proteases secreted that degrade cell-cell contact integrity. Based on Chapter 10, these 
endothelial cells connected to infection would be more likely to sonoporate and/or 
retract due to ultrasound and microbubbles. Further, endothelial cells exhibiting 
dysfunction may respond to targeted and non-targeted microbubbles contrarily or at 
varying degrees to the healthy cell responses seen in Chapter 9. Future work should 
include investigations using diseased endothelial cells, and in different diseased states, 
to understand how these physiological abnormalities impact cellular and cavitation 
nuclei responses in an ultrasound field down to the intracellular pathway level. 
Furthermore, using bacteria to induce the disease state per the desired infection model 
would be beneficial  Unraveling these unknowns would allow for the most efficient 
utilization of microbubble-mediated therapy tailored to the intended application and 
patient profile, regardless of whether the goal is drug delivery, biofilm disruption, or 
direct cell (e.g., bacteria or tumor) killing. 
 
For sonobactericide to be a viable theranostic tool for the clinic, assessing safety is a 
critical step for future success. Though different infected areas of the body will have 
varying risks to assess, the therapeutic promise of sonobactericide via bacteria 
dispersed out of biofilms also has the potential to hinder overall success for several 
infected organ systems328. Chapters 5-7 and Chapter 11 show sonobactericide-
induced disruption of different types of biofilm all leading to dispersal, which has also 
been observed post-treatment by others groups as reviewed in Chapter 2. It should be 
noted that chemical and physical bacterial dispersion/biofilm detachment occurs 
naturally, such as by changes in the micro-environment of a biofilm progressing in 
maturity that prompts the releasement of matrix degrading enzymes or 
erosion/sloughing due to fluid shear stress as observed with endovascular 
biofilms328,554. For some infection locations, for example superficially on the skin and in 
the urinary tract, biofilm disruption may be less of a danger than for others, such as 
within the cardiovascular system that grants access to the entire body. Here biofilm 
detachment could with seemingly relative ease lead to metastatic infections and/or 
down-stream emboli. Another concern, not only for the cardiovascular system, is the 
triggering of sepsis, which is a severe dysregulated bodily response that can lead to 
multiorgan failure and has a clinical mortality of 28-43%555-557. Septicemia has been 





dispersal agent558, but not for physical biofilm disruption studies as of yet328. Currently, 
none of the three negative post-treatment outcomes mentioned have been reported in 
in vivo sonobactericide studies304. Though this is promising, the differences in outcome 
compared to chemical dispersal could potentially be due to a range of factors, such as 
the degree and/or rate of bacterial dispersal, antibiotic susceptibility of liberated 
bacteria, or length of post-treatment follow-up, and should be further investigated. 
There already exist several strategies/technologies that could be used to prevent 
and/or combat these concerns if proven viable, which some are touched upon in 
Chapter 2. In the case of the septicemia induced by chemical-induced dispersion, a co-
administration of an antibiotic was able to prevent this outcome and even led to 
infection resolution558. However, Wille and Coenye (2020) point out that although 
antibiotic addition was successful for this model, other studies show that this may not 
be the case for all situations and the method of dispersal and corresponding antibiotic 
will be critical determinants on whether septicemia can be prevented or not328. 
 
Outside of these dispersal induced concerns, is also the potential deleterious issue of 
lethal mammalian cell toxicity in target cells containing intercellular bacteria or near-
by healthy cells, as an unintended off-target problem for sonobactericide. This most 
likely would be caused by the ultrasound-induced microbubble effects leading to 
synergistic drug responses and/or increases in cell membrane permeability exposing 
these non-intended cell targets to lethal doses which would otherwise not be toxic. 
This was observed in a sonobactericide study using an intracellularly infected human 
bladder cell organoid model of urinary tract infection, where ultrasound-activated 
microbubbles alone (dose-dependent) had an approximate two-fold higher cytotoxic 
effect in bladder cells than a free antibiotic therapeutic dose alone, and for 
microbubbles coated with liposomes containing an almost 100-fold less antibiotic dose 
resulted in a three-fold cytotoxicity increase70. For infective endocarditis, depending on 
(pre-existing) physiological circumstances and the infecting microbe, bacteria not only 
adhere to, but can also be internalized by or invade endothelial cells43.  If cytotoxicity is 
properly evaluated per the specific infection to treat, potential off-target lethal side-
effects can be properly addressed by choosing parameters that are within acceptable safe 




Summary and Discussion 
 
  
I envision sonobactericide in the clinic to be a non-invasive theranostic strategy, where 
patients suspected of a bacterial infection can receive a definitive diagnosis using 
broad-spectrum biofilm/bacteria-targeted microbubbles, and then in the same setting 
receive treatment with ultrasound-activated cavitation nuclei. The larger aim of 
sonobactericide is to reduce, if not eliminate, the uncertainty that currently exists with 
bacterial infection diagnosis and management. Less uncertainty should translate to 
earlier diagnosis requiring less diagnostic modalities and enhance antimicrobial 
success with lower therapeutic dosages to eliminate side-effects and lower mortality 
for overall patient life improvement. To be an effective strategy, sonobactericide may 
still require some complements, such as blood culture and antimicrobials, or open the 
door to currently contraindicated therapeutics, e.g., thrombolytics for adults with 
infective endocarditis, by local delivery via microbubbles and/or reduced dosages due 
to sonobactericide synergistic effects.  
 
Sonobactericide, in theory, could be applied anywhere in the body an infection exists. 
That means to move towards clinical trials, safety will need to be evaluated and best 
strategy determined per the specific application, such as initial dosages and types(s) of 
cavitation nuclei, complements, and acoustical parameters. In the face of those 
challenges that are already present and the ones yet to reveal themselves, it is not to 
say that sonobactericide may already be a viable option. Drugs and diagnostics often 
still have many unknowns when entering clinical trials, and even remain that way 
through and after approval because their net positive improvement overrides the 
“black box” effect. Even if this would be the case for sonobactericide, it is still of the 
utmost importance that research continues not only for maximizing diagnostic and 
therapeutic outcome which is tailored to each disease and pathogen, but also to 
predict and overcome every potential challenge face-on with the best possible solution. 
This approach is aligned with the viewpoint of Louis Pasteur, the world-renowned 
French microbiologist who forever changed how we approach infection by definitively 
proving that pathogenic microorganisms (germs) cause disease (and not spontaneous 






Contribution to science 
The contribution to science provided by the work within this thesis is severalfold. The 
extensive review of the current literature provides the scaffold on which future 
sonobactericide investigations can be built upon. With the development of a powerful 
new system by coupling two state-of-the-art, custom-built technologies, nanometer 
spatial and nanosecond temporal resolution imaging can now be accomplished in the 
same field-of-view of a single sample; this has expanded, and will continue to do so, 
our knowledge on how ultrasound-mediated microbubble behavior directly impacts 
both cells and their surroundings. Commonly used over-the-counter medicines may 
alter biofilm development, as paracetamol was seen to enhance virulence in this thesis, 
which highlights an important consideration for future research because this may 
affect theranostic capabilities and outcomes.  
 
For the first time, microbubble behavior was observed in real-time and at high-
resolution to directly lead to several anti-biofilm effects. Sonobactericide potential was 
demonstrated on four different in vitro biofilm models, three of which were developed 
in this thesis with two designed to replicate intravascular biofilms and one replicating 
biofilms grown in flow environments. Observed sonobactericide effects that could 
enhance therapy includes biofilm disruption with bacterial dispersal, sonoporation 
(membrane permeabilization), fibrin strand manipulation (bending, recovery, and 
breaking), and synergistic responses when a thrombolytic and/or antibiotic were 
present, all lending support for continued research. Through comparing targeted and 
non-targeted microbubbles, several acoustical and binding differences/advantages of 
two lipid-based microbubble coatings were observed that can aid decision making in 
new microbubble design. Additionally, certain microbubble responses corresponding 
with cell viability were found to occur more frequently within a given set of acoustic 
parameters, which provides valuable insight towards optimizing microbubble-
mediated therapies per the goal of either viable drug delivery or direct mammalian cell 
death.  
 
The investigation of microbubbles targeted to endothelial cells using high-sensitivity 
imaging revealed initial cell integrity affecting treatment outcomes. Since various 
diseases can affect cellular status to different degrees, this highlights the importance of 
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future experimental designs needing to use cells that are in the appropriate disease-
state per the intended therapeutic application. Additionally, this study also discovered 
that cell-cell contact opening is not a separate drug-delivery pathway from 
sonoporation, but is a consequence of it and not directly related to specific 
microbubble behavior. A novel targeted microbubble for gram-positive biofilm 
infections, that is non-immunogenic by using the antibiotic vancomycin, was 
successfully developed, and observed to remain bound under flow and lead to biofilm 
disruption upon ultrasound insonification. This not only provides support of the true 
potential of sonobactericide to definitively detect these often difficult to diagnose 
infections and with the same microbubble be able to produce therapeutic effects, but 
may also inspire others to develop novel targeted microbubbles for infectious diseases.  
 
The impressive potential of something so small, the microbubble, combined with the 
power of sound to solve a truly vast dynamic range of challenges and improve upon 
and beyond the current existing technologies and therapies for the betterment of all 
life on earth, speaks to its extraordinary versatility and strength that will indubitably 
echo well into the future. Therefore, it is clear, as is the hallmark of investigative 
science, that as knowledge is expanded upon more questions arise, and the adventure 









- Nelson Mandela 
       
            
 If you talk to a man in a language 
he understands, that goes to his head.  
 
 If you talk to him in his language, 
































et behandelen van bacteriële infecties wordt steeds uitdagender, aangezien we 
bijna het plafond van onze antibiotische mogelijkheden bereikt hebben. 
Onbehandelbare infecties bedreigen ons opnieuw en zullen naar verwachting alleen 
maar toenemen door de kwetsbare vergrijzende bevolking en het stijgende gebruik van 
implanteerbare levensreddende technologieën, die niches creëren die gevoelig zijn voor 
kolonisatie. Ondanks de afweer en de niet aflatende aanvallen die antibiotica en ons 
immuunsysteem kunnen bieden, zijn bacteriën in staat om met succes weerstand te 
bieden en te volharden wanneer ze groepen vormen die zijn ingekapseld in een 
beschermende matrix, genaamd biofilm. Zelfs met de grote medische vooruitgang in de 
afgelopen decennia zijn de sterftecijfers van biofilm-gerelateerde infecties nauwelijks 
verbeterd en de ontwikkeling van traditionele antibiotica is grotendeels gestagneerd. 
Het is daarom belangrijk  alternatieve en aanvullende therapeutische en theragnostische 
aanpakken te onderzoeken om met succes levensbedreigende infecties, geassocieerd met 
de vorming van een biofilm, te overwinnen. Dit is vooral belangrijk voor mensen met 
een verhoogd risico veroorzaakt door Staphylococcus aureus en waarbij het binnenste deel 
van het hart betrokken is, infectieuze endocarditis genaamd. Een mogelijke aanpak is 
wat we Sonobactericide hebben genoemd. Dat is de combinatie van ultrageluid en 
microbellen, met of zonder andere medicijnen, voor de behandeling van bacteriële 
infecties. Microscopische gasbellen, die ongeveer zo groot zijn als een rode bloedcel en  
een vetlaag als schil hebben, zetten uit en trekken samen (d.w.z. oscilleren) wanneer ze 
worden blootgesteld aan ultrageluid drukgolven. Deze oscillaties kunnen verschillende 
goed bestudeerde reacties in cellen van zoogdieren induceren, b.v. verbeterde 
endocytose, vorming van membraanporiën en celdood, maar er is weinig bekend over 
het effect op bacteriën/biofilm. Het hoofddoel van dit proefschrift was het 
onderzoeken van de mogelijkheid om van Sonobactericide een therapeutische 
behandeling voor biofilm-gerelateerde infecties te maken. 
 
Dit proefschrift begint met Hoofdstuk 1 waarin Sonobactericide geïntroduceerd wordt 
door achtergrondinformatie af te wisselen met historische details over bacteriële 
(biofilm) infecties en ultrageluid, om vervolgens uit te komen bij microbellen. 
Sonobactericide wordt vervolgens uitgebreid gereviewd (27 publicaties) en besproken 
in Hoofdstuk 2. Daarin komt naar voren dat er een grote dynamische verscheidenheid 







biofilmstructuur en inwendige omstandigheden, echografisch veld in relatie tot 
ziektelocatie en microbelcompositie en microbelgedrag. Met al deze factoren en meer 
moet rekening worden gehouden in de ontwikkeling van dit nieuwe onderzoeksveld tot 
een veelbelovende nieuwe behandelmethode voor patiënten. 
 
Om de microscopische wereld van oscillerende microbellen en de daaropvolgende 
effecten op de cellen in hetzelfde gezichtsveld in beeld te brengen, werd er een nieuw 
optisch beeldvormingsplatform ontwikkeld, beschreven en gedemonstreerd in 
Hoofdstuk 3. De koppeling van de Brandaris 128 ultrahogesnelheidscamera aan een op 
maat gemaakte confocale microscoop, die samen of afzonderlijk werden gebruikt in dit 
proefschrift, zorgde voor de hoge ruimtelijke en temporele resolutie die nodig is om 
door ultrageluid gemedieerde microbelreacties te visualiseren. Hoofdstuk 4 richt zich 
op de biofilmpathogenese en toont het potentieel van veelgebruikte, vrij verkrijgbare 
medicijnen, zoals paracetamol in deze studie, om een meer veerkrachtige 
biofilmvorming mogelijk te maken. Ook lijkt de genetische achtergrond een rol te 
spelen. Dit benadrukt dat er nog meer verschillen zijn waarmee rekening moet worden 
gehouden bij het uitvoeren van biofilmonderzoek voor klinische toepassingen. Dit geldt 
zowel voor Sonobactericide, als ook voor andere therapeutische aanpakken. 
 
In de hoofdstukken 5-7 werden met ultrageluid geactiveerde niet-getargete 
microbellen gebruikt om hun Sonobactericide potentieel te bepalen op biofilms van S. 
aureus, geïsoleerd uit patiënten met infectieuze endocarditis. Hoofdstuk 5 bestudeerde 
de door oscillerende microbellen veroorzaakte effecten van dispersie (verplaatsing) en 
permeabilisatie van celmembranen (d.w.z. sonoporatie) op bacteriën in biofilms die 
werden gekweekt in kweekmedium voor zoogdiercellen. Bacteriële dispersie was het 
belangrijkste waargenomen fenomeen, met in het algemeen minimale sonoporatie. 
Beide effecten werden versterkt door het verhogen van de druk of het aantal cycli van 
het ultrageluid. Het toevoegen van een antibioticum beïnvloedde sommige 
behandelingsgroepen significant, met een verhoogde dispersie en membraan-aangetaste 
cellen ten opzichte van alle cellen,  en een minder variabele dispersierespons bij de 
hoogste cyclus- en drukinstellingen. In Hoofdstuk 6 werd een meer cardiovasculair 








te gebruiken als kweekmedium. Zowel buiging van fibrinestrengen als bacteriële 
verspreiding werden waargenomen in de 'ultrageluid met microbellen' groepen. Dit werd 
vaak geaccentueerd en kwam vaker voor wanneer clustering van microbellen optrad. Een 
trombolyticum gecombineerd met oscillerende microbellen leidde tot zichtbare breuk 
van de fibrinestreng en een ander en sneller oplossingspatroon van fibrine. Om de 
pathofysiologie van infectieuze endocarditis in het laboratorium beter na te bootsen, 
werd in Hoofdstuk 7 een geïnfecteerd menselijk bloedstolselmodel ontwikkeld en 
onder stroming behandeld. De toevoeging van een trombolyticum en/of antibioticum 
aan microbellen en ultrageluid resulteerde in een bijna volledig verdwijnen van het 
stolsel na 30 minuten, en meer cavitatie werd gedetecteerd in deze twee groepen. De 
meeste van de weggevoerde deeltjes waren klein genoeg om maar weinig risico op een 
bloedstroomafwaartse embolie te veroorzaken. 
 
Vaak is de aanwezigheid van een infectie moeilijk te bevestigen totdat deze aanzienlijk 
is gegroeid. Door microbellen direct en selectief op biofilms te richten (d.w.z. te 
targeten), zou Sonobactericide kunnen worden verbeterd, doordat ze hierdoor mogelijk 
infecties (in een vroeg stadium) kunnen opsporen. Ze zouden effectiever zijn dan niet-
getargete microbellen, vooral in uitdagende omstandigheden zoals een turbulente 
bloedstroom. In de hoofdstukken 8-9 werden niet-getargete en getargete microbellen 
vergeleken om hun verschillen beter te kunnen begrijpen. Met behulp van verschillende 
akoestische parameters werden in Hoofdstuk 8  duidelijke verschillen in akoestische 
stabiliteit en oscillerend gedrag gevonden tussen gebonden en niet-gebonden 
microbellen. Verder varieerden deze verschillende reacties ook afhankelijk van het 
belangrijkste lipide in de schil van de microbellen. Hoofdstuk 9 onderzocht vervolgens 
de reacties van getargete en niet-getargete microbellen in relatie tot hun invloed op 
endotheelcellen. Verplaatsing was een grote bepalende factor van het lot van de cel bij 
getargete microbellen, in die zin dat verplaatsing resulteerde in omkeerbare sonoporatie 
en niet-verplaatsing in onomkeerbare sonoporatie, en dus celdood. Over het algemeen 
bewerkstelligden niet-getargete microbellen meer medicijnopname dan getargete 
microbellen, maar er wordt verwacht dat dit andersom is onder stroming. 
 
Hoofdstukken 10-11 concentreerden zich uitsluitend op getargete microbellen. 






werden onderzocht in Hoofdstuk 10. Een minimale excursie-amplitude voor het 
veroorzaken van sonoporatie werd bepaald, en grotere amplituden resulteerden in 
grotere membraanporiën. Het hersluiten van membranen bleek onafhankelijk te zijn van 
het gedrag van microbellen en het openen van cel-celcontact trad op als gevolg van 
sonoporatie en niet als gevolg van het mechanische effect van microbellen. In 
Hoofdstuk 11 werd een nieuwe getargete microbel ontwikkeld met het antibioticum 
vancomycine. De microbel bond met succes aan S. aureus biofilms en bleef gebonden 
onder stroming. Theragnostische mogelijkheden werd aangetoond met therapeutische 
bacteriële dispersie. Ten slotte worden in Hoofdstuk 12 de belangrijkste bevindingen 
die centraal staan bij Sonobactericide in een grotere context geplaatst. Besproken 
worden verschillende belangrijke onderwerpen met betrekking tot toekomstige 
klinische mogelijkheden. 
 
Dit proefschrift bouwt voort op de beperkte kennis die bestond over Sonobactericide om 
de weg vrij te maken voor de klinische vertaling ervan als een effectieve behandelings-, 
diagnostische of theragnostische strategie die wordt gebruikt in de zorg voor 
infectieziekten. Toch is het duidelijk, en dat is het kenmerk van de onderzoeks-
wetenschap, dat naarmate veelbelovende kennis wordt verworven, er meer vragen rijzen, 
en het avontuur zou zeker verder moeten gaan dan het werk dat hier op deze pagina's 
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the games even though it might not always be your thing, and your big heart that cares dearly 
for Inés, but also the people who are important to her. I wish you both a beautiful future, and 
am thankful to have been a part of it thus far.  
 
Nora, I am so fortunate to have you as my rollercoaster buddy of life, from our “rere” 
experience, to fun cycling treks together, to so many other moments. My dear paranymph, 
you are my sister from another mother and it’s been so nice to share life with you over the 
last years. I loved our daily talks when I was pregnant and all of our spontaneous meet-ups, 
including the surprise candle light one. You are such a caring person and the most empathetic 
person I know. It makes you vulnerable, but also it’s a great strength and thank you for using 
it to help me through all the loops on the coaster track. You embody the sun and vitamin 
“sea”, and I’m so happy you are getting to live by the sea now. I’m not exactly sure why, but I 
still feel your spirit animal is a giraffe, and one never too far from the water. Thank you for 
always being there for me, and I’ll never forget the feeling of comfort you gave me from 
stroking my hair while I felt so ill with a stomach bug. Thank you Luuk for sharing Nora with 
me. I’m so happy for you guys and to have been a part of the special moments, and look 
forward to the future ones. I wish you both the best in your future adventures, whether it be 
in the camper exploring distant lands or long walks on a foreign beach. I look forward to 
future nature adventures together Nora and much love, laughs, smiles, and big hugs liefie!  
 
My dear fellow bubblers, thank you for being such great company. I’ve enjoyed all the many 
laughs, and smiles, and hugs, and pick me-ups. Tom (van Rooij), I had so much fun having a 
work brother to tease and be teased back, as well as to work with and learn from in a very 
new field to me. Thank you for instantly making me feel like home in the trench, the many 
laughs, and letting me tag along during the conference adventures. You’re my first bubble friend 
and part of the three bubbles. I’m glad we’ve still stayed in touch and look forward to enjoying 




you were exiting when I was starting, it was great to get to know you for that bit and to 
continue to over the years at conferences. You’re a really sweet person and congratulations 
to you and Jason on your second mini person! Sara, grazie mille for being a great trench 
mate and teaching us the important Italian hand gestures. I wish you the best and look 
forward to meeting up one day in your beautiful country. Merel, you really made such a 
great addition to team bubble. Thank you for often thinking of me and being the cheerful 
cheerleader for all of us. Your excitement for the research you were a part of was 
contagious. It was nice getting to be a paranymph together and please keep that positive 
energy. Joop, I’m glad you decided to stay after your internship and be my first mate in the 
sonobactericide team. It’s been quite the adventure with lots of fun times and laughs. I 
enjoyed your playful spirit, from the many games to the tree climbing adventure, and 
escpeially our spontaneous starbucks coffee bets, which also provided a good reason to get 
some fresh air and re-caffeinate our brains. Thanks for letting me help you grow and in turn 
what you taught me. I’m sure we will still have more times to come as we continue 
investigating sonobactericide together.  
 
Simone, thanks for the many chats and your listening ear. I enjoyed the many games, the 
beers in the picnic, and getting to know you over the last years. We’ve both had our trials and 
I’m glad we had each other to get them off our minds. Thank you for being my photographer 
for my big day and the familiar warm face in the room. Your support is always comforting and 
I enjoy your fur baby Nala stories. This is a big year for you and having watched you grow 
over these last years, I’m sure you will rock it! Thanks Niels for having me over for games and 
letting me join your picnic dates. Margot, it was so much fun having you in the lab. Your 
enthusiasm and support for sonobactericide and experimenting was refreshing and I loved all 
the jokes and smiles. Thank you for the “I’m sorry” jar and adding your impeccable style to 
Julia’s wardrobe. Let’s go cycling together one day soon! Wish you all the best for your 
internships and hope you find a place in the specialty of your dreams. Mariël, you have been 
such a big help not only in your support in the lab, but also personally and as a friend. You’re a 
fantastic listener and your desire to do more and be more involved is motivating. Thank you, 
truly for always being there and providing mental support, whether during a long 
experimental day or just a tough day. I love the dresses you’ve added to Julia closet and I hope 
we can do a playdate soon with the warmer weather - can’t wait to meet your little ones. You’re 
incredibly sweet and I look forward to continued adventures in and out of the lab. Bram, I’ve 
enjoyed having you as a desk neighbor and thanks for all the treats. Though our research doesn’t 
overlap, it’s always nice to hear your stories (personal ones also) and to see someone doing the 




Reza, I think you’re next. Nice that you joined the bubble group. I’m glad you’ve been able to 
finally navigate your way through the sometimes murky waters of your research experience to 
getting your PhD. Thank you your support and listening. I’ve enjoyed our discussions and 
good luck in your future trajectory wherever it may lead you. Gert-Jan, thank you for being 
incredibly thoughtful. Your desk allowed us a view into your interests while also adding 
laughter and light to the office along with your bright personality. Good luck at your next 
internship! Hongchen, though we have not had much time together because of corona, it has 
been nice to get to know you both digitally and physically. I hope the future will allow for 
more discussions in person and look forward to experimenting together with bubbles and 
bacteria, as I have no doubt you’ll get the shimadzus running. I wish you much success in 
your PhD journey. Jiyeon, though you only just joined the sonobactericide adventure I 
believe we have fun times ahead pushing the fibrin biofilms to the next level together, and 
looking forward to it. Never lose expressing your enthusiasm for the things that interest 
you, it is a great trait to have. And thank you for your patience while I have had to redirect 
my focus at times towards my thesis and defense. Welcome to the bubble team Yuchen.  
 
Dear Robert(a), I don’t know where I would be without all your help. It was instrumental 
to not only to the progress of sonobactericide but also just to me. Your support whether it 
be a listening ear, sending an interesting link, or advice, or one of your hallmark Robert 
jokes, you were always there with a smile and encouraging words. Not just for me, but for 
all of us. You are a crucial cog for the department, and though you down play that because 
you’re modest, I hope you know it’s true. I think you embody the quote, “life’s too short to 
not laugh” and I like that so much about you, including the jokes that are an acquired taste. 
I don’t know how to thank you enough. Thank you for being my friend and being there for 
me. I’m really happy you have Hanneke, you two seem like a great fit and wish you lots of 
love and laughs in your new house and beyond. 
 
Frits, the Brandaris guru as Inés call you which are true words. Thank you for all the advice 
and help over the years, and a special thank you for your time and help when my external 
hard drive died. I enjoyed all our discussions and enjoyed listening to your stories. I hope 
you are able to go on new adventures soon. Gerard, thanks for all your support, despite I 
was one of the few apple users. I always enjoyed seeing your new year’s card showing 
images of your latest travels and hope that this summer you’re able to do that again. As a 
fellow cycler, it was also fun to see the impact cycling can have on someone. Thank you for 
all the technical support Michiel and Geert. You helped us to achieve the best results we 




Sharon, you’re not just the administrative rock of the department, but also a friend. You’re 
always there when I need you, or anyone needs you, whether that be for help with 
something or a listening ear. I think sometimes you are an unsung hero, and these words 
are not enough to thank you. Nonetheless, thank you for all the chats and advice and 
stories and laughs and support and encouragement. I can’t wait to enjoy yummy pisco sours 
together. Thank you for all the clothes and interest in Julia. It’s been fun to share stories 
about our children together and see them grow. You’re real and you set your boundaries 
and go above and beyond which makes you special. And thank you to your sister Blossom. 
Thank you for your time, trying, and understanding. I hope you can see I kept some 
elements and wish you the best in your future career.   
 
Lana, I’m so happy to have met you. All our desk trench talks in dutch (and English) and 
adventures together whether traveling, including to Glasgow or driving to Leuven. Your 
excitement for games is so much fun. Glad to have had many moments to play them over 
the years together and I hope many more in the future. You have brought happy tears to my 
eyes on many occasions because of your thoughtfulness and I can’t thank you enough.  
 
Jason, thank you for all the laughs (including the Granny sticker for my computer although I’m 
only a year older) and conversations along the way. I hope one day we get to have our projects 
overlap to one day work together. You’re a fellow game lover and always keen for a game if the 
time allows for it, which always puts a smile on my face. Dear Jenna, you are a warm soul and 
so thoughtful. Thank you for thinking of me for walks and playdates for our darling daughters. It 
has been wonderful to share our parenting adventures together and to see the bond between 
Julia and your adorable Juni grow, as well as with her uncle and aunt. I look forward to the 
future playdates, both for the little ones and for us, and hope for a game night soon on the 
horizon. It was a pleasure to meet you Ann, and hope you have a smooth transition to the UK. 
 
Rik, thank you for all the advice both scientifically and personally over the years, as well as 
checking in from time to time. You are always wearing a smile no matter how busy you are, 
which rubs off on the people around you. Perhaps one day we will make it to go cycling and 
wish you the best both scientifically and personally. Hans, thanks for the words of wisdom 
and listening to me over the years whenever I dropped in the office, often on the search for 
Nico. I hope you can experience more rock climbing adventures in beautiful locations soon! 
 
Gonzalo, thank you for opening up your home to me when I needed it most. I’ve enjoyed 




game nights. I’ll never forget all the fun and laughing, especially during the climbing 
adventure with Joop at the highest level in the trees at the klimbos during the PhD weekend. 
Jorinde, it was fun planning the first PhD weekend together, for which you were 
instrumental for with your ideas and house hunting. Over the years it has been nice getting 
to know you, and also sharing our PhD juggling experiences with pregnancy and baby life. I 
know you’ll produce a beautiful dissertation. Enjoy the precious moments with your darling 
Isabel. Sophie Heijmans, thanks for the chats and I hope you’re able to stay in science and 
investigate everything that interests you. Luxi, Geraldi, Annette Caenen, Sander, Fox, 
Mihai, and Deep, thank you for the nice conversations over the years. 
 
To the biomechanics group, thank you for letting me often drop by whether for a break 
with conversation or help, as well as joining in the game nights from time to time. Eric, I 
was honored to be your paranymph and look forward to see where your career takes you. I 
enjoyed our many discussions and musings about life. Your social interaction and 
presenting skills are truly a strength and hope you get to use them effectively in your next 
professional step. Eline, it was fun twining with you over the years, as well as the drinks, 
the many laughs, the desk-side chats, and walks. You’re inclusive and social, which I really 
liked and hope your path to specialization is smooth and leads you to exactly where you 
want to be.  Ayla, thanks for tagging me from the beginning with organizing the PhD 
labuitje and then a place on the coeur PhD committee. Both lead to memorable experiences 
and hope your adventure down under was great. Ruoyu, although we never pursued it 
further, I enjoyed our discussions and brainstorming about potential avenues of 
entrepreneurship. Astrid, I have fond memories from bowling to beach walks with you, 
Ruoyu, and Inés at the Dutch Biomedical engineering conference at Egmond aan Zee to 
also sharing our mini people experiences. Congratulations on your second mini and your 
wedding. Annette, Hilary, and Ali, thanks for the discussions and chats about life and 
science. Su, from the first time I met you at the PhD weekend in Bergen op Zoom, I found 
you to be very sweet and indeed with each interaction, that has only been further 
confirmed. Good luck with finishing your PhD and hope you’ll be able to spend more time 
in the lab. Kim van Gaalen, thank you for thinking of me and always being open to share 
about life and your babes. Thanks for all the hallway chats and I look forward to more of 
them in the future.   
 
Frank, I’ll never forget how you rescued me from a moment of extreme stress when I was 
surprisingly nominated to pitch my research in a min or two for an oral presentation award. 




minutes, “we want to see them, we want to kill them”. Thank you also for the many warm 
conversations, scientific help, and general guidance. Kim van der Heiden, thank you for 
your words of support over the years and your texts checking in to see how I was doing. It 
was nice to share experiences and really happy for you that it worked out with the Vidi, 
yay! Thank you also for the items for Julia. Also Jolanda, thank you too for the maxi-cosi 
and cover. It was really thoughtful and touching how even though I was unable to attend 
the labuitje because of the illness around my pregnancy, on your own time you and your 
daughter painted the activity of me for me – thank you!  
 
To the optics group, thanks for all the many discussions and support. Gijs, I still remember 
your warm welcome to the department. I’ve enjoyed all the conversations, whether over 
science or life with a beer. Congratulations on making it to full professor and I wish you much 
success with Kaminari Medical. Happy cycling! Sophinese, you are such a sweetheart. It’s 
been a pleasure to get to know you birthday twin. Thanks for the warm chats and always 
listening. Much success in Delft, and perhaps we can figure out a way to work together one 
day. Jovana, thanks for all the warm memories, whether while moving Jason and Jenna, or 
planning the labuitje together, or over breakfast, or visiting Julia. Mirjam, thank you for 
providing some much needed mental breaks when you dropped by the trench, or from 
bumping into each other in the hall, or over drinks or breakfasts. It’s funny only found out at 
the end of our tenure that you also swim and cycle. Maybe one day we can still do that 
together. Hope all is settled and enjoying your new house and job. Nuria, it was nice to learn 
you also live on the “silver lining” of the south of Rotterdam as well as see your strava 
activity. Thanks for the chats and hope the mass spec treats you nicer than it did in the 
beginning. Good luck with finishing your PhD! Ingeborg, thanks for letting me drop in the 
trench often, you make a great neighbor for Robert. It has been fun to follow you on strava. 
Thanks for all the kudos and I look forward to seeing all your future runs. Leonardo, nice 
that you were always open to always joined social events thanks for your kind words and hope 
you’re doing well in Italy. Aaron, Antonio, Shengnan, Martin, and Tianshi, thanks for all 
the nice conversations and good luck and fortune for the future. 
 
Verya, your question for a thermo-meter is a language example I often use when talking 
about language quirks, because it took me a minute too long to realize you were asking for a 
thermometer. Thanks for the invites to join you at the climbing wall, maybe one day will 
become a today. Good luck with your new adventure at Kaminari Medical. Pieter, thanks for 





years. Congrats again on your little one. I look forward to seeing you push the frontiers of 
ultrasound in the neurological world. Pim, thanks for the nice lunch discussion for when I did join. 
 
To all the BME family members whether from the past or the future, whether explicitly 
mentioned here or not, whether still in science or far away from it, I wish you all the best. To 
the current and future PhDs, persistence through the times when the science seems to not 
work and everything seems to not go as planned will get you through. Don’t forget to 
celebrate every small thing that went well, because altogether they amount to something big.  
 
To the Medical Microbiology and Infectious Diseases department, thank you for welcoming 
me into your space and for all the support over the years. To the staphylococcus working 
group, thanks for all the great discussions and feedback on sonobactericide. Andi, thanks for 
all that you taught me on biofilms and to bounce experimental design ideas with. I enjoyed 
our many talks whether in the lab or walking from or to Erasmus since we were nearby 
neighbors. Wish you all the best in Indonesia and hopefully soon we will be celebrating your 
defense. Nicole, no matter the question or help I needed over the years, you were always 
there with the answer, direction, or feedback. Thank you so much for that. Corné, thanks for 
all your help along the way. It’s been nice to get to know you and work more together since 
working on fibrin biofilms together. Look forward to hopefully continuing to together in the 
future. Enjoy your new-ish little one. Valérie, I enjoyed the conversations in the lab and 
discussions about our projects even though we didn’t end up working together in the end. 
Looking forward to seeing your future work and also celebrating your thesis. Mehri, you are 
really sweet and I enjoyed the many conversations in the lab whether over science or Julia or 
your daughter and grandchild. Thanks for the help. Michèle, thanks for the feedback on 
sonobactericide and I hope one day we can collaborate with your phage work. Good luck as 
you continue your PhD work. Jannette, thanks for all the discussions. Susan and Deborah, 
thanks for all the practical work and helping me in the lab whenever I was in search for 
assistance. Carla and Ger, thank you for always being available to help whether it’s looking 
for supplies, equipment, or making plates. Annelies, thank you for taking an interest in 
sonobactericide and all your support and positive responses as well as Karin and Nelianne, 
also for your help and guidance with the isolates. Wendy, thanks for helping with 
sonobactericide in the early stages and all the chats following. Astrid and Michel, I also 
enjoyed our lab and hallway conversations and discussion about life and science.  
 
To the pizza club members, thank you for warmly welcoming me into your tribe when I 




deriving from a multitude of pizza parlors. I hope one day we can all get together one day 
for an adventure, maybe with all our kids too. Kevin, I cannot thank you enough for letting 
me join your early morning commute every morning to the lab. Those conversations 
musing about life are some of the best memories from that time. They not only expanded 
my perspective on many topics, but through them you also became a dear friend. Thanks 
for all the laughs and guidance over the years, as well as putting up the lights in my new 
house, the fun adventures at ASA Boston with Inés and Ken among others, as well as when 
you and Tricia came over to Rotterdam together. It’s been great to get to know you both 
better over the years and see your beautiful daughters Clara and Hailey grow. Himanshu, I 
have so many fond memories of working on sonobactericide together and of outside the 
lab. Thanks for all the support and your words of wisdom then and over the years. I learned 
a lot from you along way, not only professionally. Hope the situation allows for a visit to 
Rotterdam soon so I can take you around. Was also great to see you and Karla (and 
growing Karuna) in Boston, and hope I can visit you all in India soon. It was nice to have 
you stay over Karla when you were doing some work with Rik. I enjoyed doing some Dutch 
adventuring together with nice Amsterdam memories. Thank you also for teaching me how 
to properly make rice. Ken, thank you for sharing your uniqueness, which provided many 
opportunities for laughter - especially your past life as a rodeo clown. Thanks also for the 
help and chats in and out of the lab. I’m happy I got to meet you and Kara before moving to 
Chicago. And was so nice to see you both in Glasgow and learn you also have an interest in 
Outlander. Congrats to you both on your new mini and enjoy the new adventure.  
 
To the departments of Experimental Cardiology and Experimental Anesthesiology, a warm 
thank you for all the friendly support and hallway conversations. Harold, thanks for all the 
warm chats and asking how I am doing whenever in passing. Patricia, it was always nice to 
share stories about our children and I hope you’re able to have animal experiments soon. 
Marielle, I enjoyed our chats in the lab as well and congratulations on your new little one. 
Dirk-Jan, thanks for the nice elevator and hallway conversations, whether about science, 
life, or the US. Hope there will be more in the future. Maarten, thanks for all the insight 
whether into parenthood, PhD-ing, Postdocing, or sharing your grant application 
experience. I hope it all works out with many grants in your future! Jarno, it was nice 
getting to know you a bit better during the meetings and activities while being on the 
Coeur PhD committee together. Good luck in your future endeavors. Thank you Lau, and 
Ester, for all your friendly help with the practical things and always available whenever I 





For the people I have and haven’t mentioned yet but were involved in the Sonobac and 
Bubblecure tissue studies, thank you for your help either in getting this up and running or 
your continued support as patients are included and we move forward with the ex vivo 
investigations, to include resisdents as well as: Ad Bogers, Ali Wahadat, Corstiaan den Uil, 
Jos Bekkers, Wouter van Leeuwen, Frans Oei, Tomas Szili Torok, Peter Riegman, Cindy 
Groenendijk-Kok, Marianne Bout, Jeanette Duys-Huizinga, Monica Jongenotter, Mark 
Hoogendijk, Steffanie Klosinski, Sing Yap, Yvonne Schotting, Mattie Lenzen, Rob 
Levens. Mostafa Mokhles, thanks for your help from the very beginning and the beautiful 
tissue over the years. Good luck in your new adventure at UMC Utrecht. Margreet Bekker, 
I’ve enjoyed our conversations over the years and thank you for thinking of us for every 
potential patient. Also thank you for helping me with the clinical trials program application 
and your support. I hope you’re able to go on great adventures like the one to the Galápagos 
islands soon.  Jan von der Thüsen, I appreciate the warm and informative conversations over 
the years and thank you your help and time with the pathology side of things.  
 
Felix Zijlstra, thank you truly for everything, much of this research within this thesis 
would not have been possible without your support. I also appreciate your help with my 
clinical trials application and the female top talent program. Wilma Verhoek, thank you 
for your quick assistance whenever I’ve needed it. 
 
Shirley Uitte de Willige, thanks for all the nice lunch breaks together, and for the nice 
chats over the years whether personal or over Coeur items. Also for the hematological 
assistance near the start of the project when initially looking into fibrin clots. Hope it is a 
smooth transition over to the graduate school.  
 
Michel Versluis, Guillaume Lajoinie, Tim Segers, Ine Lentacker, Ine de Cock, Heleen 
Dewitte, and Silke Roovers, thanks for always welcoming from the start to join the drinks 
and chats at the conferences. Thank you for the fond memories, support, and making it feel 
like a reunion to see all your smiles with each conference. Wish you all the best wherever 
your research or paths may lead you. 
 
Ruud van Sloon, it’s been nice to get to know more with each conference over the years. I 
always enjoyed the drinks Inés and I had with you and your Eindhoven group each time. 
Thanks for all the fun and I’m really happy for you with all your success thus far and I have 





To the Infection & Immunity program, thank you for all the opportunities you afforded 
me. It is because of the design of the program that I met Klazina and all of this happened. 
Jan Nouwen, thank you for the friendly conversation, support, and suggesting to pair up 
with Willem. Frank van Vliet, you have provided so much encouragement and belief in me 
over the years. Thank you for always willing to help whenever I needed it. I am so 
appreciative to it all, from the military funding, the applications, the tissues, to the coffee 
and conversations.  
 
My dear, dear celebration time friends, Agustin, Arthur, Denise, Jasper, and Nora, you 
have all been my strength, my support, and my foundation through it all. You have always 
been there for me, whether with laughs or hugs or kind words or encouragement or 
celebrations or a place to rest my head. How lucky am I to have met you all and to call you 
all my dear friends. I loved all our adventures, even the gruelling study days because having 
you there made them doable and fun. From our drinks and house warmings, to game nights 
and glühwein, to birthday wishes and parties, to dinners out in the town, to Christmas 
markets and walks and runs, to dancing and Nora’s wedding, to abroad calls and spinning 
classes, and to so much more. You all have added so much joy to these years and I can’t 
thank you enough which words only fall short. I so wished you could all share this day with 
me, but alas it wasn’t so. I hope in the near future we can all celebrate together again soon 
everything we’ve missed! Much, much love my dear loves. Thank you Frank and Irene to 
sharing your plus ones with me as well as joining in some of the adventures.  
 
JD, thank you for all the beautiful moments and laughs and smiles as well as all the words 
of support and encouragement along the way. The leafe is real and I hope one day stella 
works. Remember to be true to yourself, for in that is where I think happiness lies. And 
please don’t ever feel bad for being so thoughtful. Enjoy all the precious moments with 
your kids and I wish you all the best no matter where your journey leads you. 
 
Simone, thank you for all your support over the years and being there when I needed you. I 
especially enjoyed all our wine and prosecco dates in the park and by the water in the 
harbour under the sun. It’s been great to get to know you better over the last years, 
including on travels outside the Netherlands and the many events we’ve shard together. 







To my wonderful neighbors, Xamara, Guido, Mika, Kai; Lieke, Said, Kenza, Lemoon; 
Diewertje and others that have I gotten to know over the last couple years, thank you for 
always checking in, your support, and the Dutch practice. I’ve enjoyed getting to know you 
all better and the many playdates.   
 
Jessie, oh we had so many memories and fun times. You are an amazing friend, a fantastic 
writer, and just an all-around sweet person with a big heart. If I could have taken you over 
the pond I would have. Thank you for always being there for me in every way during my 
young adulthood. Much love to you and your family. Diana, my dear dear friend, I loved all 
our adventures in Columbia together, the jazz nights, the drinks, the late evenings, the 
many many coffee dates. I still have my necklace with a K. You have two beautiful kids and 
I’m so happy for you guys. I wish you much love amiga – te quiero. 
 
Stefan, thank you for everything you’ve done as a friend, including the time you gave 
during work. You’re a kind and thoughtful person, and a great friend to Johan. I appreciate 
all the times we’ve spent together, accepting my american hugs, and support. Also to your 
family as well. 
 
Ylske, I cannot thank you enough for helping me find peace during a time when I felt 
pulled in so many directions that at times it felt crushing. You allowed me a safe space to 
just talk about everything freely and without judgement, and through that it helped me 
process, find comfort, and take in everything at a healthy pace. You were my self-care 
during a time I needed it most, when that is the thing I drop when I feel time is 
overwhelming limited. Although I still did that, you were not persistent or pushing and I 
really appreciate that. I admire how well you put your boundaries out and stick to them. I 
only hope I can be as balanced as you one day. I wish you the best in all your future 
journey. Thank you for always understanding and helping me grow into a stronger person 












What is family…I know it isn’t defined by blood, but by the people who want you in their life 
and accept you for who you are…it’s love…it’s who you love and who loves you… and so I don’t 
believe I have just one family, but multiple families and people, that I am so, so fortunate have. 
Thank you for loving me and being there for me no matter what, even when time and distance 
and the busyness of life gets in the way. I hope you know I love you all dearly. You have all 
provided so much support and love over the years, especially when I needed it so, especially on 
my not straight path. Thank you for all the wonderful memories and celebrations and travels 
and so much more over the years. To Dixie, Mike, Sydney, Casey, Carol (Maw-maw), and 
Ken (Paw-paw) and to all the extended family members, thank you for accepting me as me with 
all my faults into your family as your family even though we are not blood. To Pam (mom), 
Tim, Alex, Samantha, Rachel, Ben, Caleb, Degan, Killian and mini Rachel/Ben. To 
Grandpa, Grandma, Paula, Barry, Peggy, PJ, George (godfather), Kalyn, Georgie, James 
(little bear), Brian, Michelle, Madison, Ella, Pierrette, Kristen, Alex, and Austin. To the 
Lattwein family, Birgit (godmother) and extended family members. To Ana Maria, Han, 
Chela, Maarten, Kirki, Georgie, Sophia, and Philip. Johan, we have an amazing, beautiful 
daughter together and you played a huge role in the making of this thesis over the years. Thank 
you for both of those and for the many adventures we took together and the good times. Julia, I 
love you more with each passing day, even when I thought I was already at the maximum 
possible. You constantly remind me to appreciate the smallest things and watching you grow 
and develop is amazing. You are so caring and your cuddles mean the world. I love you up to the 
sky and down again, around the world and back again…unconditionally forever….high five, box, 
buzz, mwah, hug. 
